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Összefoglalás 
 
A pituiter adenilát cikláz aktiváló polipeptid (PACAP) és a vazoaktív intesztinális 
peptid (VIP) az emls szervezet széles, egymással részben átfed hatásspektrummal 
rendelkez hírviv molekulái. Potens értágítók, neuroprotektív hatásuk pedig az agyi 
infarktus számos modelljében bizonyított. Az agyi iszkémia/reperfúzió (I/R) során endogén 
neuroprotektív mediátorként PACAP és VIP is felszabadulhat a neurovaszkuláris egység 
elemeibl. Ezeknek a peptideknek az agyi keringésszabályozásban illetve az agyi iszkémia 
patofiziológiájában betöltött pontos szerepe azonban egyelre még nem tisztázott. 
Elsdleges célunk az volt, hogy megvizsgáljuk a két PACAP izoformának (PACAP38 
és PACAP27), illetve a VIP-nek az újszülött agy vérkeringésére gyakorolt hatását. 
Munkánkban a pia mater arterioláinak reakcióit elemeztük különböz enzimbénítók, illetve 
peptid PACAP/VIP-receptor antagonisták segítségével. Kísérleteink második részében arra 
kerestünk választ, vajon PACAP illetve VIP elkezeléssel mérsékelhetk-e az I/R által 
súlyosan károsított agyi érreakciók. Az endotélium funkcionális károsodását a hiperkapniára 
adott, a neuronális–vaszkuláris csatolás zavarát a glutamát-receptor agonista 
N-metil-D-aszpartáttal (NMDA) kiváltott vazodilatáció csökkenésével jellemeztük. 
Kísérleteinket altatott, lélegeztetett újszülött malacokon végeztük. Az érátmérk 
változásait a zárt koponyaablak/intravitális mikroszkópia módszer segítségével határoztuk 
meg. A PACAP izoformák és a VIP dózisfügg, reprodukálható, nitrogén monoxid 
independens piális arteriola dilatációt váltottak ki. A PACAP38 és a kis dózisban alkalmazott 
VIP vazodilatátor hatásában a cikooxigenáz(COX)-1 aktivitása játszott fontos szerepet. A 
vizsgált peptid antagonisták közül a PACAP6–38 kivédte mindhárom vizsgált peptid értágító 
hatását, míg a PACAP6–27 csak a két PACAP izoformával szemben bizonyult hatásosnak. A 
hiperkapnia által indukált vazodilatáció károsodását I/R után mind a PACAP, mind a VIP 
elkezelés megakadályozta. Ezzel szemben csak a PACAP izoformák jelentettek védelmet az 
NMDA által kiváltott értágulat I/R-t követ károsodásával szemben. 
Összefoglalva, a vizsgált neuropeptidek csak részben átfed vaszkuláris hatásait egy 
COX-1 aktivitástól függ és egy attól független mechanizmus mediálhatja. A PACAP 
izoformák a VIP-hez képest a neurovaszkuláris egység több elemére fejtenek ki véd hatást 
I/R során, amely magyarázhatja más modellekben megfigyelt nagyobb neuroprotektív 
potenciáljukat. A PACAP és a VIP általunk tapasztalt tulajdonságai új, neuroprotektív 
stratégiák alapját képezhetik az újszülöttkori agyi vaszkuláris történések esetében is. 
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Summary 
 
Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal 
peptide (VIP) share a wide range of biological activities in mammals. These peptide 
transmitters are potent vasodilators, and were found neuroprotective in numerous models of 
cerebral ischemia. PACAP and VIP may also be released from the various elements of the 
neurovascular unit during ischemia so as to reduce the extent of neuronal injury. However, 
the mechanisms of the neurovascular actions of these neuropeptides are poorly known, 
especially in newborns. 
Our first goal was to evaluate the effects of PACAP38, PACAP27, and VIP on pial 
arterioles, and to characterize these responses using various enzyme inhibitors and 
PACAP/VIP-receptor antagonist PACAP fragments. In the second set of our experiments, we 
sought to test if PACAP or VIP pretreatments preserve endothelial and/or neuronal function-
dependent I/R-sensitive vascular responsiveness such as hypercapnia- or 
N-methyl-D-aspartate (NMDA)-induced vasodilation. 
Anesthetized, ventilated piglets were equipped with closed cranial windows. Pial 
arteriolar responses were evaluated via intravital microscopy. PACAP isoforms and VIP 
evoked dose-dependent, reproducible, nitric oxide independent vasodilation. PACAP38 and 
low dose VIP-evoked vascular responses were attenuated by cyclooxygenase (COX)-1 
inhibition. PACAP6–38 inhibited vasodilation induced by either PACAP38, PACAP27, or 
VIP. In contrast, PACAP6-27 altered only PACAP38 and PACAP27 but not VIP-induced 
vasodilation. PACAP38, PACAP27, and VIP all prevented the attenuation of hypercapnia-
induced vasodilation caused by I/R; however, PACAP isoforms, but not VIP preserved 
NMDA-dependent vascular reactivity. 
In summary, PACAP38, PACAP27, and VIP are potent vasodilators in the neonatal cerebral 
circulation with at least two distinct mechanisms of action: a COX-dependent and a COX-
independent pathway. After I/R, PACAP isoforms preserve more functions of the 
neurovascular unit than VIP possibly explaining the more pronounced neuroprotection 
afforded by PACAP. Our present findings may form the foundation of new neuroprotective 
therapies in the treatment of neonatal stroke. 
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Introduction 
 
Stroke is a rapidly developing loss of brain functions due to disturbance in the blood 
supply to the brain caused either by a hypoxic-ischemic or a hemorrhagic insult. Stroke is 
known to be one of the leading causes of adult disability and death; however, stroke also 
affects millions of human babies, especially premature infants, every year worldwide (Zanelli 
et al. 2008; Lynch 2009). Neonatal stroke may result in death, but more often, in severe, life-
long neurological dysfunction that has a considerable impact on both the health care system 
and the families taking care of the disabled children. Therefore, development of reasonable 
and effective therapies to reduce neural damage following stroke is of great importance. 
However, to develop new treatment strategies, a better understanding of stroke related 
pathophysiology is required. 
According to our present knowledge the piglet is the best model for invasively 
examining the central nervous system of the newborn. At birth, concerning the body size, the 
developmental stage of the brain, the basic hemodynamic parameters, and cerebrovascular 
responses, piglets are very similar to human babies (Book and Bustad 1974; DeRoth and 
Downie 1978; Busija 1994). Therefore, our laboratory chose this model to examine the 
central nervous system and cerebral circulation, in order to have a broader insight into the 
stroke pathology of newborns. 
Cerebral ischemia/reperfusion (I/R) induces not only neuronal injury, but also, I/R 
impacts more or less all components of the so-called neurovascular unit. The concept of the 
neurovascular unit/neurovascular coupling comprises the functional and morphological 
interactions between neurons, astrocytes, and all cerebromicrovascular cell types that provide 
adequate local cerebral blood flow to match tissue metabolic needs (Roy and Sherrington 
1890; Girouard and Iadecola 2006; Drake and Iadecola 2007). One of the major 
manifestations of postischemic neurovascular unit dysfunction is impaired cerebrovascular 
reactivity (CR) (Leffler et al. 1989b; Busija et al. 1996a; Ben-Haim and Armstead 2000; 
Kulik et al. 2008). Altered CR appears to play a significant role in stroke pathophysiology 
since it results in inadequate cerebral blood flow regulation following the original stress and 
worsens metabolic challenges of the already compromised tissue that may significantly 
aggravate the brain injury setting the stage for secondary insults (Kogure et al. 1980; 
Hossmann 1997). Thus, preservation of CR is a promising area of research to develop 
treatments that may accompany other neuroprotective therapies. Neuroprotective agents such 
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as pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal 
peptide (VIP) may be released from nerve endings and decrease the extent of ischemic injury 
(Reglodi et al. 2000; Reglodi et al. 2002; Brenneman 2007; Stumm et al. 2007). Among 
several putative mechanisms, preservation of normal vascular reactions may be an important 
contributor to the in vivo neuroprotective potential of these peptide transmitters. 
 
PACAP and VIP: structure, distribution, and receptors 
 
PACAP and VIP are structurally related endogenous peptide members of the 
VIP/glucagon/secretin superfamily (Sherwood et al. 2000; Edvinsson and Krause 2002). 
They are important intercellular messengers in both the central and peripheral nervous 
systems and in a variety of non-neural tissues (Fahrenkrug 1993; Vaudry et al. 2000b). 
PACAP was originally isolated from the ovine hypothalamus and was described as a factor 
potently stimulating adenylate cyclase activity in rat pituitary cell culture (Miyata et al. 
1989). PACAP has two naturally occurring isoforms; PACAP38, a basic, amidated 
38-residue peptide and PACAP27, the N-terminal portion consisting of 27 amino acids 
(Miyata et al. 1989; Miyata et al. 1990). PACAP38 is the more abundant form that comprises 
90% of PACAP in the body (Arimura et al. 1991; Ghatei et al. 1993; Palkovits et al. 1995). 
VIP was originally isolated from porcine duodenum and characterized as a factor inducing 
dilation of peripheral vessels (Said and Mutt 1970). VIP contains 28 amino acids and shows 
67% sequence-homology with PACAP27 (Mutt and Said 1974; Miyata et al. 1990). The 
primary structures of PACAP and VIP have been remarkably conserved throughout 
evolution. The amino acid sequence of PACAP is identical in all mammalian species 
investigated so far; and furthermore, the sequence of the first 27 amino acid residues 
necessary for the peptide`s biological activity is identical in humans, amphibians, and fish. 
The primary structure of VIP is also identical in most mammalian species (Sherwood et al. 
2000). This extremely preserved structure of PACAP and VIP throughout phylogenesis may 
indicate the vital importance of these peptides in the living organisms. 
PACAP and VIP show widespread and similar tissue-organ distribution and 
pleiotropic functions. They share at least partially the same receptors, and thus a rich 
spectrum of biological activities (Harmar et al. 1998; Vaudry et al. 2000b; Laburthe and 
Couvineau 2002; Laburthe et al. 2002). Among many examples, PACAP and VIP are widely 
expressed throughout the central and peripheral nervous system, where they act as 
hypothalamic hormones, neurotransmitters, neuromodulators, and neurotrophic factors 
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(Vaudry et al. 1999; Vaudry et al. 2000a; Edvinsson and Krause 2002). PACAP and VIP 
have been identified as regulators of hormone secretion in the pituitary gland (Arimura and 
Shioda 1995). They have also been detected in other endocrine organs like the adrenal glands 
and the endocrine pancreas (Vaudry et al. 2000b). PACAP and VIP were discovered in 
various cell types of the immune system as factors affecting the immune responses (Vaudry 
et al. 2000b). In the central nervous system, beside their obvious role in neurodevelopment, 
these neuropeptides are also involved in the homeostatic control of circadian clock and 
behavioral actions, learning and memory processes (Zhou et al. 2002; Harmar 2003). They 
are present in nerve endings of the respiratory system, gastrointestinal, and urogenital tracts, 
where PACAP and VIP are potent relaxants of the smooth musculature (Vaudry et al. 2000b). 
They also relax smooth muscle cells in the wall of arteries and veins throughout the body, 
causing vasodilation in different vascular beds (Edvinsson and Ekman 1984; Warren et al. 
1992; Henning and Sawmiller 2001; Edvinsson and Krause 2002). 
Three main VIP/PACAP receptor types have been identified so far (Harmar et al. 
1998). Generally, these receptors belong to the family of G-protein-coupled receptors with 
seven transmembrane domains and they are known as strong activators of adenylate cyclase. 
On the other hand, accumulated evidence suggests that they activate a number of additional 
intracellular signals (Vaudry et al. 2000b; Dickson and Finlayson 2009). Some of these are 
likely to be downstream of the conventional adenylate cyclase pathway, while others reflect 
other primary coupling events of the receptors. PAC1 receptors are more selective to either 
PACAP38, or PACAP27, than to VIP, and exist in at least eight splice variants. Some of the 
splice variants are linked to phosphatidyl inositol turnover and calcium mobilization. VPAC1 
and VPAC2 receptors exhibit almost equal affinity for PACAP and VIP. However, VPAC1 
receptors have low, while VPAC2 receptors show high affinity for helodermin, another 
member of the same peptide family. According to the structural similarities and the partially 
common receptors of PACAP and VIP, it is reasonable to presume that they exert their 
actions by activating at least partially overlapping mechanisms. However, based on the 
literature, it is already evident that these two peptides are not completely identical in their 
action and each of them activates multiple pathways (McCulloch et al. 2002). 
 
Vasodilation induced by PACAP and VIP 
 
Considerable data suggest that vasoactive peptides, like PACAP and VIP, are 
involved in cerebrovascular control mechanisms under physiologic conditions in newborn 
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and adult animal models as well as in humans (Wei et al. 1980; Edvinsson and Ekman 1984; 
Tong et al. 1993; Anzai et al. 1995; Gulbenkian et al. 2001). These mediators, among others, 
probably also play a role in the neurovascular coupling via connections between peptidergic 
intracortical neurons and blood vessels that may provide a mechanism by which PACAP and 
VIP participate directly in linking neuronal activity to cerebral blood flow (Benagiano et al. 
1996; Edvinsson and Krause 2002; Kulik et al. 2008). On the other hand, glial cells may also 
possibly convey information from neurons to blood vessels (Girouard and Iadecola 2006). 
Interestingly, other peptides from the same family with structural similarities (e.g. secretin, 
glucagon) have no such vasoactive effects in the central nervous system (Edvinsson and 
Krause 2002). 
PACAP and VIP have been detected in nerve endings innervating intracerebral as 
well as pial vessels (Fahrenkrug et al. 2000; Gulbenkian et al. 2001). 
PACAP-immunoreactive extrinsic perivascular nerve fibers are either of parasympathetic or 
trigeminal sensory origin, whereas VIP immunoreactive fibers appear to be exclusively 
parasympathetic originating from the sphenopalatine and otic ganglia virtually in all species 
studied including humans (Tajti et al. 1999; Uddman et al. 1999; Edvinsson and Krause 
2002). Furthermore, PACAP- and VIP-immunoreactive intrinsic cortical neurons and 
afferents from the brainstem appear to regulate blood vessel diameters of both 
intraparenchymal and pial arterioles (Morrison et al. 1984; Benagiano et al. 1996; Tajti et al. 
2001; Edvinsson and Krause 2002; Hannibal 2002; Drake and Iadecola 2007). Although 
recent studies revealed the complexity of perivascular peptidergic innervation, the 
mechanisms by which neuropeptides participate in regulation of the vessel caliber, the 
neuronal excitability, and the cerebral metabolism remains unclear. 
PACAP and VIP are thought to exert a significant direct effect on the vascular smooth 
muscle (VSM) of pial and intracerebral resistance vessels. Activation of PACAP/VIP 
receptors increases intracellular cAMP production that results in cerebrovascular dilation 
(Edvinsson and Krause 2002). On the other hand, many observations support the idea that 
other, supplementary pathways play roles in the circulatory effects of PACAP and VIP with 
the involvement of other cell types of the neurovascular unit. The activation of these indirect 
processes may result in additional vasodilation. 
The release of nitric oxide (NO) from the perivascular nerve-endings is one of the 
most important neuron-derived effector mechanisms in the regulation of vasodilatory 
responses of cerebral arteries. Immunohistochemical studies indicate that PACAP and VIP 
are co-localized with neuronal NO synthase (nNOS) in the perivascular nerves, and in the 
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parasympathetic ganglia. PACAP also coexist with nNOS in the trigeminal ganglion (Tajti et 
al. 1999; Uddman et al. 1999; Edvinsson et al. 2001). In vitro experiments suggest that there 
is not only an anatomical but also a functional connection between the vascular action of 
PACAP and the release of NO (Sano et al. 2000; Seebeck et al. 2002). VIP-mediated 
relaxation depends on NO production in isolated bovine, ovine, and rat cerebral arteries (Gaw 
et al. 1991; Gonzalez et al. 1997; Seebeck et al. 2002). The degree of inhibition of VIP-
induced cerebrovascular dilation by NOS blockers, however; is not consistent among studies, 
and it is not always observed (Edvinsson and Krause 2002). Research studies have not yet 
clarified if NO participates in mediation of the cerebrovascular effects elicited by PACAP 
and VIP in newborns. 
Accumulating data indicate that cyclooxygenase (COX)-derived arachidonic acid 
metabolites are major contributors to the regulation of cerebral circulation in the newborn 
(Peri et al. 1995; Busija et al. 1996b; Degi et al. 1998a; Degi et al. 1998b). COX-1 and 
COX-2 enzymes are both expressed in the CNS; neurons, glial cells, vascular smooth muscle 
cells, and the vascular endothelium all produce some kind of prostanoids. Outstandingly, all 
of the numerous formerly assessed COX-dependent vascular reactions; such as hypotension 
induced vasodilation, and acetylcholine (Ach) induced vasoconstriction, appeared to depend 
largely on COX-2 activity (Domoki et al. 2005b) in the newborn pig. Although some 
preceding studies revealed interaction between the prostanoid synthesis and PACAP action 
(Kis et al. 1999a; Kis et al. 1999b), our understanding of the possible role of the COX derived 
metabolites in the vascular effects of the PACAP in piglets is limited. VIP dilates the isolated 
porcine ophthalmic artery via COX-mediated mechanisms at lower (10-10-10-9 M) VIP 
concentrations (Vincent 1992); but its action is COX-independent when higher (10-8-10-7 M) 
doses are applied. VIP-induced pial arteriolar vasodilation is also indomethacin-sensitive in 
cats (Wei et al. 1980). However, according to our knowledge, VIP-induced vasodilation has 
not yet been characterized in newborns. 
 
Neuroprotection induced by PACAP and VIP 
 
Neuroprotection is one among the many functions shared by PACAP and VIP. 
Antioxidant, anti-apoptotic, neurotrophic, and anti-inflammatory effects have been promoted 
as putative mechanisms of neuroprotection in numerous in vitro and in vivo experimental 
models (Dejda et al. 2005; Brenneman 2007). Additionally, PACAP and VIP-induced 
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neuroprotection in vivo can be, at least partially, based on their cerebrovascular effects (Wei 
et al. 1980; Tong et al. 1993; Anzai et al. 1995). 
PACAP and VIP were demonstrated to protect cultured cerebellar granule cells from 
naturally occurring apoptosis, neurotoxic effects of ethanol, and hydrogen peroxide-induced 
oxidative stress. PACAP also protected cerebellar granule cells against C2 ceramide which is 
a critical mediator of cellular stress response and an important factor involved in apoptosis. 
PACAP and VIP protected neurons from cytotoxic effecs of -amyloid, aggregation of which 
is thought to be a key element of Altzheimer’s disease, and glycoprotein 120, the envelope 
protein of the human immundeficiency virus. Moreover, PACAP showed neuroprotective 
properties against the toxic effects of glutamate, and human prion protein fragment 106-126. 
The receptor(s) mediating PACAP/VIP-induced neuroprotection are still under investigation. 
The neuroprotective effect can be direct, influencing different steps of apoptotic cascade 
mechanisms within the affected neurons; or indirect, via release of glia-derived trophic 
substances associated with the protection of developing neurons. On the other hand, PACAP 
and VIP inhibit the release of proinflammatory mediators which may contribute to neuronal 
death (Dejda et al. 2005; Brenneman 2007). 
These in vitro observations were supported by results from in vivo experiments. It has 
been observed that PACAP effectively proprotected the dopaminergic nigrostriatal neurons 
from apoptotic death in a model of Parkinson’s disease (Reglodi et al. 2004b). PACAP also 
attenuated neuronal and axonal injuries evoked by brain or spinal cord trauma (Farkas et al. 
2004; Chen and Tzeng 2005; Tamas et al. 2006; Kovesdi et al. 2008). In rats, 
intracerebroventricular administration of PACAP38 before the animals underwent permanent 
middle cerebral artery occlusion; significantly reduced the infarct size measured 12 and 24 h 
after the onset of the ischemia (Reglodi et al. 2002). Similarly, in the rat model of transient 
focal ischemia produced by middle cerebral artery occlusion, PACAP administered 
intravenously for 48 h beginning 4 h after the insult, significantly reduced the infarct size 
(Reglodi et al. 2000). The results imply that PACAP might be a promising therapeutic agent 
in reducing ischemic brain damage even when its administration is delayed (Uchida et al. 
1996; Reglodi et al. 2000). 
Ideally, any compound for the treatment of stroke should sufficiently cross the 
blood-brain barrier (BBB) and reach therapeutic levels within the target, injured brain area. 
The BBB is not a rigid, static barrier but rather a dynamic interface between the circulating 
blood and the central nervous system (Zlokovic 2008). PACAP27 and VIP are transported 
into the brain by transmembrane diffusion, a non-saturable mechanism. However, transport of 
7 
PACAP38 across BBB by peptide transport system-6 underlies its effectiveness after 
intravenous administration (Banks et al. 1996). Cerebral ischemia alters the function of the 
BBB, therefore, in this case, the entry of different neuroprotective substances into the brain 
depends on the extent of BBB disruption and the physicochemical properties of the substance 
examined. For example, the passage of PACAP38 was found to selectively increase after 
unilateral middle cerebral artery occlusion in rats, independently of the generally experienced 
permeability changes (Somogyvari-Vigh et al. 2000). 
Although PACAP and VIP display neuroprotective properties against a wide range of 
pathological conditions, PACAP is generally more potent than VIP and its function has been 
more widely investigated (Tamas et al. 2002; Brenneman 2007). Of course, there are 
exceptions from this generalization. Former studies revealed the unique role for VIP in 
neuroptotection from neurotoxicity in white matter (Gressens 1999). Thus, there may be a 
more VIP-specific subtype of PACAP/VIP receptors yet to be descried, that could account for 
such neuroprotective activities. 
PACAP and VIP are among of the most promising candidates of endogenous 
neuroprotective mediators that may also be released from these neuronal-vascular elements 
during I/R that could abrogate/reduce neuronal injury (Brenneman 2007; Stumm et al. 2007). 
Cerebrospinal fluid (CSF) PACAP concentration has been determined to be ~2 ng/ml under 
resting conditions in piglets (Wilderman and Armstead 1997), and its level has been shown to 
elevate in response to different neural injuries (Somogyvari-Vigh et al. 2000; Stumm et al. 
2007). Moreover, it has also been demonstrated that PAC1 receptor expression increases in 
pathological states like ischemic insults (Gillardon et al. 1998). 
In the piglet, impaired CR in the pial circulation to different stimuli depending on 
different elements of the neurovascular unit was demonstrated after I/R, asphyxia, or hypoxic 
stress (Leffler et al. 1989a; Leffler et al. 1989b; Busija and Wei 1993; Bari et al. 1996a; Bari 
et al. 1996c; Busija et al. 1996a; Ben-Haim and Armstead 2000; Domoki et al. 2005a), and 
also, after traumatic brain injury (Armstead 1997; Armstead 2004). Specifically, previous 
studies showed that CO2- and NMDA-induced vasodilatations are severely deteriorated by 
I/R. However, natural neuroprotective mediators such as PACAP or VIP despite their and 
their receptors’ widespread presence in the elements of the neurovascular unit have not been 
considered previously whether they could possibly counteract the deleterious effect of I/R on 
CR. 
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Hypercapnia-induced pial arteriolar dilation: a sensitive indicator of I/R-induced endothelial 
dysfunction 
 
In porcine cerebral vessels, hypercapnia evokes vasodilation not only in vivo (Leffler 
et al. 1989b), but also in isolated, denervated vessels (Kokubun et al. 2009) suggesting that 
neuronal/glial factors are not essential for the hypercapnia-induced vasodilation. In the piglet, 
hypercapnia-induced vasodilation requires intact endothelium (Leffler et al. 1994b); more 
specifically, the endothelium appears to serve as a source of prostanoids for the vascular 
smooth muscle to permit the relaxation (Leffler et al. 1994a). Prostanoid synthesis increases 
in newborn pig brain microvascular endothelial cells in response to hypercapnia, but high 
CO2 level does not increase prostanoid production by cerebral microvascular smooth muscle 
or glial cells (Hsu et al. 1993). Hypercapnia-induced vasodilation is vulnerable to I/R; 
however, supplementation of arachidonic acid restores this vasodilation and hypercapnia-
related increases in the CSF 6-keto-prostaglandinF1 levels (Leffler et al. 1992). Based on 
these findings, I/R seems to reduce hypercapnia-induced dilation of pial arterioles through 
endothelial damage in piglets. Although most data suggest the principal involvement of 
endothelium, the role of other cell types cannot be excluded, since neuronal/glial components 
also contribute to hypercapnia-induced cerebrovascular dilation in other experimental models 
(Wang et al. 1999; Xu et al. 2004). 
 
NMDA-induced pial arteriolar dilation: a sensitive indicator of I/R-induced neuronal-
vascular dysfunction 
 
Glutamate is one of the most abundant excitatory neurotransmitter in the mammalian 
brain (Bonvento et al. 2002; Fellin et al. 2006) that activates a number of ionotropic and 
metabotropic receptors on neurons and astrocytes (Fergus and Lee 1997; Zonta et al. 2003; 
Busija et al. 2007; Koehler et al. 2009). The linkage between neural activity-based release 
and actions of glutamate on parenchymal cells, and the associated decrease in cerebral 
vascular resistance provides one possible functional explanation for the neurovascular unit 
(Leffler et al. 1989b; Busija et al. 2007; Drake and Iadecola 2007). Three types of ionotropic 
glutamatergic receptors are characterized by the names of their synthetic agonists: N-methyl-
D-aspartate (NMDA), kainate, and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate 
(AMPA) (McDonald et al. 1990; Garthwaite 1991; Lerma et al. 1997). Glutamate or its 
analogues are devoid of any vasoactive effects on isolated arteries from various species, 
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including humans and piglets, studied in vitro (Hardebo et al. 1989; Faraci and Breese 1993; 
Simandle et al. 2005). However, when applied topically in vivo, glutamate agonists elicit 
apparent dose-dependent vasodilation in the intact cerebral circulation (Busija et al. 2007). 
Although glutamate has the potential to exert vasoactive influences via activation of any of 
the three ionotropic glutamate receptors, topical application to the surface of the cerebral 
cortex appears to dilate pial arterioles predominantly via NMDA receptor activation (Faraci 
and Breese 1993; Meng et al. 1995). 
It has been hypothesized that stimulation of NMDA receptors on neurons and the 
consequent membrane depolarization/Ca++ influx result in the activation of subsequent 
neurons, and production of vasodilator mediators such as NO that ultimately leads to cerebral 
vascular relaxation, thereby adjusting the cortical blood flow (CoBF) to the local metabolic 
activity. 
Faraci and Breese (Faraci and Breese 1993) first demonstrated that dilation to NMDA 
was eliminated or reduced by treatment with the general NOS inhibitor, N--nitro-L-arginine 
methyl ester (L-NAME) in rabbits, that results were later confirmed in the piglet (Meng et al. 
1995). Subsequent studies showed that administration of 7-nitroindazole, the selective 
inhibitor of the neuronal type of NOS (nNOS), exerted similar, inhibitory effect on 
NMDA-induced vasodilation in these animal models (Faraci and Brian 1995; Bari et al. 
1996b). Furthermore, supporting these pharmacological findings, NMDA application to the 
cortex resulted in accumulation of NO degradation products in the CSF surrounding the 
arterioles (Domoki et al. 2002). The presence of a vein underlying the pial arteriole reduced 
its ability to dilate to NMDA compared to an arteriole lying directly on the cortical surface 
(Domoki et al. 2002), thereby further reinforcing the concept that diffusion of a vasoactive 
substance from the cortex reaches and dilates the arteriole in response to NMDA application. 
Studies using double immunostaining showed that NMDA receptor positive neurons 
were more abundant than nNOS immunoreactive neurons in the cerebral cortex, and 
additionally, NMDA receptors and nNOS seem to occur in separate pool of neurons (Bari et 
al. 1998). Administration of the voltage-gated sodium channel blocker tetrodotoxin 
completely eliminates NMDA-induced cerebrovascular dilation in vivo in rabbits (Faraci and 
Breese 1993), and rats (Pelligrino et al. 1995), indicating the involvement of a chain of 
activated neurons in this process. NMDA or glutamate does not dilate isolated vessels, that 
finding further strengthens the possible role of neuronal components in the process of 
dilation. The absence of functional NMDA and AMPA receptors in rat and human 
cerebromicrovascular endothelial cells has also been demonstrated (Morley et al. 1998). 
10 
Moreover, endothelial damage in vivo failed to affect NMDA-induced dilation while 
responses to other endothelium-dependent dilator stimuli were blocked (Domoki et al. 2002). 
The response was also unaffected by blockade of prostaglandin synthesis. Piglet 
cerebrovascular endothelial cells were also insensitive to either glutamate or NMDA-induced 
toxicity under both in vitro and in vivo conditions (Domoki et al. 2008).  
Briefly, the activation of neuronal NMDA receptors leads to the subsequent activation 
of a specific population of nNOS positive neurons via local neuronal connections (Faraci and 
Breese 1993; Bari et al. 1996b). The released NO then diffuses to and acts on the vascular 
smooth muscle, resulting in dilation of the pial arterioles (Meng et al. 1995; Domoki et al. 
2002). In addition to the unequivocal role of NO, the participation of other species-specific 
factors such as adenosine (Iliff et al. 2003), carbon monoxide (CO) (Leffler et al. 2006), 
ATP-sensitive potassium (KATP), and/or calcium-activated potassium (KCa) channels (Philip 
and Armstead 2004) has been proposed. 
Dilator responses to NMDA were repeatable several times in the same preparation 
(Busija and Leffler 1989; Busija et al. 1996a; Philip and Armstead 2004) and even prolonged 
application to the cortical surface did not appear to damage the cortex in vivo or affect pial 
arteriolar responsiveness to other, non-glutamatergic dilator stimuli (Busija and Leffler 
1989). However, NMDA-induced vasodilation has been shown to be vulnerable to even short 
periods of global cerebral ischemia or asphyxia (Bari et al. 1996a; Busija et al. 1996a). 
Importantly, the pial arteriolar response to NO itself was unaffected by I/R (Busija et al. 
1996a). All available evidence strongly suggests the causative role of reactive oxygen species 
(ROS) in the attenuation of NMDA-induced vasodilation after I/R (Girouard and Iadecola 
2006). In piglets, topical application of ROS scavengers preserves cerebral arteriolar dilator 
responses to NMDA after I/R (Bari et al. 1996a). The primary site of ROS action appears to 
be at the level of the NMDA receptor (Choi et al. 2000; Guerguerian et al. 2002). 
Alternatively, the functional coupling between NMDA receptor and nNOS expressing 
neuronal populations may be disrupted after I/R. 
 
Cortical spreading depression (CSD) may be involved in the mediation of NMDA-induced 
vasodilation in the newborn 
 
NMDA, when applied to the exposed surface of the piglet cerebral cortex, dilated 
overlying pial arterioles in a dose-dependent fashion (Busija and Leffler 1989; Armstead 
2001; Busija et al. 2007). All of the original studies in piglets have been replicated numerous 
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times in other species such as the rabbit (Faraci and Breese 1993) and rat (Faraci and Heistad 
1994; Iliff et al. 2003; Sun and Mayhan 2005). Thus, the fundamental finding that NMDA 
elicits cerebrovascular dilation in vivo appears to be a universal finding across species. 
However, Ayata and Moskowitz (Ayata and Moskowitz 2006) suggested an alternative 
mechanism of NMDA-induced pial arteriolar vasodilation in mice. Using 
electrophysiological recordings and vessel-diameter measurements, they demonstrated the 
involvement of cortical spreading depression (CSD) in the complex vascular responses 
evoked by topical application of NMDA. 
The concept of NMDA receptor activation contributing to the generation and 
propagation of CSD is well established; synthetic antagonists of NMDA receptors are potent 
inhibitors of CSD development in numerous experimental models (Marrannes et al. 1988; 
Gill et al. 1992; Lauritzen and Hansen 1992; Richter et al. 2008). CSD is a self-propagating 
wave of cellular depolarization in the cerebral cortex that is typically evoked by localized 
trauma, excess neuronal firing, potassium chloride or neurotransmitter application, and is 
associated with short-lived but dramatic increases in cortical blood flow (CoBF). The 
underlying mechanisms of this cerebral hyperemia are very complex and probably require the 
contribution of diverse cell types within the neurovascular unit as well as a wide range of 
vasoactive factors depending on age, species, and metabolic status of the cerebral cortex 
(Busija et al. 2008). Because NMDA dilates pial arterioles via species- and age-dependent 
mechanisms and is implicated in CSD initiation and propagation, it is possible, that under 
some circumstances NMDA-evoked CSDs contribute to the overall vascular responses. The 
recent findings of Ayata and Moskowitz (Ayata and Moskowitz 2006) support this concept 
by providing evidence that in mice NMDA-induced pial arteriolar dilation is at least partially 
mediated by CSD. These authors also suggest that, in some former studies where 
electrophysiological analyses were not performed, the virtual dose-dependent nature of the 
pial arterial responses was due to the increasing prevalence of CSDs in conjunction with the 
increasing concentration of NMDA. Most data on NMDA-induced cerebrovascular changes 
have been acquired through studies on pial arteriolar diameters which may or may not fully 
represent the overall response of the cerebral vasculature (Busija et al. 1981; Busija et al. 
1982; Shibata et al. 1991). However, using Laser-Doppler flowmetry, it has been proven that 
similar CSD occurs in response to NMDA in adult rats (Lenti et al. 2009). In these 
experiments the CoBF response to NMDA was a combination of a CSD-related hyperemia 
and a CSD-independent, dose-dependent component. It is unclear, however, whether a 
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similar complex interaction between CSD and the direct effects of NMDA occurs in other 
animal models, especially in newborns. 
Interestingly, the blood flow response to CSD is rather immune to many moderate to 
severe disease conditions in different animal models (Busija et al. 2008), while the response 
to NMDA is very susceptible to even moderate brain insults as it was discussed above. 
Therefore, it is of high importance to critically examine the effect of NMDA on CoBF using 
laser-Doppler flowmetry and to test whether CSD-related cortical hyperemia contributes to 
the overall NMDA-induced cerebrovascular response in the piglet. Because the newborn pig 
seems to be resistant to KCl-induced CSDs (Domoki et al. 1999), NMDA-induced 
cerebrovascular changes are likely not confounded by CSDs in this subject. In this case, the 
use of piglets would allow us to compare the NMDA-evoked CSD-independent cerebral 
hyperemia across experimental models. 
 
Aims of the present studies 
 
The purpose of the first set of our experiments was to (1) evaluate the vasoactive 
potency of PACAP isoforms, as well as short PACAP fragments, and VIP on the newborn 
pial vasculature; (2) compare the magnitude of vasodilation induced by PACAP38 and 
PACAP27; (3) explore the mechanism of cerebral arteriolar responses to PACAP38, 
PACAP27, and VIP using putative receptor antagonists, non-selective NOS, and COX 
inhibitors. The results emanating from these studies urged us to (4) investigate the roles of 
COX-1 and COX-2 activity in the mechanism of PACAP38 and VIP-induced vasodilation 
using selective enzyme inhibitors and to (5) test the effect of the soluble phospholipase A2 
(PLA2) blocker PX-18 on PACAP38-evoked vascular caliber changes. 
The major goal of our second study was to determine whether (1) PACAP38, 
PACAP27 and/or VIP preserves CR to hypercapnia and/or NMDA after I/R, and whether 
preservation of pial arteriolar reactivity to these stimuli can possibly play a role in PACAP- 
and VIP-induced neuroprotection. We also tested (2) whether the protective effects of these 
neuropeptides are dependent on their vasoactivity. 
Additionally, modifying our original protocol, we sought to test if CSD contributed to 
NMDA-induced cortical hyperemia in piglets, as it was described in other animal models, by 
measuring not pial arteriolar diameter but CoBF and DC potential changes. 
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Materials and methods 
 
Animals 
 
In our experiments, we employed the newborn pig animal model that most closely 
reflects the brain developmental stage, metabolism, and basic circulatory parameters of the 
human term neonate. This model is widely accepted and relevant to study the cerebral 
circulation as well as the cardiovascular, respiratory, and endocrine systems of newborns 
(Book and Bustad 1974; DeRoth and Downie 1978; Busija 1994). 
1-3 days old piglets of either sex (body weight 1–3 kg, n=305) were used in our 
experiments. Animals were maintained and used in compliance with the principles set forth 
by the Institutional Animal Care and Use Committee of the University of Szeged and by the 
Animal Care and Use Committee of Wake Forest University Health Sciences. 
 
Surgery 
 
Anesthesia was initiated with thiopental sodium (40 mg/kg ip.; Biochemie, Vienna, 
Austria) and a bolus injection of -chloralose (40 mg/kg iv.; Sigma, St. Louis, MO, USA). 
Additional doses of -chloralose (2-7 mg/kg/h iv.) were given to maintain a constant level of 
anesthesia. A catheter was inserted into the right femoral artery to monitor mean arterial 
blood pressure (MABP) and to sample blood for determination of blood gas tensions and pH. 
Fluid and drugs were administered through a second catheter placed in the right femoral vein. 
The animals were intubated via tracheotomy and mechanically ventilated with a pressure 
controlled animal respirator (TSE GMBH, Bad Homburg, Germany) using room air. The 
ventilation rate (~30 breaths/min) and tidal volume (~20 ml) were adjusted to maintain 
arterial blood gas values and pH in the physiological range. A water-circulating heating pad 
was used to maintain the body temperature at ~37 °C. Core temperature was monitored with a 
rectal probe. 
At the end of the experiments, the animals were euthanized with an intravenous 
injection of saturated KCl solution. 
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The closed cranial window technique 
 
Although several investigators have used variations of the cranial window technique 
to study the cerebral microcirculation, the first detailed description of the closed cranial 
window was published by Levasseur and his co-workers (Levasseur et al. 1975). They 
employed this technique in both acute and chronic experiments using cats and rabbits. 
According to Busija and his co-workers we used basically the same method adapted to the 
newborn pig (Busija et al. 1985). 
The head of the animal was fixed in a stereotactic frame. The scalp was incised and 
removed along with the connective tissue over the calvaria. A circular (19 mm diameter) 
craniotomy was made in the left parietal cranium. The dura was cut and reflected over the 
skull. The complete window consisted of two parts; a stainless steel ring and a circular glass 
cover slip through which the pial vessels were visualized. The junction between the ring and 
the glass was sealed with melted beeswax. Three needle ports were connected to the steel ring 
serving as inlets and/or outlets to enable drug administration and flushing of the brain 
surface. The window was placed into the craniotomy, sealed with bone wax, and cemented 
with cyanoacrylate ester and dental acrylic. Following surgery, the closed window was filled 
with artificial cerebrospinal fluid (aCSF) which was similar to the endogenous CSF (aCSF 
composition: KCl 220, MgCl2 132, CaCl2 221, NaCl 7710, urea 402, dextrose 665, and 
NaHCO3 2066, in mg/l), warmed to 37 °C and equilibrated with a gas mixture containing 6% 
O2, 6.5% CO2 and 87.5% N2 to obtain pH 7.33, pCO2=46 mm Hg and pO2=43 mm Hg. 
There are several advantages of this method. First, it allows the investigator to 
continuously observe the pial circulation. Second, the closed cranial window restores the 
integrity of the skull, therefore the intracranial pressure (ICP) remains around normal, 
physiological levels. Also, aCSF provides physiological environment for the pial vessels 
observed. Finally, the mechanical stability of the preparation allows the induction of induce 
global cerebral ischemia via elevated ICP. 
 
Assessment of cerebrovascular reactivity (CR) 
 
Pial vessels were observed with an operating microscope (Wild, Switzerland) equipped 
with a video camera (Sanyo digital color CCD camera, Japan), and a video monitor 
(Panasonic, Japan). Vascular diameters were measured using a video microscaler. In each 
experiment, a ~100 m-diameter (range 74–114 m) pial arteriole was selected. We chose 
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this vessel size because this is the level of the first-order pial arterioles and the primary site of 
vascular resistance. Some authors separate the resistance vessels into two groups 
corresponding their size (e.g. arterioles and small arteries) to rule out the possibility that 
regional changes in the reactivity modify the results of the experiments (Armstead 1995). 
However, in our experiments, arterioles at both end of the range studied displayed 
statistically identical reactivity to the stimuli used thus data from all observed vessels were 
combined as shown in the Results. 
After the arteriole reached a stable baseline diameter, the window was flushed with 
aCSF as control. Graded hypercapnia was elicited by ventilation with a gas mixture (5 or 
10% CO2, 21% O2, balance N2). Vasodilator drugs were applied to the pial surface through 
one of the injectable ports of the cranial window. The pial arterioles were exposed to each 
vasodilator stimulus for 5 min, while arteriolar diameters were observed continuously. After 
completion of a stimulus, the cranial window was repeatedly flushed with aCSF and the 
vessel diameter was allowed to return to the baseline level. 
 
Global cerebral ischemia 
 
To induce global cerebral ischemia, before inserting the cranial window, a 3-mm hole 
was made with an electric drill with a toothless bit in the left frontal cranium rostral to the 
cranial window and the dura was exposed. A hollow brass bolt was inserted and secured in 
place with bone wax, cyanoacrylate ester, and dental acrylic. Cerebral ischemia was induced 
by the infusion of aCSF so as to raise ICP above the arterial pressure for 10 minutes. 
Ischemia was verified by the cessation of blood flow in the vessels observed through the 
cranial window. Using microspheres, former studies of Beasley and his colleagues (Beasley 
et al. 1998) provided evidence that cerebral blood flow was virtually zero in all examined 
brain areas during the ischemic period. Venous blood was withdrawn as necessary to MABP 
near the normal values. At the end of the ischemic period, the infusion tube was clamped and 
the intracranial pressure returned to the preischemic level. The withdrawn and heparinized 
blood was reinfused (Domoki et al. 2005a). 
 
Measurement of cortical blood flow (CoBF) 
 
The effect of NMDA on pial arteriolar diameters has been demonstrated in several 
previous studies (Leffler et al. 1989b; Busija and Wei 1993; Faraci and Breese 1993; Faraci 
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and Breese 1994; Faraci and Heistad 1994; Meng et al. 1995); however, the temporal 
resolution of diameter measurements may exclude the possibility to record dynamic – short 
lasting changes in CoBF. Therefore, in 5 male piglets, we minimally modified the surgical 
procedure and the experimental setup in order to critically examine the integrated CoBF 
responses and the contribution of possible CSDs to NMDA-induced cortical hyperemia. 
Anesthesia was induced with pentobarbital (50-60 mg/kg ip.) and minimally 
supplemented by -chloralose (Sigma, St. Louis, MO; 5-10 mg/kg iv.) only when needed (in 
2 animals). These anesthetics were chosen because they are known to have no influence on 
CSD generation and propagation (Kitahara et al. 2001; Kudo et al. 2008). In addition to the 
blood gas parameter measurements, end-tidal CO2 levels were also continuously monitored 
using a capnometer (Micro-Capnograph CI240, Columbus Instrument, Columbus, OH). The 
cranial window consisted of the same kind of stainless steel ring with three needle ports as in 
the previously described experiments; however, it was sealed with Parafilm (American 
National Can, Greenwich, CT) instead of glass cover slips through which a laser-Doppler 
probe (referred to as probe 1) and a DC electrode were guided onto the brain surface. 
Following surgery, this closed window was filled with aCSF. For the placement of Doppler 
probe 2, a hole was drilled 5-8 mm anterior to the window (distance between the two probes 
was ~9-13 mm) and the dura was removed. The Doppler probes were mounted on 
micromanipulators and positioned so that they touched the surface of the brain, avoiding 
larger pial vessels. CoBF was monitored and recorded using a two-channel laser-Doppler 
flowmeter (Periflux 4001 master, Perimed, Sweden). Data were analyzed offline. The fibre 
separation of the Doppler probes used was 0.25 mm. Using this fibre separation in brain 
tissue, most of the recorded signal is reflected from a ~200 m depth (Jakobsson and Nilsson 
1993). Therefore, any interference from the other, ~10 mm distant light source was 
negligible. For the measurement of DC potential changes in response to topically applied 
NMDA, an Ag-AgCl electrode (1 mm diameter) was positioned on the brain surface under 
the cranial window and was connected to a DC amplifier (DAM 50, Differential Amplifier, 
World Precision Instruments, Sarasota, FL). The reference platinum electrode (Grass, Astro-
Med, West Warwick, RI) was fixed in the neck muscles. 
 
Drugs 
 
VIP (Sigma Chemical Co., St. Louis, MI, USA), PACAP38, PACAP27, PACAP6–38, 
PACAP6–27, PACAP1-15, PACAP6-15, and PACAP20-31 (Department of Medical 
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Chemistry, University of Szeged, Hungary) were prepared as stock solutions in saline (10-4 
M) and, before use, were diluted with aCSF (10-9 to 10-5 M). Indomethacin (Merck & Co, 
Whitehouse Station, NJ) and L-NAME (Sigma Chemical Co.) were dissolved in saline (30 
mg/ml and 10 mg/ml, respectively). NS-398 (Sigma Chemical Co.) and SC-560 (Sigma 
Chemical Co.) were dissolved in dimethyl sulfoxide (DMSO, 5 mg/ml) and further diluted 
with saline to 1 ml. NMDA (Sigma Chemical Co.) was dissolved in aCSF (10-5 to 103 M). 
PX-18 (Dept. of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Freie Universität 
Berlin, Germany) formulated as drug nanosuspension with an active content of 3% (w/w) 
applying high pressure homogenization. PX-18 nanosuspension was further diluted in aCSF 
to a concentration of 10-8 to 10-4 M. A 1% (w/w) Tween 80 solution isotonized with glycerol 
85% served as vehicle control of the experiments where PX-18 was used. 
 
Protocol and experimental groups 
 
Time control experiments were executed first to obtain arteriolar responses to PACAP 
isoforms and VIP initially and then 20 min after vehicle (1 ml of intravenous saline, or 
diluted DMSO) treatment. This procedure allowed us to test PACAP/VIP-induced caliber 
changes and identify the presence of potential tachyphylaxis or sensitization. In groups 1, 2, 
and 3; PACAP38 (n=9), PACAP27 (n=7), or VIP (n=8) was applied repeatedly onto the brain 
surface at 10-8-10-7-10-6 M concentrations cumulatively. Moreover, we compared the efficacy 
of the two PACAP isoforms on the same subjects; in group 4 (n=9) PACAP38 and PACAP27 
were applied alternately with a 40-minute delay. 
The second set of our experiments was designed similarly, with one modification. 
Between the first and the second topical application of the respective vasodilator peptide, a 
COX enzyme blocker was administered intravenously. In groups 5-7, we examined the 
responses of pial arterioles to PACAP38 (n=9), PACAP27 (n=10), or VIP (n=7) before and 
after intravenous administration of the non-selective COX inhibitor indomethacin (5 mg/kg). 
The effect of the selective COX-1 inhibitor SC-560 (1 mg/kg) was tested in groups 8 (n=9) 
and 9 (n=6) on PACAP38 and VIP induced vasodilation, respectively. In groups 10 (n=9) and 
11 (n=7), the effect of selective COX-2-inhibition by NS-398 (1 mg/kg iv.) was analyzed on 
the above mentioned processes. 
In group 12 (n=5), pial arteriolar reactivity was determined for local PX-18 
nanosupension (10-8 to 10-5 M) and prior to PX-18, for its vehicle in the corresponding 
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dilutions. In Group 13 (n=7), vasodilation was determined to 10-6 M PACAP38 before and 
after local treatment with PX-18 nanosuspension (10-5 M, 20 min). 
In the next series of experiments, the brain surface was exposed to the vasoactive 
neuropeptides before and after the inhibition of the NOS enzyme. In groups 14 and 15, 
vasodilation to PACAP38 (n=13) or PACAP27 (n=7); in group 16, vasodilaton in response to 
VIP (n=8) was tested before and after parenteral L-NAME (15 mg/kg iv.) administration. 
In groups 16-20 arteriolar responses to short PACAP fragments were measured 
(PACAP6-38, PACAP6-27, PACAP1–15, PACAP6–15, and PACAP20–31 with n=4 in each 
subgroup, respectively). Each of the peptides was applied in ascending concentration manner 
(108-107-106 M cumulatively). Additionally, we determined the effect of these short 
fragments on PACAP38 and PACAP27-induced vasodilation. In these experiments we co-
applied short PACAP sequences to examine their effects on vascular reactions evoked by the 
entire PACAP segments. First 106 M of PACAP38 or PACAP27 was used topically. 
Following a ~30-minute exposure-free period, when arterioles regained stable baseline 
diameters, one short segment was applied onto the brain surface in a tenfold (10-5M) 
concentration for 10 min. Next, we co-applied PACAP6–38, PACAP6–27, PACAP1–15, 
PACAP6–15, or PACAP20–31 with PACAP38 (groups 21, 24, 27, 29 and 31) or PACAP27 
(groups 22, 25, 28, 30, and 32; n=5 in each subgroups) for a subsequent 5 min. Pial arteriolar 
dilation to 10-6 M VIP was also determined before and after 20 min topical application of 
PACAP6-38 (group 23, n=6, 10-5 M) or PACAP6-27 (group 26, n=7, 10-5 M). 
In the final experiments, the effect of global cerebral I/R (10 min of ischemia followed 
by 1 h of reperfusion) was tested on CO2- and NMDA-induced vasodilation, with or without 
PACAP38, PACAP27 or VIP treatment. Prior to the induction of ischemia, the brain surface 
was incubated for 30 min with vehicle (aCSF, groups 33 and 37, n=6-6), 10-8 M PACAP38 
(groups 34 and 38, n=6-6), 10-8 M PACAP27 (groups 35 and 39, n=6-6), or 10-9 M VIP 
(groups 36 and 40, n=8-6). Pial arteriolar caliber changes to 5 and 10% CO2 ventilation 
(groups 33-36), or to topical, 10-4 M NMDA (groups 37-40) were measured before the 
pretreatments and after 1 h of reperfusion. We performed additional experiments on 4-4 
animals in groups 40b and 40c to test whether a higher (10-8 M) dose of VIP can protect 
NMDA-induced vasodilation after I/R. In group 40b we used the NMDA at 10-4 M 
concentration similar to the original experiments, while in group 40c we tested if the vascular 
response to a lower, 10-5 M and 5x10-5 M concentration of NMDA can be protected by VIP 
(10-8 M) after I/R. The effects of the same PACAP38, PACAP27 or VIP pretreatments in the 
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absence of I/R were also tested on the vasodilation evoked by hypercapnia (groups 41-43, 
n=6-5-6) or by NMDA (groups 44-46, n=5-7-5), respectively. 
In additional experiments (group 47, n=5) we tested, whether NMDA induces CSD in the 
piglet. The effects of topical NMDA (10-4 and 10-3 M) on CoBF were determined. The brain 
surface was exposed to each NMDA concentration for 10 minutes after which this stimulus 
was removed with aCSF. DC potential and CoBF recording continued for an additional 20 
minutes. At least 30 minutes after the removal of the highest dose of NMDA, we attempted to 
evoke CSDs using repeated pinpricks (26 G needle, 1-2 mm in depth) as a mechanical 
stimulation. CoBF and DC potential were recorded in a 30-minute period following each 
pinprick.  
 
Statistical analysis 
 
Pial arteriolar diameters were determined under baseline conditions and then at each 30 
seconds during application of vasodilator stimuli. Results are presented as the maximal 
vasodilation maintained for at least 1 minute, and expressed as % changes from 
corresponding baseline diameters. CoBF was recorded in arbitrary perfusion units. The 
biological zero was subtracted from the absolute values and CoBF data were normalized to 
the average flow of 5 minutes prior to drug application. Maximal CoBF response was 
determined occurring over a one minute interval. The pial artery diameter and CoBF data 
were analyzed with statistical software (SigmaStat, Systat Software Inc., San Jose, CA, USA) 
using one-way repeated measures ANOVA. For post hoc analysis Tukey`s test was 
performed where appropriate. Values of p<0.05 were considered significant. Data are 
reported as mean±SEM. 
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Figure 1. Experimental protocol. 
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Results 
 
Physiological variables 
 
MABP values were always within the range characteristic for anesthetized newborn 
pigs. In each animal, care was taken to avoid any fluctuation in MABP during recordings so 
as to prevent effects of short-term changes in arterial pressure on vascular diameters. 
Additionally, the blood pressure of the animals did not differ significantly between groups, 
for example, in control groups 33 and 37, MABP values were 70±3 mm Hg and 
69±3 mm Hg, respectively. Body temperature, arterial pH, and blood gases were kept in the 
normal ranges as well and did not vary significantly among the different groups or throughout 
the experiments, except pH and CO2 levels in groups where hypercapnia was induced. In 
group 33, for instance, core temperature was 37±0.2 °C, pH was 7.43±0.03, pCO2 was 
38±2 mm Hg, and pO2 was 91±5 mm Hg under baseline conditions. In group 41, where 
ventilation parameters were set to reach the normal end tidal CO2 value of 5% (40 mm Hg), 
pH was 7.41±0.01, and arterial oxygen tension was 88±4 mm Hg. 
Graded (5 and 10%) hypercapnia significantly elevated the arterial pCO2 levels in all 
experimental groups where CR to hypercapnia was tested (groups 27-30). The pCO2 changes 
were similar before and after I/R and between groups. For instance, in group 36, 5 and 10% 
CO2 elevated pCO2 from 34±2.5 to 52±2.1 and 79±5 mm Hg and from 37±2.7 to 56±2.7 and 
84±5.9 mm Hg before and after I/R, respectively. The respective pO2 levels were 
90±5.9-94±6.4-94±7.4 and 90±7.6-89±5.8-88±4.2 mm Hg in this group and were similar in 
all groups. 
There were no significant differences between the baseline arteriolar diameters during 
experiments and among experimental groups. For example, in group 3, mean pial arteriolar 
diameters were 92±3 m and 95±5 m before the first and the second VIP application, 
respectively. Similarly, in the experiments where CoBF was measured (group 41), raw 
baseline laser-Doppler flowmetry data (in arbitrary perfusion units; PU) did not shift 
considerably over the course of experiments. Baseline perfusions under the window were 
163±16 PU and 160±28 PU in group 41, before the first and the second NMDA-application 
onto the brain surface, respectively. Flushing of the brain surface with aCSF did not affect the 
pial arteriolar diameter or the CoBF significantly. 
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Effects of PACAP38, PACAP27, and VIP on pial arteriolar diameter 
 
Topical application of PACAP38 (group 1) and PACAP27 (group 2) resulted in similar, 
concentration-dependent (108 to 106 M), reproducible pial arteriolar dilation (Figure 2). 
Indeed, PACAP38 and PACAP27 produced equally prominent vascular changes compared in 
the same animals (group 4, 43±7% vasodilation to 106 M PACAP38 and 36±5% 
vasodilation in response to 106 M PACAP27). Topically applied VIP also induced dose-
dependent, reproducible pial arteriolar dilation at 10-8 to 10-6 M concentrations (group 3, 
Figure 2). However, VIP was significantly more potent than either PACAP38 or PACAP27, 
since even the lowest, 10-8 M concentration of VIP evoked significant, 16±3% dilation, while 
PACAP isoforms were vasoactive only at higher, 10-7-10-6 M doses (Figure 2). 
 
Effects of COX enzyme inhibitors on PACAP38-, PACAP27-, and VIP-induced pial arteriolar 
dilation 
 
The non-selective COX enzyme inhibitor indomethacin (5 mg/kg iv.) apparently 
abolished the vasodilator effect of 10-8-10-7-10-6 M PACAP38 (group 5). In contrast, 
PACAP27-induced dilation remained completely intact after indomethacin treatment (group 
6) at all concentrations used. Interestingly, VIP-induced vasodilation was only partially 
COX-dependent, since administration of indomethacin blocked the vasodilation evoked by 
the lowest (10-8 M) dose of VIP, but COX-inhibition was not effective when 10-7, or 10-6 M 
VIP was applied (Figure 2). 
In group 8, the selective COX-1 blocker SC-560 (1 mg/kg iv.) completely eliminated 
the diameter changes evoked by 10-8-10-7-10-6 M PACAP38, similarly to indomethacin. 
SC-560 also mimicked the effect of indomethacin on VIP-induced vasodilation (group 9). 
SC-560 treatment abolished the pial arteriolar reactions in response to 10-8 M, but not to 10-7 
and 10-6 M VIP (Figure 2.). 
Importantly, the selective COX-2 inhibitor NS-398 (1 mg/kg iv.) failed to exert any 
inhibitory effect on either PACAP38- or VIP-induced vasodilation (groups 10 and 11, 
Figure 2). 
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Effect of PLA2 inhibition on PACAP38-induced pial arteriolar dilation 
 
PX-18 nanosuspension or its vehicle did not induce significant increase in pial 
arteriolar diameters when applied locally at 10-8 to 10-5 M concentrations (group 12). Mean 
arteriolar diameters were 86±6 m and 88±8 m before and after 10-5 M PX-18 application, 
and 86±6 m and 89±5 m before and after vehicle (at the respective concentration) 
administration onto the brain surface. PACAP38 (10-6 M) elicited robust pial arteriolar 
vasodilation in group 13, that was reduced by PX-18 from 67±11% to 24±6%*. 
 
Effects of NOS enzyme inhibition on PACAP38-, PACAP27-, and VIP-induced pial arteriolar 
dilation 
 
The inhibition of NOS enzyme by L-NAME (15 mg/kg, iv.) had no significant effect 
on PACAP/VIP-induced vascular reactions. PACAP38, PACAP27, and VIP elicited similar 
dilation of pial arterioles before and after L-NAME treatment (Figure 2). 
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Figure 2. Effects of different enzyme inhibitors on PACAP38-, PACAP27-, and VIP-
induced pial arteriolar dilation. Topical PACAP38, PACAP27, and VIP elicited dose-
dependent, reproducible increases in pial arteriolar diameters. The non-selective 
cyclooxygenase (COX) inhibitor abolished pial arteriolar dilation to PACAP38, whereas it 
left vasodilation to PACAP27 intact at all concentrations applied. VIP-induced vasodilation 
was indomethacin-sensitive at 10-8 M, but not at 10-7 and 10-6 M concentrations. Inhibition of 
COX-1 enzyme by SC-560-treatment resembled the effect of indomethacin; it abolished both 
PACAP38 (10-8 to 10-6 M) and 10-8 M VIP-induced pial arteriolar dilations. In contrast, the 
COX-2-inhibitor NS-398, or the nitric oxide synthase (NOS)-inhibitor L-NAME did not 
influence either PACAP- or VIP-evoked vascular caliber changes. (Data are mean+SEM, 
n=6–10, *p <0.05 significantly different from vasodilation in response to aCSF, †p <0.05 
significantly less than corresponding values before treatment.) 
 
 
Effects of various length PACAP fragments on pial arteriolar diameter 
 
In contrast to PACAP38, PACAP27, and VIP, PACAP fragments did not display any 
vasoactivity, even when repeatedly applied (groups 16-20). Percent changes in diameters to 
the highest (10-6 M) concentration used were: 1±1 and 2±2 to PACAP6–38 and PACAP6–
27; 2±3, 0±0 and 2±1 to fragments PACAP1–15, PACAP6–15, and PACAP20–31, 
respectively, during the first application. The vascular responses were 1±1% and 1±1% to 
PACAP6–38 and PACAP6–27, 2±2%, 0±0% and 1±1% to fragments PACAP1–15, 
PACAP6–15, and PACAP20-31, respectively, during the second application. 
 
Effect of co-application with PACAP fragments on PACAP38, PACAP27, and VIP-induced 
pial arteriolar dilation 
 
In comparison to the control values, arteriolar dilations to PACAP38 or PACAP27 
showed statistically significant decreases when these peptides were co-applied with 
PACAP6–38 or PACAP6–27 (groups 21-22 and groups 24-25, respectively). PACAP6-38 
(10-5 M) pretreatment effectively diminished VIP-induced vasodilation (group 23, 62±10% 
and 33±6%* vasodilation in response to 10-6 M VIP, before and after PACAP6-38); however, 
in group 26, PACAP6-27 (10-5 M) failed to exhibit any inhibitory effect on the VIP-related 
pial arteriolar dilation (61±12% and 66±11% changes in diameter before and after topical 
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PACAP6-27 treatment). The other applied short segments (PACAP1–15, PACAP6–15, and 
PACAP20–31) did not affect either PACAP38 or PACAP27-induced vasodilation (Figure 3). 
 
 
 
 
Figure 3. Effects of PACAP fragments on PACAP38-, PACAP27-, and VIP-induced pial 
arteriolar dilation. PACAP6-38 (10-5 M) pretreatment effectively decreased the PACAP38-, 
PACAP27-, and VIP (10-6 M)-induced vasodilation. PACAP6-27 (10-5 M) also inhibited the 
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pial arteriolar dilation in response to PACAP38 and PACAP27 (10-6 M); however, it failed to 
exhibit any inhibitory effect on the VIP (10-6 M)-related vasodilation. PACAP1–15, 
PACAP6–15, and PACAP20–31 (10-5 M) failed to alter either PACAP38- or PACAP27 
(10-6 M)-induced vascular responses. (Data are mean+SEM, n=5-7, *p <0.05 significantly 
less than corresponding values before the co-application.) 
 
 
Effects of PACAP38, PACAP27, and VIP pretreatment on pial arteriolar responsiveness to 
CO2 after I/R 
 
Graded hypercapnia (5-10% CO2 ventilation) resulted in large, dose-dependent, 
reversible increases in pial arteriolar diameters. In vehicle-treated animals (group 33), I/R 
severely attenuated the hypercapnia-induced arteriolar vasodilation (Figure 4, left). 
Incubation of the brain surface with PACAP38 (10-8 M), PACAP27 (10-8 M) or VIP (10-9 M) 
for 30 minutes did not affect the diameter of pial arterioles significantly (2±1%, 2±1%, and 
3±1% maximal dilation in response to PACAP27, PACAP38, and VIP, respectively); 
however, they efficiently preserved CR to both levels of hypercapnia after I/R (groups 34, 35, 
and 36; Figure 4, left). 
 
Effects of PACAP38, PACAP27, and VIP pretreatment on pial arteriolar responsiveness to 
NMDA after I/R 
 
Topical application of NMDA (10-4 M) induced a marked vasodilation that was also sensitive 
to I/R (group 37, Figure 4, right). PACAP38 (10-8 M) or PACAP27 (10-8 M) pretreatment of 
the brain surface effectively preserved the NMDA-evoked pial arteriolar dilation after I/R, 
whereas incubation of the brain surface with 10-9 M VIP was not protective (groups 38, 39, 
and 40; Figure 4, right). Furthermore, a higher dose of VIP (10-8 M, group 40b) was still 
unable to preserve CR to 10-4 M NMDA reduced by I/R. CR values were 36±12% vs 51±6% 
(vehicle vs VIP, CR expressed as a percentage of the preischemic response). In group 40c, 
lower, 10-5 M and 5x10-5 M concentrations of NMDA also dilated the pial arterioles with 
4.4±0.2% and 12.6±0.4%*, respectively. I/R reduced these vascular reactions significantly, 
and moreover, a tendency towards vasoconstriction was observed after I/R (-2±3% and 
-3±4% changes in diameter to 10-5 M and 5x10-5 M NMDA), irrespectively of the VIP 
(10-8 M) treatment. 
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Figure 4. Effects of ischemia-reperfusion (I/R) on hypercapnia- or NMDA-induced pial 
arteriolar vasodilation. Arteriolar responses to 5-10% CO2 ventilation and topical NMDA 
were recorded before and after 10 min of global cerebral ischemia followed by 1 h of 
reperfusion. Hypercapnia elicited dose-dependent pial arteriolar dilation, which was 
markedly attenuated after I/R in vehicle-treated piglets. PACAP isoforms and VIP preserved 
vascular responsiveness to CO2. Vasodilation in response to 10-4 M NMDA was also 
deteriorated after I/R. PACAP38 and PACAP27, but not VIP, protected the vasodilator effect 
of NMDA. (Data are mean±SEM, n=6–8, *p<0.05.) 
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Effects of PACAP38, PACAP27, and VIP treatment on CO2- and NMDA-induced pial 
arteriolar dilation 
 
Topical PACAP38 (10-8 M), PACAP27 (10-8 M) or VIP (10-9 M) treatment alone did not 
affect the vasodilation induced by either hypercapnia or NMDA. Vascular responses to 10% 
CO2 were 63±5% and 64±6% before and after PACAP38 (group 41), and 50±2% and 57±7% 
before and after PACAP27 (group 42) incubation. Topical NMDA (10-4 M) evoked 37±5% 
and 43±7% vasodilation before and after PACAP38, and 36±7% and 33±5% vasodilation 
before and after PACAP27 application (groups 44 and 45). Responses to 10% CO2 were 
60±9% and 56±11% (group 43), and to 10-4 M NMDA were 49±7% and 48±7% (group 46), 
before and after VIP treatment. Accordingly, the protective effects of the tested neuropeptides 
are not caused by direct facilitation of the vascular reactivity to hypercapnia or to NMDA. 
 
NMDA elicits dose-dependent CoBF increase without generating CSD in the piglet 
 
Topical application of NMDA (group 47) produced concentration-dependent 
increases in CoBF as recorded with Laser-Doppler flowmetry under the cranial window 
(Figure 5). The pattern of the CoBF responses was not consistent with those seen during CSD 
(Ayata and Moskowitz 2006; Lenti et al. 2009). Also, we did not detect significant CoBF 
changes at the second, distant registration site outside the window (3±2% and 2±1% to 10-4 
and 10-3 M NMDA) verifying that no CSD propagated from the site of NMDA application. 
The DC potential decreased gradually (by 5-10 mV) and returned to the baseline level in ~2-3 
minutes after removal of the NMDA with aCSF.  
Local activation of cortical neurons with “pinpricks” using a sterile needle, although 
sufficient to cause CSD in other models, also failed to initiate CSD (0/5 animals) or 
significantly change CoBF in piglets (3.2±1.2% in response to the first pinprick). 
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Figure 5. NMDA evoked dose-dependent cortical blood flow (CoBF) increases without 
generating cortical spreading depression (CSD) in newborn pigs. Left panel: 
NMDA (10-3 M) application onto the cortex elicited a transient CoBF increase (CoBF 1) and 
a prolonged direct current (DC) potential deflection registered under the window; however, 
propagation of the CoBF response was not detected with the distant probe (CoBF 2, 
representative recording). On the time axis the 0 time point indicates the beginning of drug 
application onto the brain surface. The stimulus was removed 10 minutes later, when the 
window was flushed with artificial cerebrospinal fluid. Right panel: Average CoBF change 
per minute was calculated during a 10-minute period of drug application. Bars represent the 
maximal CoBF changes under the window, within the examined time interval. Artificial 
cerebrospinal fluid did not produce significant CoBF changes, while topical NMDA (10-4 and 
10-3 M) increased CoBF in a concentration-dependent manner. (Data are mean±SEM, n=5, 
*p<0.05.) 
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Discussion 
 
The major findings of the present studies were the following: 
 
1. Both PACAP38 and PACAP27 were similarly potent dilators of pial resistance 
vessels in newborn pigs. VIP also evoked concentration-dependent, reproducible pial 
arteriolar dilation; however, it was more potent than either of the natural PACAP isoforms. 
2. PACAP38-induced vasodilation was abolished by indomethacin and the selective 
COX-1 inhibitor SC-560, but not by the selective COX-2 inhibitor NS-398. In contrast, 
PACAP27 evoked vasodilation independently of COX activation. The effect of VIP on the 
pial vasculature resembled that of PACAP38 at low, but PACAP27 at higher concentrations; 
since arteriolar dilation was blocked by indomethacin and SC-560 only when VIP was 
applied at the lowest, 10-8 M dose (Table 1). There was also a significant decrease in 
PACAP38-induced vasodilation when PX-18, the soluble PLA2 blocker was administered 
locally. Interestingly, NOS activity did not appear to play a significant role in the dilatory 
effect of either PACAP or VIP. 
3. The short PACAP sequences were not vasoactive per se, but both PACAP6–38 and 
PACAP6–27 inhibited the vasodilation induced by PACAP38 or PACAP27. VIP-induced 
vasodilation was attenuated only by PACAP6-38, but not by PACAP6–27. 
4. I/R deteriorated CR to both hypercapnia, an endothelial function-dependent, and 
NMDA, a neuron-dependent stimulus. PACAP38, PACAP27, and VIP prevented the 
attenuation of hypercapnia-induced vasodilation caused by I/R; however, PACAP38 and 
PACAP27, but not VIP preserved NMDA-induced vasodilation. 
5. NMDA induced dose-dependent CoBF increases in the piglet measured by 
Laser-Doppler flowmetry. NMDA-evoked CSDs did not contribute to this integrated CoBF 
response. Moreover, we were unable to evoke CSDs even with mechanical stimulation of the 
cortex. 
One remarkable property of PACAP and VIP is their ability to relax cerebral arteries 
both in vitro and in vivo (Suzuki et al. 1984; Seki et al. 1995; Edvinsson and Krause 2002). 
This effect is probably of physiological relevance since nerve fibers containing PACAP and 
VIP have been demonstrated in the adventitia and adventitia-media border of cerebral arteries 
from different species (Uddman et al. 1993; Fahrenkrug et al. 2000). Moreover, PACAP and 
VIP were detected by immunohistochemistry in cell bodies of autonomic ganglia and also, 
cortical and brainstem neurons (Edvinsson and Krause 2002; Drake and Iadecola 2007). 
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Receptors for PACAP and VIP have been identified in practically all cell types of the central 
nervous system in numerous species including humans. Knutsson and Edvinsson detected 
mRNA of all three (VPAC1, VPAC2, and PAC1) receptor types in human cerebral ganglia and 
arteries (Knutsson and Edvinsson 2002). The expression of the receptor mRNA remained 
unaltered after removal of the endothelium. In rats, VPAC1 receptor immunoreactivity was 
found in the smooth muscle cell layer of the superficial cerebral arteries and arterioles 
(Fahrenkrug et al. 2000); however, VIP/PACAP receptors were also found on neuroglia as 
well as on neurons (Joo et al. 2004). Previous functional studies in rat cerebral arteries 
demonstrated that the vasorelaxant effects of PACAP38 and VIP are not impaired in 
endothelium-denuded arteries (Lee et al. 1984; Gaw et al. 1991; Anzai et al. 1995). In porcine 
coronary arteries, PACAP38 and PACAP27 were also found to be endothelium-independent 
relaxing factors (Kastner et al. 1995). On the contrary, beside VSM VPAC2 receptors, 
functioning endothelial VPAC1 receptors were detected in the porcine basilar artery by Grant 
et al (Grant et al. 2006). Unfortunately, no data exist on the expression of these receptors in 
the newborn pig. 
Previous studies in piglets have shown that PACAP38 and PACAP27 dilate pial 
arterioles in a dose-dependent manner, and that the dilator capabilities of these peptides are 
very similar in this animal model (Tong et al. 1993). In piglets, the observed vascular caliber 
changes to PACAP38 and PACAP27 have been associated with elevated cortical 
periarachnoid CSF cAMP concentration (Tong et al. 1993; Armstead 1997). Both PACAP38, 
and PACAP27 increase cAMP level in rat cerebral microvessels (Kobayashi et al. 1994), and 
also, VIP was found to stimulate cortical cAMP formation in mammals (Dejda et al. 2004). 
PACAP and VIP are thought to exert a significant direct effect on the VSM of pial resistance 
vessels: activation of PACAP/VIP receptors on smooth muscle cells increases intracellular 
cAMP production resulting in cerebrovascular vasodilation (Dickson and Finlayson 2009). 
Additionally, the pial arteriolar dilation produced by PACAP27 can be blocked by 
iberiotoxin, a potent antagonist of the KCa channels, but unaltered by the KATP channel 
inhibitor glibenclamide (Armstead 1997). Other indirect pathways of PACAP-induced 
dilation are also possible. 
Our present results confirm that PACAP38, and PACAP27 are similarly potent pial 
arteriolar dilators in the newborn pig; however, in our model, VIP proved to be more potent 
than either of the PACAP isoforms. The caliber changes evoked by all these peptides were 
apparently dose dependent, and more importantly, these responses were reproducible over 
time. Although tachyphylaxis to either PACAP or VIP was observed in some experimental 
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models (Edvinsson and Krause 2002), this desensitization was absent when employing the 
piglet, using our protocol. This reproducibility allowed us to perform pharmacological 
experiments concerning the evaluation of mechanisms in the background of vasodilation. 
One of the most interesting findings of our work was that PACAP38-induced 
vasodilation was extremely indomethacin sensitive, in contrast to the effect of PACAP27. 
Vasodilation to 10-8 M VIP resembled the vasodilator effect of PACAP38 characterized by 
indomethacin-sensitivity. In contrast, at 10-7-10-6 M VIP concentrations, the response was 
unaffected by COX-inhibition, similar to PACAP27 (Table 1). Correspondingly, VIP dilates 
the isolated porcine ophthalmic artery via COX-mediated mechanisms only at lower 
(10-10-10-9 M), but not at higher (10-8-10-7 M) VIP concentrations (Vincent 1992). 
VIP-induced pial arteriolar vasodilation is also indomethacin-sensitive in cats (Wei et al. 
1980), whereas we are not aware of studies where PACAP-induced cerebrovascular dilation 
was reduced by COX-inhibition. 
By dissecting the role of the two COX isoforms in the PACAP38- and VIP-induced 
response using selective COX-1 and COX-2 inhibitors we found that administration of 
SC-560 virtually abolished the PACAP38-, as well as the low-dose VIP-elicited arteriolar 
dilation, while these vascular reactions remained unchanged after NS-398 treatment. These 
data suggest that COX-1 derived prostanoids are substantially involved in PACAP38 
dependent, and only partially involved in VIP-dependent vascular caliber changes, while the 
role of the COX- 2 enzyme seems to be ancillary. The importance of COX-derived 
prostanoids in the cerebrovascular control of newborns is well established, however, there are 
many open questions related to the functional significance of the two distinct COX isoforms. 
In the piglet brain, COX-2 is the dominant constitutive enzyme. Unlike COX-1, COX-2 
mRNA is expressed abundantly in the cerebral cortex and microvasculature, and this isoform 
comprises the main part of the total COX protein level here. Moreover, data show that 
COX-2 contributes approximately 80–90% to the central nervous system prostanoid levels in 
the newborn; as NS-398, a specific COX-2 inhibitor, produces great decrease in the overall 
prostanoid synthesis during both basal and certain stimulated conditions. The remnant 
10-20% is attributed to the activity of the COX-1 enzyme (Peri et al. 1995; Parfenova et al. 
1997). In concert with these observations, other functional studies found that COX-dependent 
vascular reactions (such as hypotension-induced vasodilation or Ach-induced 
vasoconstriction) appear to depend largely on COX-2 activity (Domoki et al. 2005b), while to 
the best of our knowledge our studies are the first to demonstrate COX-1 dependent 
vasoactive mechanisms in the pial vasculature of piglets. 
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Surprisingly, the involvement of NOS activity in PACAP- and VIP-induced 
vasodilation has not been supported by our experiments with L-NAME, despite numerous 
anatomical and functional studies suggesting otherwise in other species. In the human and rat 
parasympathetic and trigeminal ganglia high numbers of nerve cell bodies containing both 
NOS and PACAP were visualized by fluorescent immunohistochemistry (Tajti et al., 1999; 
Uddman et al., 1999; Edvinsson et al., 2001). Activation of nitrergic neurons, at least in part, 
plays a role in the PACAP-induced vasorelaxant mechanism in isolated rat basilar arteries 
(Seebeck et al., 2002). The inhibition of NO production results in tachyphylaxis to PACAP27 
in rat mesenteric and abdominal aortic artery (Whalen et al., 1999). Involvement of NOS 
activity in VIP-induced vasodilation was also reported in a number of adult animal models 
(Gaw et al. 1991; Grant et al. 2006). 
However, there may be significant differences between the cerebrovascular regulatory 
processes seen in newborns and in adults. In the piglet, several former studies demonstrated 
marked age-related changes in the cerebrovascular regulation, predominantly in the 
NO-mediated responsiveness. The expression and activity of NOS in newborn and adult pigs 
are different: NOS enzyme level as well as NOS activity increases during maturation, while 
e.g. the COX expression and activity remain constant (Parfenova et al. 2000). This 
phenomenon results in the predominance of prostanoids over NO in the newborn period and 
gives a possible explanation of our results. Since neither COX nor NOS inhibition had any 
effect on PACAP27 (10-8-10-6 M) and VIP (10-7-10-6 M)-induced vasodilation, PACAP27 and 
VIP probably exert a robust direct effect on vascular smooth muscle cells at these doses. 
In any pharmacological study, the specificity of the used drugs limits the 
interpretation of the results. Indomethacin at the used dose was found to be a strong inhibitor 
of the prostanoid synthesis in many experiments in which its ability to block either COX-1 or 
COX-2 dependent mechanisms was investigated. The dose of NS-398 was chosen for similar 
reasons since it proved to be a selective and effective inhibitor of the COX-2 enzyme 
(Domoki et al. 2005b). The COX-1 activity was targeted with SC-560. In piglets, our 
laboratory was the first (and to the best of our knowledge the only) where SC-560 was used 
in vivo (Domoki et al. 2005b), though in that series of experiments none of the assessed 
vascular reactions appeared to be COX-1 dependent. On the other hand, other investigators 
found this dose effective in blocking the COX-1-mediated prostaglandin production in the rat 
brain, even after COX-1 gene transfer (Lin et al. 2002). However, SC-560 is known to act, at 
least in some cell types, as an unselective COX enzyme blocker (Brenneis et al. 2006). In our 
model, PACAP38 may act on a particular cell type in which SC-560 has the potential to 
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block both COX-1 and COX-2, such as indomethacin. Nonetheless it seems to be more likely 
that PACAP38 (and VIP at low concentration) uniquely activates COX-1 present in small 
amounts inducing the synthesis of such vasodilator prostanoids as prostacyclin or PGE2 that 
stimulates cAMP formation by VSM resulting in vasodilation (Parfenova et al. 1995). The 
effectiveness of PLA2-inhibition on PACAP38-induced caliber changes seems to support this 
concept as well. The selected dose of L-NAME (15 mg/kg iv) was also reported to provide 
appropriate NOS inhibition in former studies (Lacza et al. 2002). 
 
 
 PACAP38 
10-8-10-6M 
PACAP27 
10-8-10-6M 
VIP 
10-8M 
VIP 
10-7-10-6M 
COX-1 + - + - 
COX-2 - - - 
NOS - - - 
 
Table 1. Summary of the effects of different cyclooxygenase (COX) and nitric oxide 
synthase (NOS) enzyme inhibitors on PACAP38-, PACAP27-, and VIP-induced 
vasodilation. The non-selective COX-inhibitor indomethacin and the selective 
COX-1-inhibitor SC-560 had remarkable inhibitory effect on PACAP38-induced 
vasodilation, and partially, on VIP-induced vasodilation. COX-2 inhibition by NS-398 or 
non-selective NOS-inhibition by L-NAME proved to be ineffective. 
 
 
The short PACAP sequences used in our experiments provide novel insight into the 
mechanism of PACAP- and VIP-induced vascular changes since their role has not been 
investigated in the cerebral circulation before. PACAP6-38 and PACAP6-27 were established 
as competitive VIP/PACAP receptor antagonists in other experimental models (Harmar et al. 
1998; Vaudry et al. 2000b). Our knowledge is limited on the degradation of PACAP in vivo, 
but PACAP6-27 can be an important endogenous inhibitor providing negative feedback since 
PACAP27 is rapidly degraded by dipeptidylpeptidase IV to produce PACAP6-27 among 
other metabolites in vitro (Green et al. 2006). 
The VIP/PACAP receptor antagonist PACAP fragments (PACAP6-38 and 
PACAP6-27) inhibited both PACAP38- and PACAP27-induced vasodilation, supporting 
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previous results; however, in our present study, only PACAP6-38 but not PACAP6-27 
attenuated VIP-induced vasodilation. PACAP6-38, unlike PACAP6-27, is often reported to 
be a selective blocker of the PAC1 receptor group (Edvinsson and Krause 2002), while others 
identify PACAP6-38 as a nonspecific VIP/PACAP antagonist (Harmar et al. 1998). Possibly, 
PACAP6-38 simply is a more potent inhibitor than PACAP6-27 on the VIP/PACAP 
receptors involved in VIP-induced vasodilation. Unfortunately, we are unaware of the 
existence of any widely accepted, subtype-selective VIP/PACAP receptor blockers that 
would be required to unveil the functional relevance of each receptor subtype in 
cerebrovascular and neuroprotective effects of these neuropeptides (Edvinsson and Krause 
2002). The other short fragments (PACAP1-15, PACAP6-15, and PACAP20-31) were 
designed only for mapping purposes, given that a short fragment is a much better starting 
compound for any further pharmacological development. These short PACAP fragments did 
not show any vasoactivity or inhibitory effects suggesting that they were not capable of 
sufficient binding to the VPAC/PACAP receptors. 
Considering the discrepancy between the probable signal transduction pathways 
related to PACAP isoforms and VIP, it seems feasible that these related peptides act on 
different cells or different subtypes of the PACAP/VIP receptor group. Currently this field is 
hampered by the lack of potent, subtype selective blockers necessary to reveal the functional 
relevance of VIP/PACAP receptor subtypes in the newborn cerebral circulation. 
A remarkable, novel finding of our studies is that PACAP and VIP exert a protective 
effect on the functional integrity of the neurovascular unit after I/R, adding a new mechanism 
of action to the diversity of neuroprotective mechanisms, fully consistent with the multiple 
pathways that are activated or inhibited by these peptides. 
In the piglet, hypercapnia evokes cerebral vasodilation not only in vivo (Leffler et al. 
1989a), but also in isolated, denervated vessels (Kokubun et al. 2009). Hypercapnia-induced 
vasodilation requires intact endothelium; however, the function of neuronal and glial 
components in this vascular response seems to be unneccessary. Based on these findings, I/R 
seems to reduce hypercapnia-induced dilation of pial arterioles through endothelial damage in 
piglets. Our data show that PACAP38, PACAP27, and VIP pretreatments are all capable to 
preserve hypercapnia-induced vasodilation after I/R even in non-vasoactive doses, indicating 
a decreased/shortened postischemic endothelial dysfunction by PACAP or VIP pretreatment. 
We are not aware of any studies in which similar protective effects of PACAP and VIP have 
been demonstrated on the cerebrovascular endothelium. Our results are in agreement with the 
findings of Lange et al., who demonstrated both the synthesis of VIP and the expression of 
37 
VIP receptor associated protein in microvascular endothelial cells of pial vessels in piglets 
(Lange et al. 1999), allowing a direct protective effect of both VIP and PACAP. The function 
of endothelial VIP production/effects is unclear, but an autocrine growth factor role involved 
in postnatal endothelial cell differentiation has been suggested. The exact mechanism of 
endothelial protection by PACAP and VIP is unclear and its exploration demands further 
experiments. 
The mechanism of NMDA-induced vasodilation has been extensively studied in 
numerous models including the newborn pig. NMDA-induced vasodilation is considered to 
be a neuronal-triggered multi-step process involving the activation of nNOS and production 
of NO that diffuses to the vascular smooth muscle, causing dilation of the pial arterioles 
(Meng et al. 1995; Domoki et al. 2002). The response has been shown to be susceptible to I/R 
as well as to asphyxia (Bari et al. 1996a; Busija et al. 1996a); however, the patomechanism of 
this decreased neuronal-vascular responsiveness is only partly understood. Most probably, the 
increased ROS-production-induced NMDA-receptor dysfunction is responsible for the altered 
CR to NMDA. This notion is supported by experiments where ROS scavengers like 
superoxide dismutase and oxypurinol preserved the pial arteriolar responsiveness to NMDA 
(Busija and Wei 1993; Bari et al. 1996a). NMDA-induced vasodilation was also unaltered 
when piglets were pretreated with indomethacin that further supports this presumption, since 
COX has been revealed as the main source of superoxide anions after I/R in the piglet 
(Domoki et al. 2001). Our present study clearly demonstrated that PACAP27 and PACAP38, 
but not VIP preserved CR to NMDA after I/R. This preservation seemed to be independent of 
the increase in cerebral blood flow mediated by vasodilation to PACAP38 or PACAP27. In 
fact, PACAP isoforms effectively preserved NMDA-induced vasodilation in non-vasoactive 
doses, whereas VIP was ineffective in even an equimolar, vasoactive dose. The reported 
antioxidant property of PACAP can be an important factor in the preservation of the NMDA-
receptor function, especially that an analogous antioxidant capacity of VIP is absent (Reglodi 
et al. 2004a). The PACAP-induced initiation of anti-apoptotic and anti-inflammatory 
mechanisms may also lead to increased general viability of the neurons. More specifically, 
PAC1 receptor stimulation leads to activation of Bcl-2/inhibition of Bad resulting in 
enhanced mitochondrial integrity/decreased release of apoptotic cytochrom c. Conceivably, 
preservation of mitochondrial function fastens the restoration of cellular ATP levels and also 
reduces postischemic ROS production. PACAP binding sites in the rat cerebral cortex are ten 
times more numerous as compared to VIP; this difference may also explain in part the higher 
general neuroprotective potency of PACAP (Masuo et al. 1991). Alternatively, PACAP 
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isoforms may act on PAC1 receptors expressed on a specific population of cortical neurons 
critically involved in NMDA-induced vasodilation. Furthermore, the differences observed 
between PACAP and VIP can be due to different signal transduction mechanisms coupled to 
PACAP and/or VIP-stimulated receptors in these cells. 
Two recent works have challenged the concept that glutamate- or NMDA-mediated 
dilator responses involve sequential stimulation of neuronal NMDA receptors, activation of 
nNOS in associated neurons, and direct relaxation of vascular smooth muscle by NO. First, 
Ayata and Moskowitz (Ayata and Moskowitz 2006) have reported that NMDA application 
elicits CSD which complicates the elucidation of mechanism involved in NMDA-induced 
cerebral vasodilation. Second, our laboratory had very similar observations in rats, although 
with detailed analysis of the blood flow response to NMDA, we found both CSD-dependent 
and CSD-independent components (Lenti et al. 2009). 
In our present work, we examined the effect of NMDA on CoBF in newborn pigs 
since NMDA-induced cortical hyperemia had not yet been studied in this species, although 
NMDA-induced pial arteriolar vasodilation had been extensively studied. The integrated 
CoBF responses to NMDA confirmed earlier results concerning the dose-dependent nature of 
microvascular responses to NMDA based upon measurements of pial arteriolar diameters in 
our model (Busija and Leffler 1989). Our results also provided novel evidence that the 
hemodynamic changes in response to NMDA were not consequences of CSD-related events 
in piglets, but rather represented a direct, specific effect on cortical neurons in this important 
experimental model (Busija et al. 2007). In contrast, cerebral vascular responses to NMDA 
are confounded by CSD-related hyperemia in mice (Ayata and Moskowitz 2006) and rats 
(Lenti et al. 2009). While CSD has been shown to occur in the mature brains of all 
mammalian species studied, the neonatal brain appears to be relatively resistant to generation 
of CSD. For example, the capacity of the developing cerebral cortex to respond to certain 
stimuli with CSD appears first between 24 and 30 days after birth in rabbits (Schade 1959) 
and some days earlier in the rat (Richter et al. 1998). This period is characterized by an 
increase in the neuron size and by branching of the axons (Schade 1959). However, 
morphological and structural state of the CNS may not adequately explain the decreased 
susceptibility of the immature brain to generating CSDs. The development of sodium and 
chloride channels such as the different expression of the NMDA receptor subunits in 
newborn and adult animals can be responsible for this phenomenon observed in the examined 
species (Takahashi 2005). In the piglet, we have not been able to induce CSD even with 
mechanical means (pinpricks) during the first days of life. Moreover, previous results of our 
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laboratory showed that locally applied, concentrated KCl solution also failed to evoke CSD 
(Domoki et al. 1999). The elevated threshold or incapability of the piglet brain to produce 
CSDs is probably due to this immaturity of the nervous system, rather than to a difference 
between species or differences between the lyssencephalic (mouse, rat, rabbit) and 
gyrencephalic (piglet, cat) brains, since CSD apparently can be evoked in the adult swine 
(Bowyer et al. 1999) and cats (Van Harreveld et al. 1956). 
 
Conclusions 
 
In conclusion, PACAP and VIP are powerful vasodilators in the newborn cerebral 
circulation. The actions of PACAP38, PACAP27, and VIP seem to be independent of NOS 
activation, but the COX-1 activity appears to be essential for PACAP38-induced 
vasodilation. The presumed activation of COX-1 by PACAP38 and the low dose of VIP is 
unique, since COX-2 is known to be the predominant COX isoform in the newborn central 
nervous system, and SC-560 did not affect the vasodilation in response to any other 
COX-dependent stimuli studied so far. 
PACAP38, PACAP27, and VIP all protected postischemic vascular reactivity to 
hypercapnia, an ischemia-sensitive indicator of endothelial function, in the newborn pig. 
However, PACAP isoforms but not VIP preserved the NMDA-induced neuron-dependent 
vasodilation. Although PACAP27, PACAP38, and VIP all induce dose-dependent pial 
arteriolar dilation, the protective effects of these neuropeptides were independent of their 
vasoactivity. This neurovascular protection probably supports the restoration of adequate 
perfusion of the brain tissue after I/R likely enhancing the direct neuroprotective effects of 
PACAP and VIP. 
NMDA elicited dose-dependent CoBF increases in piglets, similarly to previous data 
obtained by pial arteriolar diameter measurements. In piglets, the CoBF increase/pial 
arteriolar dilation seems to be solely the result of the local activation of neuronal NMDA 
receptors without the confounding effect of CSDs, unlike in adult rodents. 
Our results indicate that PACAP and VIP are markedly different in their respective 
vasodilator and protective actions, indicating that these neuropeptides may activate only 
partially overlapping mechanisms. Nevertheless, the protection of CR provided by PACAP 
and VIP may form the foundation of new neuroprotective strategies in the treatment of 
neonatal stroke. 
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Pituitary adenylate cyclase-activating polypeptide (PACAP) is a cerebrovascular dilator and
was found neuroprotective in numerous in vitro and in vivo models of cerebral ischemia.
However, the mechanism of its cerebrovascular action is poorly known, especially in
newborns. Therefore, we tested pial arteriolar responses to the two naturally occurring
forms PACAP27 and 38 as well as to shorter sequences (PACAP6–27, 6–38, 1–15, 6–15, 20–31).
We also investigated the involvement of nitric oxide synthase (NOS), cyclooxygenase-1 and
-2 (COX-1 and -2) activity in PACAP-induced pial arteriolar responses using the NOS inhibitor
N-ω-nitro-L-arginine methyl ester (L-NAME 15 mg/kg iv), the non-selective COX inhibitor
indomethacin (5 mg/kg iv), and the selective COX-1 and COX-2 inhibitors SC-560 (1 mg/kg iv)
and NS-398 (1 mg/kg iv), respectively. Anesthetized, ventilated piglets (n=127) were
equipped with closed cranial windows, and pial arteriolar diameters were determined via
intravital microscopy. Topical application of both natural PACAPs, but none of the PACAP
segments, resulted in prominent, repeatable, dose-dependent vasodilation. Percentage
changes ranged 5±1–29±6 (n=7) and 4±1–36±7 (n=9) to 10−8 to 10−6 M PACAP27 and 38
(mean±SEM), respectively. Vasodilation to both natural PACAPs was significantly reduced
by co-application with PACAP6–27 or 6–38, but not by L-NAME. Indomethacin abolished
PACAP38 but not PACAP27-induced vasodilation. Arteriolar responses to PACAP38 were also
sensitive to SC-560 but not to NS-398 suggesting the unique involvement of COX-1 activity in
this response. In summary, PACAP27 and 38 are potent vasodilators in the neonatal cerebral
circulation with at least two distinct mechanisms of action: a COX-dependent and a COX-
independent pathway.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Cerebrovascular control mechanisms play an essential role in
providing adequate blood supply to nervous tissue in order to
meet metabolic demands. Hypoxic/ischemic (H/I) brain injury
which frequently occurs in the perinatal period (Berger and
Garnier, 2000) has been shown to deteriorate cerebrovascular
control by impairing the “ischemia-sensitive” mechanisms of
the neurovascular axis (Leffler et al., 1989). Thus, impaired
cerebrovascular regulation probably contributes to neuronal
cell death following H/I brain injury. However, neuroprotective
mediators may also be released from these neuronal-vascular
elements during H/I stress that could abrogate neuronal in-
jury. These neuroprotectivemechanisms are attractive targets
for developing new strategies in the treatment of neonatal
stroke.
Pituitary adenylate cyclase-activating peptide (PACAP) is
one of themost promising of these neuroprotectivemediators.
PACAP has displayed marked protective effects in numerous
in vivo and in vitro models of cerebral injury, including
ischemia (Uchida et al., 1996; Reglodi et al., 2000; Suk et al.,
2004; Vaudry et al., 2004; Chen et al., 2006). PACAP-induced
neuroprotection in vivo can be, at least partially, based on its
cerebrovascular effects (Tong et al., 1993; Anzai et al., 1995),
therefore the characterization of PACAP-induced vascular
changes and the mechanism of the vascular actions are of
high importance.
PACAP belongs to the vasoactive intestinal polypeptide
(VIP)/glucagon/secretin superfamily that includes structurally
related neuroendocrine peptides. It exists in two molecular
forms: PACAP38, a basic, amidated 38-residue peptide; and
PACAP27, the N-terminal portion consisting of 27 amino acids
(Miyata et al., 1989, 1990). PACAP has been detected in the
neural tissue and cerebrospinal fluid (CSF) as well, and under
resting conditions its concentration in the CSF is ∼2 ng/ml
(Wilderman and Armstead, 1997). The peptide has been
shown to act as a neurotransmitter, neuromodulator, and a
neurotrophic factor. Although recent studies revealed the
complexity of perivascular peptidergic innervation, the
mechanisms by which neuropeptides participate in regula-
tion of the vessel caliber, the neuronal excitability, and the
cerebral metabolism remains unclear. Considerable data
suggest that vasoactive peptides, including PACAP, are
involved in cerebrovascular control (Edvinsson and Krause,
2002).
In this study, we employed the newborn pig animal model
that most closely reflects the brain developmental stage,
metabolism, and basic circulatory parameters of human
babies. We studied the effects of PACAP on the neonatal
cortical pial microcirculation that significantly (∼50%) con-
tributes to the total cerebrovascular resistance.
Previous studies in piglets have shown that the dilator
capabilities of PACAP27 and 38 are very similar and that they
are potent dilators of pial arterioles (Tong et al., 1993).
Immunohistochemical studies indicate that PACAP is co-
localized with neuronal nitric oxide (NO) synthase (NOS) in
the perivascular nerves and the sensory and parasym-
pathetic ganglia (Tajti et al., 1999; Uddman et al., 1999;
Edvinsson et al., 2001). In vitro experiments suggest that
there is not only an anatomical but also a functional
connection between PACAP and NO (Seebeck et al., 2002).
Currently, research studies have not clarified if NO does
indeed participate in mediation of the cerebrovascular effects
elicited by PACAP. Accumulating data indicate that cycloox-
ygenase (COX)-derived arachidonic acid metabolites are
major contributors to the regulation of cerebral circulation
in the newborn (Peri et al., 1995; Busija et al., 1996; Parfenova
et al., 1997; Degi et al., 1998). Although numerous preceding
in vitro and in vivo studies revealed tight interaction
between the prostanoid synthesis and PACAP action (Kis et
al., 1999), our understanding of the possible role of the COX
derived metabolites in the vascular effects of the PACAP in
piglets is still limited.
The purpose of this study was to (1) compare the
vasoactivity of the natural PACAP forms as well as short
PACAP sequences; (2) explore the mechanism of cerebral
arteriolar responses to PACAP using supposed PACAP recep-
tor antagonists, NOS and COX inhibitors. The results
emanating from these studies urged us to (3) investigate
the roles of COX-1 and COX-2 activity in the mechanism of
PACAP38-induced vasodilation using selective COX-1 and -2
inhibitors.
2. Results
2.1. Physiological variables
Body temperature, arterial pH, and blood gases were kept in
the respective normal ranges and did not vary significantly
among different groups throughout the experiments. For
instance, in group 1a the values were the following: core
temperature=36.9±0.1 °C, pH=7.4±0.02, pCO2=33.9±1.9 mm
Hg, pO2=93.7±3.6 mm Hg. Similarly, MABP values were
within normal range and were not significantly different
between groups (e.g. 73±3 mm Hg and 71±2 mm Hg in group
1a and group 1b respectively). Furthermore, in each animal
care was taken to avoid any fluctuation in MABP during
recordings to prevent effects of short-term changes in
arterial pressure on vascular diameters. There were no
significant differences between the baseline diameters in
any group, for example, in group 11 the values were 92±6 and
91±6 μm before the first and second PACAP application,
respectively.
2.2. Effect of various length PACAP sequences on pial
arteriolar diameter
Topical application of PACAP27 (group 1a) and PACAP38
(group 1b) resulted in similar, concentration-dependent (10−8
to 10−6 M), repeatable pial arteriolar dilation (Fig. 1). Indeed,
PACAP27 and PACAP38 produced equally prominent vascular
changes compared in the same animals (group 1c, 36±5% to
10−6 M PACAP27 and 43±7% to 10−6 M PACAP38).
In contrast, in groups 2a–e, even repeated application of
shorter PACAP peptide segments did not display any
vasoactivity. Percent changes in diameters at the highest
concentration used were: −2±2 and 1±1 to PACAP6–27 and
6–38; 2±3, 0±0 and 2±1 to fragment 1–15, 6–15 and 20–31,
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respectively, during the first application. The vascular res-
ponses were 1±1% and 1±1% to PACAP6–27 and 6–38, 2±2%,
0±0% and 1±1% to fragment 1–15, 6–15 and 20–31, res-
pectively, during the second application.
2.3. Effect of co-application with short segments on
PACAP27 and 38 elicited vasodilation
In comparison to the control values, arteriolar dilations to
PACAP27 or PACAP38 showed a statistically significant dec-
reasewhen these peptideswere co-appliedwith PACAP6–27 or
PACAP6–38. The other applied short segments (PACAP1–15,
6–15, and 20–31) did not affect either PACAP27 or PACAP38-
induced vasodilation (Fig. 2).
2.4. Effect of NOS and COX inhibitors on PACAP-induced
vascular reactions
The inhibition of NOS enzyme had no significant effect on the
PACAP-induced vascular reactions (Fig. 1). Both PACAP27 and
PACAP38 elicited similar vasodilation on pial arterioles before
and after L-NAME treatment. The non-selective COX enzyme
Fig. 1 – Characterization of PACAP27 and PACAP38-induced pial arteriolar vasodilation. PACAP27 (A, left) and PACAP38
(A, right) elicited dose-dependent, repeatable increases in pial arteriolar diameters. Inhibition of NOS by L-NAME did not alter
vascular responses to either PACAP27 or PACAP38 (B). In contrast, the COX inhibitor indomethacin virtually abolished pial
arteriolar dilation to PACAP38 (C, right), whereas it left vasodilation to PACAP27 essentially intact (C, left). Data are mean+SEM,
n=7–13, *p<0.05 significantly less than corresponding values at first application.
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inhibitor indomethacin reduced the vasorelaxant effect of
PACAP38 (group 9b), however in group 9a (when PACAP27 was
applied), this prominent influence was absent (Fig. 1). Inter-
estingly, the selective COX-2 inhibitor NS-398 had no inhibi-
tory effect on PACAP38-induced vasodilation (group 10),
whereas in group 11 the COX-1 blocker SC-560 was able to
abolish these diameter changes in the used dosages (Fig. 3).
3. Discussion
The major findings of the present studies are as follows: (1)
both PACAP27 and PACAP38 are similarly potent dilators of
pial resistance vessels in newborn pigs confirming previous
work (Tong et al., 1993). (2) The short PACAP sequences are not
vasoactive per se, but PACAP6–27 and 6–38 can inhibit
PACAP27 and 38-induced vasodilation. (3) NOS activity does
not appear to play a significant role in the dilatory effect of
PACAP. (4) Finally, PACAP38 (but not PACAP27) induced
vasodilation was abolished by indomethacin and the selective
COX-1 inhibitor SC-560 but not by the selective COX-2 inhibitor
NS-398.
Threemain types of PACAP/VIP-recognizing receptors have
been reported so far to mediate the various effects of PACAP
(Harmar et al., 1998; Vaudry et al., 2000). VPAC receptors are
closely related proteins binding VIP and PACAP with almost
the same efficacy, while PAC1 receptors (at least eight variants
exist) exhibit a high affinity for PACAP and a much lower
affinity for VIP. Most of these subtypes are G-protein-coupled
receptors that principally stimulate adenylate cyclase. VIP/
PACAP receptors have been identified in many brain/cerebro-
vascular cell types studied inmany species including humans.
Knutsson and Edvinsson detected mRNA of all three receptor
types in human cerebral ganglia and arteries (Knutsson and
Edvinsson, 2002). The expression of the receptor mRNA
remained unaltered after removal of the endothelium. In
rats, VPAC1 receptor immunoreactivity was attached to the
smooth muscle cell layer of the superficial cerebral arteries
and arterioles (Fahrenkrug et al., 2000), and VIP/PACAP
receptors were also found on neuroglia as well as on neurons
(Joo et al., 2004). Unfortunately, no data exist on the expression
of these receptors in the newborn piglet, however, endothelial
VPAC1 and VSM VPAC2 receptors have been described in the
basilar artery of adult pigs (Grant et al., 2006). Moreover,
PACAP-immunoreactive nerve fibers originating from either
sensory or parasympathetic ganglia do innervate the pial
Fig. 3 – Pial arteriolar vasodilation to PACAP38 is
differentially affected by selective COX inhibitors. The COX-1
inhibitor SC-560 (A) abolished arteriolar responses to
PACAP38, whereas the COX-2 inhibitor NS-398 (B) did not
alter the vasodilation. Data are the mean+SEM, n=9–9,
*p<0.05 significantly less than corresponding control values.
Fig. 2 – Co-application of specific PACAP segments modifies
pial arteriolar dilations to PACAP27 (A) and PACAP38 (B).
Co-application of PACAP6–27 and 6–38 resulted in significant
reduction of PACAP27 and PACAP38-induced vasodilation as
compared with the control vascular reactivity determined
earlier. In contrast, PACAP1–15, 6–15, and 20–31 failed to alter
these responses. Data are mean+SEM, n=5–5, *p<0.05
significantly less than corresponding values before the
co-application.
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blood vessels in piglets (our unpublished observations), and
these nerves are the most important source of PACAP to the
pial arterioles (Uddman et al., 1993).
The short PACAP sequences used in the present study
provide novel insight into the mechanism of PACAP-induced
vascular changes since their role has not been investigated in
the cerebral circulation before. PACAP6–27 and PACAP6–38 are
supposed competitive PACAP antagonists established in other
experimental models (Harmar et al., 1998; Vaudry et al., 2000),
and our results concur since they abolish the vascular effect
of both PACAP27 and 38. Our knowledge is limited on the
degradation of PACAP in vivo, but PACAP 6–27 can be an
important endogenous inhibitor providing negative feedback
since PACAP27 is rapidly degraded by dipeptidylpeptidase IV
(DPP IV) to produce PACAP6–27 among other metabolites in
vitro (Green et al., 2006). The other short fragments (PACAP1–
15, 6–15, and 20–31) were designed only for mapping
purposes, given that a short fragment is a much better
starting compound for any mutual pharmacological develop-
ment. These short PACAPs do not show any vasoactivity or
inhibitory effects suggesting that they are not capable of
sufficient binding to the VPAC/PACAP receptors.
PACAP is thought to exert a significant direct effect on the
vascular smooth muscle (VSM) of pial resistance vessels.
PACAP increases intracellular cAMP production resulting in
cerebrovascular vasodilation via subsequent activation of
plasmolemmal K+ channels in rats (Kobayashi et al., 1994). In
piglets, the observed vascular caliber changes to both
PACAP27 and 38 have been associated with elevated cortical
periarachnoid CSF cAMP concentration (Tong et al., 1993;
Armstead, 1997). Furthermore, the pial arteriolar dilation
produced by PACAP27 can be blocked by iberiotoxin, a potent
antagonist of the Ca2+-sensitive K+ channels, but unaltered
by the ATP-sensitive K+ channel inhibitor glibenclamide
(Armstead, 1997). PACAP was found to be an endothelium-
independent relaxing factor in several experiments (Kastner
et al., 1995), but other indirect pathways of PACAP-induced
dilation are possible.
Surprisingly, the involvement of NOS activity in PACAP-
induced vasodilation has not been supported by our experi-
ments with L-NAME despite numerous anatomical and func-
tional studies suggesting otherwise in other species. The
PACAP-containing perivascular nerve fibers originate from
several sources, e.g. from the trigeminal, sphenopalatine, and
otic ganglia. In the human and rat parasympathetic and
trigeminal ganglia high numbers of nerve cell bodies contain-
ing both NOS and PACAP were visualized by fluorescent
immunohistochemistry (Tajti et al., 1999; Uddman et al., 1999;
Edvinsson et al., 2001). Activation of nitrergic neurons, at least
in part, plays a role in the PACAP-induced vasorelaxant
mechanism in isolated rat basilar arteries (Seebeck et al.,
2002). The inhibition of NO production results in tachyphy-
laxis to PACAP27 in rat mesenteric and abdominal aortic
artery (Whalen et al., 1999). However, in the piglet, several
former studies demonstrate age-related changes in the
cerebrovascular regulation, predominantly in the NO-
mediated responsiveness. The expression and activity of
NOS in newborn and adult pigs are different: NOS enzyme is
up-regulated during maturation as well as the NOS activity
increases, while e.g. the COX expression and activity remain
constant (Parfenova et al., 2000). This phenomenon results in
the predominance of COX-derived products over NO in the
newborn period and gives a possible explanation of our
negative result. The selected dose of L-NAME (15 mg/kg iv),
however, was reported to provide appropriate NOS inhibition
in former studies (Lacza et al., 2002).
The major finding of our work is that, in contrast to the
effect of PACAP27, PACAP38-induced vasodilation is extremely
indomethacin sensitive similarly to VIP-induced pial arteriolar
vasodilation in cats (Wei et al., 1980). By dissecting the role of
the two COX isoforms in the PACAP38-induced response using
selective COX-1 and COX-2 inhibitors we find that adminis-
tration of SC-560 virtually abolishes the PACAP38 elicited
arteriolar dilation, while these vascular reactions remain
unchanged after NS-398. These data suggest that COX-1
derived prostanoids are substantially involved in PACAP38
dependent vascular caliber changes while the role of the COX-
2 enzyme seems to be ancillary.
The importance of cyclooxygenase (COX)-derived prosta-
noids in the cerebrovascular control of newborns is well
established, however, there are many open questions related
to the functional significance of the two distinct COX isoforms.
In the piglet brain, COX-2 is the dominant constitutive
enzyme: unlike COX-1, COX-2 mRNA is expressed in large
quantities in the cerebral cortex and microvasculature, and
this isoform comprises the main part of the total COX protein
level here. Moreover, data show that COX-2 gives the major,
approximately 80–90% contribution to the central nervous
system prostanoid level in the newborns as NS-398, a specific
COX-2 inhibitor, produces great decrease in the overall
prostanoid synthesis during both basal and certain stimulated
conditions. The remnant 10–20% is expected to be the
contribution of the COX-1 enzyme (Peri et al., 1995; Parfenova
et al., 1997). In concert with these observations, other
functional studies found that COX-dependent vascular reac-
tions (such as hypotension-induced vasodilation or Ach-
induced vasoconstriction) appear to depend largely on COX-2
activity (Domoki et al., 2005), while to the best of our
knowledge this study is the first to show a COX-1 dependent
vasoactive mechanism observed on the pial vasculature of
piglets.
In any pharmacological study, the specificity of the used
drugs limits the interpretation of the results. Indomethacin at
the used dose was found to be a strong inhibitor of the
prostanoid synthesis in many experiments in which its ability
to block either COX-1 or COX-2 dependent mechanisms was
investigated. The dose of NS-398 was chosen for similar
reasons since it proved to be a selective and effective inhibitor
of the COX-2 enzyme (Domoki et al., 2005). The COX-1 activity
was targeted with SC-560. In piglets, our laboratory was the
first (and to the best of our knowledge the only) where SC-560
was used in vivo (Domoki et al., 2005), though in that series of
experiments none of the assessed vascular reactions appeared
to be COX-1 dependent. On the other hand, other investigators
found this dose effective in blocking the COX-1 mediated
prostaglandin production in the rat brain, even after COX-1
gene transfer (Lin et al., 2002). However, SC-560 is known to
act, at least in some cell types, as an unselective COX enzyme
blocker (Brenneis et al., 2006). In our model, PACAP38 may act
on a particular cell type in which SC-560 has the potential to
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block both COX-1 and COX-2. Nonetheless it seems to be more
likely that PACAP38 uniquely activates COX-1 present in small
amounts inducing the synthesis of such vasodilator prosta-
noids as prostacyclin or PGE2 that stimulates cAMP formation
by VSM resulting in vasodilation (Parfenova et al., 1995).
In conclusion, PACAP is a powerful vasodilator in the
newborn cerebral circulation. The action of PACAP27 and
PACAP38 seems to be independent of NOS activation, but the
COX-1 activity appears to be essential only for PACAP38
elicited vascular effects. Considering the discrepancy between
the probable signal transduction courses related to the distinct
entire PACAP sequences, it seems feasible that PACAP27 and
PACAP38 act on different cells or different subtypes of the
PACAP receptor group. Currently our field is hampered by the
lack of potent, subtype selective blockers necessary to reveal
the functional relevance of VIP/PACAP receptor subtypes in
the newborn cerebral circulation. As a perspective, the
findings in the present paper may give crucial information
for the future investigations on PACAP-induced neuroprotec-
tion and are critical for understanding the mechanism of
neonatal cerebrovascular disorders and endogenous protec-
tive processions.
4. Experimental procedures
4.1. Animals
Newborn piglets of either sex (∼1 day old, body weight 1.2–
2.5 kg, n=127) were used. All protocols were approved by the
Institutional Animal Care and Use Committee of the Uni-
versity of Szeged.
4.2. Surgery
Anesthesia was initiatedwith thiopental sodium (40mg/kg ip.;
Biochemie, Vienna, Austria) and a bolus injection of α-
chloralose (40 mg/kg iv.; Sigma, St. Louis, MO, USA). Supple-
mental doses of α-chloralose were given to maintain a
constant level of anesthesia. A catheter was inserted in the
right femoral artery to monitor blood pressure and to sample
blood for determination of blood gas tensions and pH. Drugs
and fluids were administered through a second catheter
placed in the right femoral vein. The animals were intubated
via tracheotomy and mechanically ventilated with room air.
The ventilation rate (∼30 breaths/min) and tidal volume
(∼20 ml) were adjusted to maintain arterial blood gas values
and pH in the physiological range. A water-circulating heating
pad was used to maintain the body temperature at ∼37 °C
(core temperature was monitored with a rectal probe).
The animals were equipped with a closed cranial window
as previously described (Domoki et al., 2005). Following
surgery, the closed window was filled with artificial CSF
(aCSF) which was similar to endogenous CSF (aCSF composi-
tion: KCl 220, MgCl2 132, CaCl2 221, NaCl 7710, urea 402,
dextrose 665, and NaHCO 2066 in mg/l), warmed to 37 °C and
equilibrated with a gas mixture containing 6% O2, 6.5% CO2
and 87.5% N2 to obtain pH 7.33, pCO2=46 mm Hg and
pO2=43 mm Hg. Different PACAP sequences were dissolved
in aCSF and applied to the pial surface through one of the
injectable ports of the cranial window. Pial arterial vessels
were observed with an operating microscope (Wild, Switzer-
land), equipped with a video camera (Sanyo digital color CCD
camera, Japan), and a video monitor (Panasonic, Japan).
Vascular diameter was measured using a video microscaler.
In each experiment, a ∼100-μm-diameter (range 85–115 μm)
pial arteriole was selected. We chose this vessel size because
this is the level of the first order pial arterioles and the primary
site of vascular resistance. Some authors separate the re-
sistance vessels into two groups corresponding their size (e.g.
arterioles and small arteries) to rule out the possibility that
regional changes in the reactivity modify the results of the
experiments (Armstead, 1995). However, in the present work,
arterioles at both end of the range studied displayed virtually
identical reactivity to the stimuli employed (data are not
shown).
At the end of the experiments the animalswere euthanized
with an iv injection of saturated KCl solution.
4.3. Drugs
NS-398 (Sigma Chemical Co.) and SC-560 (Sigma Chemical Co.)
were dissolved in DMSO (5 mg/ml). L-NAME (Sigma Chemical
Co.) and indomethacin (Merck & Co, Whitehouse Station, NJ)
were dissolved in saline (30 mg/ml and 10 mg/ml res-
pectively). PACAP1–27, 1–38, 6–27, 6–38, 1–15, 6–15 and 20–31
(Department of Medical Chemistry, University of Szeged,
Hungary) were prepared as stock solutions in saline (10−4)
and then were diluted with aCSF (10−8, 10−7, 10−6 or 10−5 M).
4.4. Assessment of cerebrovascular reactivity
4.4.1. Protocol I. Determination of PACAP-induced
vasodilation and repeatability
Time control experiments were executed first in separate
series of animals to obtain arteriolar responses to different
PACAP sequences initially and then 40 min later. In group 1
PACAP27 (subgroup 1a, n=7) or PACAP38 (subgroup 1b, n=9)
was applied repeatedly. Additionally, we compared the
efficacy of the two natural peptides; in subgroup 1c (n=9)
PACAP27 and 38 were applied alternately with 40-minute
delay. In group 2 arteriolar responses to short PACAP seg-
ments were measured (PACAP6–27, 6–38, 1–15, 6–15 and 20–31
in subgroups 2a, b, c, d and e with n=4 in each subgroup,
respectively). Each of the peptides was applied in ascending
concentration manner (10−8, 10−7 and 10−6 M cumulatively).
Arteriolar diameters were measured every minute during a
5-minute exposure period for each PACAP concentration.
After the highest concentration of the series was applied the
area under the window was gently flushed with aCSF to
eliminate the previous stimulus, and the arteriolar diameters
were allowed to return to the baseline value. Then the
stimulus was repeated. In this manner we were able to detect
the PACAP-induced caliber changes and identify the presence
of potential tachyphylaxis or sensitization.
4.4.2. Protocol II. Determination of the effect of short
sequences on PACAP-induced vasodilation
In these experiments we co-applied short PACAP sequences
to examine their effects on vascular reactions evoked by the
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entire PACAP segments. Co-application of PACAP6–27, 6–38,
1–15, 6–15, and 20–31 with PACAP27 or PACAP38 occurred in
groups 3–7a and b (n=5 in each subgroups) respectively. First
PACAP27 or 38 in 10−6 M concentration was used topically
for 5 min. Following a 30-minute exposure-free period, when
arterioles regained stable baseline diameters, one short
segment was applied in a tenfold concentration for 10 min.
Next we co-applied the entire peptide sequence with the
short PACAP used previously for a subsequent 5 min.
Vascular diameters were measured continuously during the
stimuli.
4.4.3. Protocol III. Determination the effect of enzyme
inhibitors on PACAP-induced vasodilation
This experiment was designed the same as protocol I with one
addition. Between the first and the second local application of
the distinct entire PACAP sequence, a COX or NOS enzyme
blocker was administered intravenously. After obtaining
stable arteriolar baseline diameters, we examined the res-
ponses of pial arterioles to PACAP27 or PACAP38 before and 20
min after iv administration of the NOS inhibitor L-NAME in
group 8, on PACAP27 and 38 elicited vasodilation (subgroup
8a, n=7 and 8b, n=13), respectively. In group 9 the effect of the
non-selective COX inhibitor indomethacin (5 mg/kg iv) on
PACAP-induced arteriolar dilation was detected. We used
PACAP27 in subgroup 9a (n=10) and PACAP38 in subgroup 9b
(n=9) topically before and after the parenteral indomethacin
administration. In group 10 (n=9) the effect of the selective
COX-2-inhibitor NS-398 (1 mg/kg) was tested. The effect of the
selective COX-1 inhibitor SC-560 (1 mg/kg) was analyzed in
group 11 (n=9).
4.5. Statistical analysis
Themeasured pial artery diameter values (absolute diameters
or percentage change from control values) were analyzed by
ANOVA for repeated measures. For post hoc analysis Holm–
Sidak's exact test was performed where appropriate. A value
of p<0.05 was considered significant. Data are represented as
mean±SEM. The n number reflects data for one vessel in each
animal.
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Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide
(VIP) are neuroprotective in numerous models. Impairment of cerebrovascular reactivity
(CR) contributes to ischemia/reperfusion (I/R)-induced neuronal damage.We testedwhether
PACAP and/or VIP preserve CR to I/R-sensitive dilator responses dependent on endothelial
and/or neuronal function. Accordingly, changes in pial arteriolar diameters in response to
hypercapnia (5–10% CO2 ventilation) or topical N-methyl-D-aspartate (NMDA, 10−4 M) were
determined before and after I/R via intravital microscopy in anesthetized/ventilated piglets.
Local pretreatment with non-vasoactive doses of PACAP (10−8 M) and VIP (10−9 M) prevented
the attenuation of postischemic CR to hypercapnia; to 10% CO2, the CR values were 27±8% vs
92±5%⁎ vs 88±13%⁎ (vehicle vs PACAP38 vs VIP, CR expressed as a percentage of the
response before I/R,mean±SEM, n=8–8, ⁎p<0.05). PACAP, but not VIP, preserved CR to NMDA
after I/R, with CR values of 31±10% vs 87±8%⁎ vs 35±12% (vehicle vs PACAP38 vs VIP, n=6–6).
Unlike PACAP, VIP-induced vasodilation has not yet been investigated in the piglet. We
tested whether VIP-induced arteriolar dilation was sensitive to inhibitors of cyclooxygenase
(COX)-1 (SC-560, 1mg/kg), COX-2 (NS-398, 1mg/kg), indomethacin (5mg/kg), and nitric oxide
synthase (L-NAME, 15 mg/kg). VIP (10−8–10−7–10−6 M, n=8) induced reproducible, dose-
dependent vasodilation of 16±3%, 33±6%⁎, and 70±8%⁎. The response was unaffected by all
drugs, except that the vasodilation to 10−8MVIPwas abolished by SC-560 and indomethacin.
In conclusion, PACAP and VIP differentially preserve postischemic CR; independent of their
vasodilatory effect.
© 2009 Elsevier B.V. All rights reserved.
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1. Introduction
Pituitary adenylate cyclase activating polypeptide (PACAP)
and vasoactive intestinal peptide (VIP) are structurally related
neuropeptides. PACAP has two naturally occurring isoforms;
PACAP38, a basic, amidated 38-residue peptide, and PACAP27,
the N-terminal portion consisting of 27 amino acids (Miyata
et al. 1989; Miyata et al. 1990). PACAP possesses specific
receptors (8 subtypes of PAC1), but also shares common
receptors with VIP (VPAC1, VPAC2) (Harmar et al. 1998; Vaudry
et al. 2000). Thus, despite the high sequence homology, these
peptides are expected to activate multiple pathways resulting
in distinct biological actions.
In the cerebral circulation of the newborn pig, PACAP27 and
PACAP38 have been reported to induce prominent pial
arteriolar dilation (Tong et al. 1993; Lenti et al. 2007). We
found that PACAP38-induced vasodilation was abolished by a
cyclooxygenase (COX)-1-inhibitor, while PACAP27-induced
vasodilation was insensitive to either COX-1 or COX-2 block-
ade (Lenti et al. 2007). Ischemia/reperfusion (I/R), which
frequently occurs in the perinatal period (Berger et al. 2002),
has been shown to impair several cerebrovascular regulatory
mechanisms of the neurovascular axis in piglets (Leffler et al.
1989a; Leffler et al. 1989b; Busija et al. 1996). Impaired
cerebrovascular reactivity (CR) probably contributes to and
aggravates neuronal cell death following hypoxic/ischemic
brain injury. Previous studies identified N-methyl-D-aspartate
(NMDA)- and CO2-induced vasodilatory responses as proto-
types of such I/R-sensitive mechanisms. However, these
stimuli dilate cerebral arterioles by completely different
mechanisms. NMDA-induced pial arteriolar dilation is a
neuronal-triggeredmulti-step process involving the activation
of neuronal nitric oxide (NO) synthase (NOS) (Meng et al. 1995;
Domoki et al. 2002), while CO2 induces vasodilation via an
endothelium-dependent, indomethacin-sensitive process in
the newborn pig (Leffler et al. 1993; Leffler et al. 1994b).
PACAP and VIP are considered as endogenous neuropro-
tective mediators that may be released from neural and
vascular cells during I/R and could possibly reduce neuronal
injury (Brenneman 2007; Stumm et al. 2007). Conceivably,
these neuroprotective peptides may protect CR after I/R as
well. Therefore, the major goal of our study was to determine
whether PACAP27, PACAP38 and/or VIP preserves CR to NMDA
and/or hypercapnia after I/R, and whether the protective
effects of the neuropeptides are dependent on their vasoac-
tivity. Since the pial arteriolar response to VIP has not yet been
described in the piglet, we also characterized VIP-induced
vasodilation using peptide antagonists (PACAP6-38 and
PACAP6-27), COX- and NOS inhibitors.
2. Results
2.1. Effects of PACAP/VIP pretreatment on pial arteriolar
responsiveness to CO2 after I/R
Graded hypercapnia (5–10% CO2 ventilation) resulted in large,
dose-dependent, reversible increases in pial arteriolar dia-
meters. In the vehicle-treated animals (group 1), I/R (10 min of
ischemia and 1 h of reperfusion) severely attenuated the
hypercapnia-induced arteriolar vasodilation (Fig. 1A, left).
Incubation of the brain surface with PACAP27 (10−8 M),
PACAP38 (10−8 M) or VIP (10−9 M) for 30 min did not affect the
pial arterioles significantly (2±1%, 2±1%, and 3±1% maximal
dilation in response to PACAP27, PACAP38, and VIP, respec-
tively); however, they efficiently preserved CR to both levels of
hypercapnia after I/R (groups 3, 5, and 7; Figs. 1B–D, left).
2.2. Effects of PACAP/VIP pretreatment on pial arteriolar
responsiveness to NMDA after I/R
Topical application of NMDA (10−4 M) induced a marked
vasodilation that was also sensitive to I/R (group 2, Fig. 1A,
right). PACAP27 (10−8 M) or PACAP38 (10−8 M) pretreatment of
the brain surface protected the NMDA-evoked pial arteriolar
dilation after I/R, whereas incubation of the brain surface with
10−9 M VIP was not effective (groups 4, 6, and 8; Figs. 1B–D,
Fig. 1 – Effects of ischemia/reperfusion (I/R) on
hypercapnia- or NMDA-induced pial arteriolar vasodilation.
Arteriolar responses to 5–10% CO2 ventilation and topical
NMDA were recorded before and after 10 min of global
cerebral ischemia followed by 1 h of reperfusion.
Hypercapnia elicited concentration-dependent pial arteriolar
vasodilation, which was markedly attenuated after I/R in
vehicle-treated piglets (A, left). PACAP isoforms and VIP
preserved the vascular responsiveness to CO2 (B–D, left).
Vasodilation in response to 10−4 M NMDA was also
deteriorated after I/R (A, right). PACAP27 and PACAP38 (B–C,
right), but not VIP (D, right), protected the vasodilator effect of
NMDA. (Data are mean±SEM, n=6–8, *p<0.05.)
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right). Furthermore, a higher dose of VIP (10−8 M, group 8b) was
still unable to preserve CR to 10−4 M NMDA reduced by I/R. CR
values were 36±12% vs 51±6% (vehicle vs VIP, CR expressed as
a percentage of the preischemic response). In group 8c, lower,
10−5 M and 5×10−5 M concentrations of NMDA also dilated the
pial arterioles with 4.4±0.2% and 12.6±0.4%⁎, respectively
(⁎p<0.05). I/R reduced these vascular reactions significantly,
and moreover, a tendency towards vasoconstriction was
observed after I/R (−2±3% and −3±4% changes in diameter
to 10−5 M and 5×10−5 M NMDA), irrespectively of the VIP
(10−8 M) treatment.
2.3. Effects of PACAP/VIP treatment on CO2- and
NMDA-induced pial arteriolar dilation
Topical PACAP27 (10−8 M), PACAP38 (10−8 M) or VIP (10−9 M)
treatment alone did not affect the vasodilation induced by
either hypercapnia or NMDA. Vascular responses to 10% CO2
were 50±2% and 57±7% before and after PACAP27 (group 9),
and 63±5% and 64±6% before and after PACAP38 incubation
(group 11). Topical NMDA (10−4 M) evoked 36±7% and 33±5%
vasodilation before and after PACAP27, and 37±5% and 43±7%
vasodilation before and after PACAP38 application (groups 10
and 12). Responses to 10% CO2were 60±9% and 56±11% (group
13), and to 10−4 M NMDA were 49±7% and 48±7% (group 14),
before and after VIP treatment. Accordingly, the protective
effects of these neuropeptides are not caused by direct
facilitation of the vascular reactivity to hypercapnia or to
NMDA.
2.4. Effects of different enzyme inhibitors on VIP-induced
pial arteriolar vasodilation
VIP induced dose-dependent, reproducible pial arteriolar
vasodilation at 10−8–10−6 M concentrations (Fig. 2A). The
VIP-induced vasodilation was partially indomethacin-sensi-
tive (Fig. 2B), since administration (5 mg/kg iv) of this non-
selective COX inhibitor significantly blocked the vasodilation
evoked by the lowest (10−8 M) dose of VIP. Indomethacin was
not effective when 10−7 or 10−6 M VIP was applied. Selective
inhibition of COX-1 by SC-560 (1 mg/kg iv) produced a very
similar outcome (Fig. 2C), but the COX-2 inhibitor NS-398
(1 mg/kg iv) failed to exert any inhibitory effect (Fig. 2D). Nitric
oxide synthase (NOS) blockade had also no influence on the
VIP-induced vasodilation; application of 10−8–10−6 M VIP onto
the brain surface resulted in significant, 15±3–61±10% and
Fig. 2 – Characterization of VIP-induced pial arteriolar
vasodilation. VIP elicited significant, dose-dependent,
reproducible increases in pial arteriolar diameters, while
artificial cerebrospinal fluid (aCSF) did not evoke vasodilation
(A). The non-selective cyclooxygenase (COX) inhibitor
indomethacin abolished the pial arteriolar dilation in
response to 10−8 M VIP, whereas it left the vasodilation to
higher concentrations (10−7–10−6 M) of VIP essentially intact
(B). The pial arteriolar response to VIP was differentially
affected by selective COX inhibitors; the COX-1 inhibitor
SC-560 abolished the arteriolar responses to 10−8 M VIP (C),
whereas the COX-2 inhibitor NS-398was ineffective (D). (Data
are mean±SEM, n=6–8, *p<0.05: significantly higher than
vasodilation to all smaller VIP concentrations, †p<0.05:
significantly less than the corresponding value before
treatment.)
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17±7–62±9% caliber changes before and after intravenous
N-ω-nitro-L-arginine methyl ester (L-NAME, 15 mg/kg)
administration.
2.5. Effects of PACAP receptor antagonists on VIP-induced
pial arteriolar vasodilation
PACAP6-38 (10−5 M, group 20) pretreatment effectively dimin-
ished the VIP-induced vasodilation (62±10% and 33±6%⁎
vasodilation in response to 10−6 M VIP, before and after
PACAP6-38, ⁎p<0.05); however, in group 21, PACAP6-27
(10−5 M) failed to exhibit any inhibitory effect on the VIP-
related pial arteriolar dilation (61±12% and 66±11% changes
in diameter before and after topical PACAP6-27 treatment).
2.6. Physiological variables
Graded (5 and 10%) hypercapnia significantly elevated the
arterial pCO2 levels in all experimental groups where CR to
hypercapnia was tested. The pCO2 changes were similar
before and after I/R and between groups. For instance, in
group 7, 5 and 10% CO2 elevated pCO2 from 34±2.5 to 52±2.1
and 79±5 mm Hg and from 37±2.7 to 56±2.7 and 84±5.9 mm
Hg before and after I/R, respectively. The respective pO2 levels
were 90±5.9–94±6.4–94±7.4 and 90±7.6–89±5.8–88±4.2 mm
Hg in this group and were similar in all groups. Otherwise,
body temperature, arterial pH, and blood gases were kept in
the normal ranges and did not vary significantly among the
different groups throughout the experiments. In group 1, for
instance, the baseline values were as follows: core tempera-
ture=37±0.2 °C, pH=7.43±0.03, pCO2=38±2 mm Hg, pO2=91±
5 mm Hg. Similarly, the mean arterial blood pressure (MABP)
values were always within the range characteristic for
anesthetized newborn pigs and did not differ significantly
between groups (e.g. 70±3 mm Hg and 69±3 mm Hg in
groups 1 and 2, respectively). Furthermore, in each animal,
care was taken to avoid any fluctuation in MABP during
recordings so as to prevent effects of short-term changes in
arterial pressure on vascular diameters. There were no
significant differences between the baseline diameters in
the groups; for example, in group 15 the values were 92±3 μm
and 95±5 μm before the first and the second VIP application,
respectively.
3. Discussion
The major findings of the present study: (1) PACAP27,
PACAP38, and VIP prevent the attenuation of hypercapnia-
induced vasodilation caused by I/R; (2) PACAP27 and PACAP38,
but not VIP preserves NMDA-induced vasodilation; (3) VIP
evokes concentration-dependent, reproducible pial arteriolar
dilation that is independent of NOS activity, and essentially
unaffected by COX inhibitors. Finally, (4) VIP-induced vasodi-
lation is attenuated by PACAP6-38, but not by PACAP6-27.
PACAP and VIP are widely distributed throughout the
central and peripheral nervous system, and they have been
identified in nerve endings innervating pial and intraparench-
ymal vessels of the cerebral cortex (Fahrenkrug et al. 2000).
These perivascular nerve fibers are of either parasympathetic,
trigeminal sensory or cortical neuronal origin (Edvinsson and
Krause 2002). Our results indicate that PACAP and VIP are
markedly different in their respective protective and vasodi-
lator actions also indicating that these neuropeptides may
activate only partially overlapping mechanisms.
In porcine cerebral vessels, hypercapnia evokes vasodila-
tion not only in vivo (Leffler et al. 1989a), but also in isolated,
denervated vessels (Kokubun et al. 2009) suggesting that
neuronal/glial factors are not essential for the hypercapnia-
induced vasodilation. In the piglet, hypercapnia-induced
vasodilation requires intact endothelium (Leffler et al.
1994b); more specifically, the endothelium appears to serve
as a source of prostanoids for the vascular smooth muscle to
permit the relaxation (Leffler et al. 1994a). Prostanoid synth-
esis increases in newborn pig brain microvascular endothelial
cells in response to hypercapnia, but high CO2 level does not
increase prostanoid production by cerebral microvascular
smooth muscle or glial cells (Hsu et al. 1993). Hypercapnia-
induced vasodilation is vulnerable to I/R; however, supple-
mentation of arachidonic acid restores this vasodilation and
hypercapnia-related increases in the cerebrospinal fluid 6-
keto-prostaglandinF1α levels (Leffler et al. 1992). Based on
these findings, I/R seems to reduce hypercapnia-induced
dilation of pial arterioles through endothelial damage in
piglets. Therefore, the present data indicate decreased/shor-
tened postischemic endothelial dysfunction by PACAP or VIP
pretreatment, as suggested by the preserved hypercapnia-
induced vasodilation. We are not aware of any studies in
which similar protective effects of PACAP and VIP have been
demonstrated on the cerebrovascular endothelium. Our find-
ings are in agreement with the findings of Lange et al., who
demonstrated both the synthesis of VIP and the expression of
VIP receptor associated protein in microvascular endothelial
cells of pial vessels in piglets (Lange et al. 1999), allowing a
direct protective effect of both VIP and PACAP. The function of
endothelial VIP production/effects is unclear, but an autocrine
growth factor role involved in postnatal endothelial cell
differentiation has been suggested. The exact mechanism of
endothelial protection by these neuropeptides is unclear and
its exploration demands further experiments. Although most
data suggest the principal involvement of endothelium, the
role of other cell types cannot be excluded, since neuronal/
glial components also contribute to hypercapnia-induced
cerebrovascular dilation in other experimental models
(Wang et al. 1999; Xu et al. 2004).
Our present study clearly demonstrates that PACAP27 and
PACAP38, but not VIP preserves CR to NMDA after I/R. The
mechanisms of NMDA-induced pial arteriolar dilation and
the attenuation of this response after hypoxic/ischemic stress
in piglets has been recently reviewed (Busija et al. 2007).
Briefly, the activation of neuronal NMDA receptors leads to
the subsequent activation of a specific population of neuro-
nal NOS positive neurons via local neuronal connections
(Faraci and Breese 1993; Bari et al. 1996b). The released NO
then diffuses to and acts on the vascular smooth muscle,
resulting in dilation of the pial arterioles (Meng et al. 1995;
Domoki et al. 2002). The response is unaffected by damage to
the vascular endothelium (Domoki et al. 2002), but have been
shown to be vulnerable to even short periods of hypoxic
stress (Bari et al. 1996a; Busija et al. 1996). In contrast, the pial
53B R A I N R E S E A R C H 1 2 8 3 ( 2 0 0 9 ) 5 0 – 5 7
arteriolar response to NO itself is unaffected by I/R (Busija
et al. 1996). All available evidence strongly suggests the
causative role of reactive oxygen species (ROS) in the
attenuation of NMDA-induced vasodilation after I/R. In
piglets, topical application of ROS scavengers preserves
cerebral arteriolar dilator responses to NMDA after I/R (Bari
et al. 1996a). The primary site of ROS action appears to be at
the level of the NMDA receptor (Choi et al. 2000; Guerguerian
et al. 2002). Alternatively, the functional coupling between
NMDA receptor and nNOS expressing neuronal populations
may be disrupted after I/R.
Although PACAP and VIP display neuroprotective proper-
ties against a wide range of pathological conditions, PACAP
is generally more potent than VIP and its function has been
more widely investigated (Tamas et al. 2002). Vasodilatory,
antioxidant, anti-apoptotic, neurotrophic, and anti-inflam-
matory effects have been promoted as the putative mechan-
isms of neuroprotection in various experimental models. Our
present results suggest that preservation of CR to NMDA
after I/R is independent of the increase in cerebral blood flow
mediated by vasodilation to PACAP. In fact, PACAP effec-
tively preserved NMDA-induced vasodilation in a non-
vasoactive dose, whereas VIP was ineffective in an equimo-
lar, vasoactive dose. However, the reported antioxidant
property of PACAP can be an important factor in the
preservation of the NMDA receptor function, especially that
an analogous antioxidant capacity of VIP is absent (Reglodi
et al. 2004). The PACAP-induced initiation of anti-apoptotic
and anti-inflammatory mechanisms may also lead to
increased general viability of the neurons. More specifically,
PAC1 receptor stimulation leads to activation of Bcl-2/
inhibition of Bad resulting in enhanced mitochondrial
integrity/decreased release of apoptotic cytochrome c. Con-
ceivably, preservation of mitochondrial function fastens the
restoration of cellular ATP levels and also reduces postis-
chemic ROS production. PACAP binding sites in the rat
cerebral cortex are ten times more numerous as compared to
VIP; this difference may also explain the higher general
neuroprotective potency of PACAP (Masuo et al. 1991).
Alternatively, PACAP isoforms may act on PAC1 receptors
expressed on a specific population of cortical neurons
critically involved in NMDA-induced vasodilation. Further-
more, the differences observed between PACAP and VIP can
be due to different signal transduction mechanisms coupled
to PACAP and/or VIP-stimulated receptors in these cells.
Vasodilator neuropeptides such as PACAP and VIP have
substantial roles in cerebrovascular control mechanisms
(Edvinsson and Krause 2002). In our previous study indo-
methacin and the selective COX-1 inhibitor SC-560 abolished
PACAP38-induced vasodilation to all concentrations used
(10−8–10−6 M); however, the vascular action of PACAP27 was
completely independent of COX activity (Lenti et al. 2007).
Our present results show that vasodilation to 10−8 M VIP
resembles the vasodilator effect of PACAP38 characterized
by indomethacin- and SC-560-sensitivity. In contrast, at
10−7–10−6 M VIP concentrations the response is unaffected
by COX-1 inhibition similar to PACAP27. Since NOS inhibition
has also no effect on VIP-induced vasodilation, VIP probably
exerts a robust direct effect on vascular smooth muscle cells
at these doses. Similarly, VIP dilates the isolated porcine
ophthalmic artery via COX-mediated mechanisms only at
lower (10−10–10−9 M) VIP concentrations (Vincent 1992). VIP-
induced pial arteriolar vasodilation is also indomethacin-
sensitive in cats (Wei et al. 1980), whereas involvement of
NOS activity in VIP-induced vasodilation was also reported in
other, adult animal models (Gaw et al. 1991; Grant et al.
2006). The presumed activation of COX-1 by VIP and
PACAP38 is unique, since COX-2 is known to be the
predominant COX isoform in the newborn central nervous
system (Peri et al. 1995; Parfenova et al. 1997), and SC-560 did
not affect the vasodilation in response to any other COX-
dependent stimuli studied (Domoki et al. 2005b).
The VIP/PACAP receptor antagonist PACAP fragments
(PACAP6-38 and PACAP6-27) inhibited both PACAP27- and
PACAP38-induced vasodilation in our previous study (Lenti et
al. 2007). PACAP6-38, unlike PACAP6-27, is often reported to be
a selective blocker of the PAC1 receptor group (Edvinsson and
Krause 2002); however, in the present study, only PACAP6-38
but not PACAP6-27 attenuates VIP-induced vasodilation. This
finding is in accordance with studies identifying PACAP6-38 as
a nonspecific VIP/PACAP antagonist (Harmar et al. 1998).
Possibly, PACAP6-38 simply is a more potent inhibitor than
PACAP6-27 on the VIP/PACAP receptors involved in VIP-
induced vasodilation. Unfortunately, we are unaware of the
existence of any widely accepted, subtype-selective VIP/
PACAP receptor blockers that would be required to unveil
the functional relevance of each receptor subtype in cerebro-
vascular and neuroprotective effects of these neuropeptides
(Edvinsson and Krause 2002).
In conclusion, PACAP27, PACAP38, and VIP all protect
postischemic vascular reactivity to CO2, an ischemia-sensitive
indicator of endothelial function in the newborn pig. However,
PACAP isoforms but not VIP preserves the NMDA-induced
neuron-dependent vasodilation. Although PACAP27,
PACAP38, and VIP all induce dose-dependent pial arteriolar
dilation by activating partially overlapping mechanisms, the
protective effect of these neuropeptides is independent of
their vasoactivity. This neurovascular protection probably
supports the restoration of adequate perfusion of the brain
tissue after I/R likely enhancing the direct neuroprotective
effects of VIP and PACAP.
4. Experimental procedures
4.1. Animals
Newborn piglets of either sex (1–2 days old, bodyweight 1–3 kg,
n=138) were used. All protocols were approved by the
Institutional Animal Care and Use Committee of the Uni-
versity of Szeged.
Anesthesia was initiated with thiopental sodium (40 mg/
kg ip.; Biochemie, Vienna, Austria) and a bolus injection of α-
chloralose (40 mg/kg iv.; Sigma, St. Louis, MO, USA). Addi-
tional doses of α-chloralose (3–7 mg/kg/h iv.) were given to
maintain a constant level of anesthesia. A catheter was
inserted into the right femoral artery to monitor blood
pressure and to sample blood for determination of blood
gas tensions and pH. Fluid and drugs were administered
through a second catheter placed in the right femoral vein.
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The animals were intubated via tracheotomy andmechanically
ventilatedwith roomair. The ventilation rate (~30 breaths/min)
and tidal volume (~20 ml) were adjusted to maintain arterial
blood gas values and pH in the physiological range. A water-
circulating heating pad was used to maintain the body
temperature at ~37°C. Core temperature was monitored with a
rectal probe. The animals were equipped with a closed cranial
window as previously described (Domoki et al. 2005b).
Following surgery, the closed window was filled with
artificial cerebrospinal fluid (aCSF) which was similar to the
endogenous CSF (aCSF composition: KCl 220, MgCl2 132, CaCl2
221, NaCl 7710, urea 402, dextrose 665, and NaHCO3 2066, in
mg/l), warmed to 37 °C and equilibrated with a gas mixture
containing 6% O2, 6.5% CO2 and 87.5% N2 to obtain pH 7.33,
pCO2=46 mm Hg and pO2=43 mm Hg. Pial arterial vessels
were observed with an operating microscope (Wild, Switzer-
land) equipped with a video camera (Sanyo digital color CCD
camera, Japan), and a video monitor (Panasonic, Japan).
Vascular diameters were measured with a video microscaler.
In each experiment, a ~100-μm-diameter (range 76–114 μm)
pial arteriole was selected. We chose this vessel size because
this is the level of the first-order pial arterioles and the
primary site of vascular resistance. After a stable baseline
diameter was reached, the window was flushed with aCSF as
control. Topical stimuli were applied to the pial surface
through one of the injectable ports of the cranial window.
The pial arterioles were exposed to each vasodilator stimulus
for 5 min, while arteriolar diameters were measured con-
tinuously. After completion of a stimulus, the cranial window
was flushedwith aCSF and the vessel diameter was allowed to
return to the baseline level.
To induce global cerebral ischemia, a 3-mmhole wasmade
with an electric drill in the left frontal cranium rostral to the
cranial window and the dura was exposed. A hollow brass bolt
was inserted and secured in place with dental acrylic. Cerebral
ischemiawas induced by the infusion of aCSF so as to raise the
intracranial pressure above the arterial pressure. Ischemia
was verified by the cessation of blood flow in the vessels
observed through the cranial window. Venous blood was
withdrawn as necessary to keepMABP near the normal values.
At the end of the ischemic period, the infusion tube was
clamped and the intracranial pressure returned to the
preischemic levels. The withdrawn and heparinized blood
was reinfused (Domoki et al. 2005a).
At the end of the experiments, the animals were eutha-
nized with an iv. injection of saturated KCl solution.
4.2. Drugs
VIP (Sigma Chemical Co.), PACAP38, PACAP27, PACAP6-27, and
PACAP6-38 (Department of Medical Chemistry, University of
Szeged, Hungary) were prepared as stock solutions in saline
(10−4 M) and, before use, were diluted with aCSF (10−9–10−5 M).
Indomethacin (Merck & Co, Whitehouse Station, NJ) and L-
NAME (Sigma Chemical Co.) were dissolved in saline
(30 mg/ml and 10 mg/ml, respectively). NS-398 (Sigma
Chemical Co.) and SC-560 (Sigma Chemical Co.) were dissolved
in dimethyl sulfoxide (DMSO, 5 mg/ml) and further diluted
with saline to 1ml. NMDA (Sigma Chemical Co.) was dissolved
in aCSF. Selection of enzyme inhibitor doses was based on
previous results in this experimental model (Bari et al. 1996b;
Domoki et al. 2005b; Lenti et al. 2007).
4.3. Protocol
In the first series of experiments, the effect of global cerebral I/
R (10 min of ischemia and 1 h of reperfusion) was tested on
CO2- and NMDA-induced vasodilation, with or without PACAP
or VIP treatment. Prior to the induction of ischemia, the brain
surface was incubated for 30 min with vehicle (aCSF, groups
1–2, n=6–6), 10−8 M PACAP27 (groups 3–4, n=6–6), 10−8 M
PACAP38 (groups 5–6, n=6–6), or 10−9 M VIP (groups 7–8,
n=8–6). Pial arteriolar caliber changes to 5 and 10% CO2
ventilation (groups 1, 3, 5, and 7), or to topical, 10−4 M NMDA
(groups 2, 4, 6, and 8) weremeasured before the pretreatments
and after 1 h of reperfusion. We performed additional
experiments on 4–4 animals in groups 8b and 8c to test
whether a higher (10−8 M) dose of VIP can protect NMDA-
induced vasodilation after I/R. In group 8b we used the NMDA
at 10−4 M concentration similar to the original experiments,
while in group 8c we tested if the vascular response to a lower,
10−5 M and 5×10−5 M concentration of NMDA can be protected
by VIP (10−8 M) after I/R. The effects of the same PACAP27,
PACAP38 or VIP pretreatments in the absence of I/R were also
tested on the vasodilation evoked by hypercapnia (groups 9,
11, and 13, n=6–5–6) or by NMDA (groups 10, 12, and 14,
n=5–7–5), respectively.
In the second series of experiments, the brain surface was
exposed to VIP before and after the intravenous administra-
tion of different enzyme inhibitors or topical application of
different PACAP fragments. VIP application (10−8–10−6 M
cumulatively) was repeated 20 min after the intravenous
administration of vehicle (group 15, saline in 5, and diluted
DMSO in 3 animals), indomethacin (group 16, n=7, 5 mg/kg),
SC-560 (group 17, n=6, 1 mg/kg), NS-398 (group 18, n=7,
1 mg/kg) or L-NAME (group 19, n=8, 15 mg/kg). Pial arteriolar
dilation to 10−6 M VIP was determined before and after 20 min
topical application of PACAP6-38 (group 20, n=6, 10−5 M) or
PACAP6-27 (group 21, n=7, 10−5 M).
4.4. Statistical analysis
The pial artery diameter data (absolute diameters or maximal
percentage changes from the baseline values) were analyzed
by one-way repeated measures ANOVA. For post hoc analysis,
Tukey's test was performed where appropriate. Values of
p<0.05 were considered significant. Data are reported as
mean±SEM.
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N-Methyl-D-Aspartate Induces Cortical Hyperemia
through Cortical Spreading Depression-Dependent
and -Independent Mechanisms in Rats
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ABSTRACT
Objective: N-methyl-D-aspartate (NMDA) is a powerful cerebrovascular dilator in vivo. Cortical
spreading depression (CSD) has recently been shown to contribute to the pial arteriolar dilation in
mice. Our main aim was to examine the participation of CSD in the overall cerebrovascular response
to NMDA in the rat.
Methods: Anesthetized Wistar rats (eight weeks old) were equipped with a closed cranial window to
allow topical application of NMDA (105103 M) to the parietal cortex. Cortical blood flow (CoBF)
under and outside the cranial window was simultaneously monitored by using a two-channel laser-
Doppler flowmeter. CSDs were detected by recording the changes in the cortical DC potential.
Results: Concentrations of 104 and 103 M of NMDA evoked single CSDs associated with rapid,
transient hyperemia, followed by a sustained, but reduced, increase in CoBF. The latency and
magnitude of the CoBF responses were dose dependent. The higher dose resulted in shorter latency
(10095* vs. 146911 seconds, *PB0.05; mean9standard error of the mean) and larger overall
flow response (77912* vs. 2893% from baseline) under, but not outside, the cranial window.
Conclusions: NMDA elicits dose-dependent increases in CoBF that are composed of CSD-dependent
and -independent components in rats.
Microcirculation (2009) iFirst, 111. doi:10.1080/10739680903131510
KEY WORDS: glutamate, AMPA, kainate, cerebral blood ﬂow, laser-Doppler ﬂowmetry, piglet
INTRODUCTION
Glutamatergic neurotransmission is ubiquitous in the
brain and plays a key role in neurovascular coupling
via activation of ionotropic [N-methyl-D-aspartate
(NMDA), alpha-amino-3-hydroxy-5-methylisoxazole-
4-propionate (AMPA), and kainate] and metabotro-
pic receptors [8,21,27,45]. Activation of NMDA
receptors has been shown to elicit dose-dependent
cerebrovascular dilation in vivo in numerous species,
including rats, rabbits, and newborn pigs
[10,16,19,32]. It has been hypothesized that the
stimulation of NMDA receptors on neurons and the
consequent membrane depolarization/Ca influx
result in the production of vasodilator mediators,
such as nitric oxide (NO), and ultimately leads to
cerebral vascular relaxation, thereby adjusting the
cortical blood flow (CoBF) to the local metabolic
activity [4,14,16,21].
The concept of NMDA-receptor activation contri-
buting to the generation and propagation of cortical
spreading depression (CSD) is well established;
synthetic antagonists of NMDA receptors are potent
inhibitors of CSD development in numerous experi-
mental models [22,29,31,37]. CSD is a self-propa-
gating wave of cellular depolarization in the cerebral
cortex that is typically evoked by localized trauma,
excess neuronal firing, potassium chloride, or neu-
rotransmitter application and is associated with
short-lived, but dramatic, increases in CoBF. The
underlying mechanisms of this cerebral hyperemia
are very complex and probably require the con-
tribution of diverse cell types within the neurovas-
cular unit as well as a wide range of vasoactive
Address correspondence to Laura Lenti, Department of
Physiology, Faculty of Medicine, University of Szeged, Do´m te´r
10, Szeged 6720, Hungary. E-mail: lentilaura@gmail.com
Received 21 April 2009; accepted 20 June 2009.
Microcirculation. iFirst: 111. 2009
Copyright # 2009 Informa UK Ltd.
ISSN: 1073-9688 print / 1549-8719 online
DOI: 10.1080/10739680903131510
D
o
w
n
l
o
a
d
e
d
 
B
y
:
 
[
W
a
k
e
 
F
o
r
e
s
t
 
U
n
i
v
 
H
e
a
l
t
h
 
S
c
i
e
n
c
e
s
]
 
A
t
:
 
0
9
:
2
7
 
2
3
 
S
e
p
t
e
m
b
e
r
 
2
0
0
9
factors, depending on age, species, and metabolic
status of the cerebral cortex [8].
Because NMDA dilates pial arterioles via species-
and age-dependent mechanisms and is implicated in
CSD initiation and propagation, it is possible that,
under some circumstances, NMDA-evoked CSDs
contribute to the overall vascular responses. The
recent findings of Ayata and Moskowitz [2] support
this concept by providing evidence that, in mice,
NMDA-induced pial arteriolar dilation is, at least
partially, mediated by CSD. These researchers also
suggest that, in some former studies where electro-
physiological analyses were not performed, the
apparent dose-dependent nature of the pial arterial
responses was due to the increasing prevalence of
CSDs in conjunction with the increasing concentra-
tion of NMDA. It is unclear, however, whether a
similar complex interaction between CSD and the
direct effects of NMDA occurs in other animal
models.
Most data on NMDA-induced cerebrovascular
changes have been acquired through studies on
pial arteriolar diameters, which may or may not
fully represent the overall response of the cerebral
vasculature. We have shown previously that pial
arterial responses most likely underestimate CoBF
responses, and that in some situations the changes in
diameter of pial arterioles may not accurately reflect
alterations in resistance occurring in parenchymal or
large arteries [9,11,40]. The aim of our study was to
critically examine the effect of NMDA on CoBF,
using laser-Doppler flowmetry, and to test whether
CSD-related cortical hyperemia contributes to the
overall NMDA-induced cerebrovascular response in
the rat. To further clarify the glutamatergic cere-
brovascular responses, we also determined if gluta-
mate, AMPA, or kainate induced cortical
hyperemia/CSD similar to NMDA, and if coapplica-
tion of glutamate or AMPA with NMDA would
modify the NMDA-induced CoBF response by af-
fecting CSD. Additionally, we studied the effect of
NMDA on CoBF in newborn pigs, since NMDA-
induced cortical hyperemia has not been reported in
this species, although dose-dependent NMDA-in-
duced pial arteriolar vasodilation has been exten-
sively studied. Because the newborn pig is resistant
to KCl-induced CSDs [15], NMDA-induced cere-
brovascular changes are likely not confounded by
CSDs in this subject. Therefore, use of piglets will
allow us to compare the NMDA-evoked CSD-inde-
pendent cerebral hyperemia across experimental
models.
MATERIALS AND METHODS
Animals
AdultWistar rats (male, eight weeks old, body weight
270320 g, n57) and newborn pigs (male, one to
three days old, body weight 1.62.4 kg, n9) were
used in our experiments. Animals were maintained
and used in compliance with the principles set forth
by the Animal Care and Use Committee of Wake
Forest University Health Sciences.
Surgical Procedures
Rats were anesthetized with pentobarbital [Nembu-
tal; Hospira Inc., Lake Forest, Illinois, USA; 6070
mg/kg intraperitoneally (i.p.) for induction and 25
mg/kg intravenously (i.v.) for maintenance]. This
anesthetic is known to have no influence on CSD
generation and propagation [26,28]. The surgical
sites were treated with lidocaine (2%; Abbott
Laboratories, North Chicago, Illinois, USA) locally
for analgesia. Rats were intubated via tracheotomy
and mechanically ventilated with room air and
supplemental oxygen. Ventilation parameters were
adjusted to maintain normal end-tidal CO2 levels
(40 mmHg), which were continuously monitored
by a capnometer (Micro-Capnometer; Columbus
Instruments, Columbus, Ohio, USA). The right
femoral artery and vein were cannulated to measure
arterial blood pressure and to administer drugs and
fluids. A water-circulating heating mat was used to
maintain the body temperature at 378C, which
was monitored with a rectal probe. Arterial blood-
gas tensions and pH were determined to verify the
end-tidal pCO2 levels.
The heads of the rats were fixed in a stereotaxic
frame, and a closed cranial window was inserted in
the following manner. An incision was made on the
scalp, and the soft tissues were retracted from
the calvaria. A circular craniotomy was made over
the right parietal cortex (4 mm in diameter; the
center of the window was 3 mm lateral and 4 mm
caudal to the bregma), and then the dura was
carefully removed. A 2-mm-high rim was formed
around the craniotomy, using bone wax, and was
stabilized with cyanoacrylate. Two plastic tubes
were inserted into the rim as input and output ports
to enable drug administration and flushing of the
brain surface. The window was sealed with Parafilm
(American National Can, Greenwich, Connecticut,
USA), through which a laser-Doppler probe
NMDA evokes CSDs and cortical hyperemia in rats
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(referred to as probe 1) was guided onto the surface
(Figure 1). The window was filled with artificial
cerebrospinal fluid (aCSF; composition in mg/L:
220 KCl, 7714 NaCl, 665 dextrose, 251.4 CaCl2,
61.9 MgCl2, and 2066.6 NaHCO3; bubbled with 5%
CO2 in N2 and maintained at 37388C). Two
additional holes were drilled under saline cooling
over the right frontal cortex close to each other, one
for a second laser-Doppler probe (probe 2) and one
for a DC electrode, to verify the presence of possible
CSDs. The distance between the two Doppler probes
(78 mm) was measured to calculate CSD velocity.
The dura was also removed under probe 2. The
Doppler probes were mounted on micromanipula-
tors and positioned so that they touched the surface
of the brain, avoiding larger pial vessels. CoBF was
monitored by using a two-channel laser-Doppler flow-
meter (Periflux 4001 master; Perimed, Stockholm,
Sweden). An Ag-AgCl electrode (1 mm in diameter)
was connected to a DC amplifier (DAM 50, Differ-
ential Amplifier; World Precision Instruments, Sar-
asota, Florida, USA) for the measurement of DC
potentials. A reference platinum electrode (Grass;
Astro-Med, West Warwick, Rhode Island, USA) was
fixed in the neck muscles.
Piglets were anesthetized and underwent surgery,
as previously described [10], with some modifica-
tions. Anesthesia was induced with pentobarbital
(5060 mg/kg, i.p.) and minimally supplemented by
a-chloralose only when needed (in four of nine
animals; Sigma, St. Louis, Missouri, USA; 5
10 mg/kg, i.v.). a-chloralose is known to have no
effect on CSD, similar to barbiturates [28]. A
catheter was inserted in the right femoral artery to
monitor blood pressure and blood chemistry. Drugs
and fluids were administered through a second
catheter placed in the right femoral vein. The
animals were intubated via tracheotomy and me-
chanically ventilated with room air. The ventilation
rate (30 breaths/min) and tidal volume (20
mL) were adjusted to maintain the end-tidal CO2
level and arterial blood-gas parameters in the
physiological range. The end-tidal CO2 level was
monitored continuously, using a capnometer (Micro-
Capnograph CI240; Columbus Instruments).
A water-circulating heating pad was used to main-
tain the body temperature at 378C; core tempera-
ture was monitored with a rectal probe. The cranial
window consisted of a stainless steel ring with three
needle ports for drug administration, and aCSF
flushing and was covered with Parafilm to facilitate
the placement of Doppler probe 1 and the DC
electrode onto the brain surface. For DC potential
measurement, the same types of recording and
reference electrodes were used as in the rat experi-
ments, with appropriate changes in placement
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Figure 1. Experimental design and representative recordings of cortical blood ﬂow (CoBF) and direct current (DC)
potential in the rat. On the left side, schematic ﬁgures show the position of the two laser-Doppler probes and the DC
electrode during the experiments. The cranial window, where the drugs were applied, was placed over the parietal
cortex, and additional holes were drilled anteriorly to the window. The ﬁrst Doppler probe was placed under the
window. The second probe and the DC electrode were positioned at a distant site, to detect the spread of depolarization
and related cortical blood ﬂow (CoBF) changes. In the presented experiment, NMDA (103 M) applied under the
window evoked characteristic CoBF changes at the site of application (CoBF 1). Similar CoBF change was detected
after a short delay outside the window (CoBF 2), accompanied by a negative DC-potential shift. The calculated rate of
propagation between the two sites was consistent with that of cortical spreading depression. On the time axis, the 0 time
point indicates the beginning of drug application onto the brain surface. The stimulus was removed 10 minutes later,
when the window was ﬂushed with artiﬁcial cerebrospinal ﬂuid.
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according to the morphology of the piglet. Following
surgery, the closed window was filled with aCSF
[10]. For the placement of Doppler probe 2, a hole
was drilled 58 mm anterior to the window (so that
the maximal distance was 10 mm between the two
probes) and the dura was removed.
Protocol
After reaching a stable baseline CoBF, the vehicle
(aCSF) was superfused through the window to
provide an experimental control for drug application
in all animals. In rats, NMDA (group 1A; n8) or
glutamate (group 1B; n10) (both drugs were
purchased from Sigma, dissolved in aCSF) were
administered topically at 105, 104, and 103M
concentrations for 10 minutes, interrupted by 10-
minute-long drug-free periods when the surface was
flushed with aCSF. To examine reproducibility,
104 or 103 M (n6) of NMDA was applied on
the surface twice (group 2). In group 3 (n11),
glutamate (103 M) was applied for 10 minutes
prior to the coapplication of 104 and 103 M of
NMDA. In group 4 (n8), the CoBF responses to
AMPA (105 and 104 M, dissolved in 0.1 M of
NaOH to 2102 M and further diluted with
aCSF; Acros Organics, Morris Plains, New Jersey)
were characterized. In group 5 (n8), NMDA
(104 and 103 M) was coapplied with AMPA
(104 M) after a 10-minute incubation period with
this latter agonist. In group 6 (n6), the brain
surface was treated with 105 and 104 M of
kainate (Sigma, dissolved in aCSF) for 10 minutes.
In piglets, the effects of topical NMDA (104 and
103 M, group 7A; n5) on CoBF were deter-
mined. The brain surface was exposed to NMDA for
10 minutes, after which this stimulus was removed
with aCSF. DC potential and CoBF recording
continued for an additional 20 minutes. In group
7B, CoBF responses to glutamate (104 and 103
M, n4) were evaluated similarly. In five animals,
at least 30 minutes after the removal of the highest
dose of NMDA/glutamate, we attempted to evoke
CSDs by using repeated pinpricks (26-G needle, 12
mm in depth) as a mechanical stimulation. CoBF
and DC potential were recorded in a 30-minute
period following each pinprick.
CoBF, DC potential, blood pressure, and end-tidal
CO2 were recorded continuously by PC-based soft-
ware (IOX; EMKA Technologies, Falls Church,
Virginia, USA). At the end of the experiments, the
anesthetized animals were euthanized with an i.v.
injection of saturated KCl solution. At this time, a
biological zero for the laser-Doppler signal was
determined. Data were analyzed offline.
Data Analysis
CoBF was recorded in arbitrary perfusion units. The
biological zero was subtracted from the absolute
values, and CoBF data were normalized to the
average flow of fiveminutes prior to drug application.
We evaluatedCoBF responses in twoways, depending
upon the experimental protocol and whether a CSD
occurred during the application of drugs. In situations
in which a CSD was absent, we determined the
maximal CoBF response occurring over a one-minute
interval. In situations in which a CSD occurred, we
determined the maximal increase or peak CoBF
response, the latency between the beginning of drug
application and peak CoBF, and integrated CoBF
responses within different time intervals.
Data were analyzed by one- or two-way ANOVA for
repeated measures or by one-way ANOVA, followed
by Tukey’s exact test, where appropriate. Reprodu-
cibility of NMDA-induced CoBF responses (group 2)
was tested with the one-sample t-test. To compare
the frequency of CSD occurrence between groups,
Fisher’s exact test was used. A value of PB0.05 was
considered significant. Data are represented as
mean9standard error of the mean; n reflects the
number of animals.
RESULTS
Body temperature, arterial blood pressure, end-tidal
CO2 level, and blood gases were maintained within
the normal range and did not vary significantly
among different groups or during experiments. For
example, in group 1A, rectal temperature was
37.190.18C, mean arterial blood pressure was
10695 mmHg, and while ventilation parameters
were set to reach the normal end-tidal CO2, which
was approximately 5%, arterial oxygen tension was
14795 mmHg, arterial carbon dioxide tension was
4091 mmHg, and pH was 7.3990.01. Also, raw
baseline laser-Doppler flowmetry data (in arbitrary
perfusion units; PUs) were similar among groups
and did not shift considerably over the course of
experiments. Baseline perfusions under the window
were 163916 and 147914 PU in group 1A and 1B,
NMDA evokes CSDs and cortical hyperemia in rats
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respectively. Flushing of the brain surface with
aCSF did not affect the CoBF significantly.
NMDA Induces CSD and Dose-Dependent CoBF
Increase in the Rat
Topical NMDA at 105 M did not change the local
CoBF significantly (593%) and did not evoke any
CSDs (0/8 trials). However, after the application of
higher concentrations of NMDA (104103 M), a
rapid onset, but transient hyperemia, was observed,
followed by a reduced, but sustained, elevation of
CoBF under the cranial window (recorded by probe
1). Subsequently, a negative direct current (DC)
potential shift (510 mV) and a characteristic CoBF
increase were detected at the distant registration site
(probe 2), confirming the induction of a CSD by
NMDA (Figure 1).
The CoBF responses to 104 and 103 M of NMDA
were significantly different (Figure 2, upper panel).
The higher dose of NMDA evoked CSD-related
hyperemia with a significantly shorter latency (i.e.,
the time from the beginning of drug application to
the maximal elevation in the flow) than the lower
concentration (Figure 3A). The total CoBF increase
(expressed as the integrated average of eight minutes
after the flow maximum), the amplitude of the first,
rapid CoBF increase (referred to as a peak), and the
second, sustained CoBF increase or wave (defined as
a five-minute period starting one minute after the
peak) all showed prominent dose dependency (Fig-
ure 3B3D) at the site of NMDA application.
However, at the distant recording site, features of
the CoBF responses were not concentration depen-
dent (Figure 2, lower panel). The total CoBF
responses detected by probe 2 were 2195 and
3698% (P0.094), the peak CoBF increases
were 213921 and 278928% (P0.058), and the
magnitude of the waves were 1093 and 2196%
(P0.102) after the 104 and 103M NMDA
doses, respectively.
The time intervals between the two peaks detected
at the two sites were similar: 9196 and 9897
seconds when administering NMDA at 104 and
103M concentrations, respectively (P0.24). The
calculated velocities of 5.190.4 and 4.890.4 mm/
min for 104 and 103 M, respectively, are con-
sistent with published rates of CSD propagation
[20], and confirmed that the detected CSD spread
from the initiation site within the cranial window.
We demonstrated that repeated application of the
same concentration of NMDA (group 2) induced
remarkably similar CoBF elevations, which verified
that dose-dependent responses seen at the site of the
drug application were not due to hypersensitivity
caused by the previously induced CSD. The ratios of
second to first CoBF responses with NMDA applica-
tion were 0.9690.09, 1.0490.11, and 1.0590.12
for the peak, total, and wave values, respectively,
which were not significantly different from the
expected value of 1.
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Figure 2. The effect of topical NMDA on cortical blood
ﬂow (CoBF) in rats. CoBF was recorded under and away
from the cranial window (marked as probes 1 and 2,
respectively). NMDA evoked a rapid, cortical spreading
depression (CSD)-related hyperemia (peak) followed by
a sustained, but reduced, increase in CoBF (wave) that
was concentration dependent only under the cranial
window and not at the distant site. The CoBF data are
represented as mean9standard error of the mean (SEM)
(SEM plotted as curve thickness; n8). The intervals
between the 0 time point and the peaks represent the
average latency (without error) from the beginning of
drug application in both cases.
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Glutamate Does Not Elicit CSD or CoBF Increase
In contrast to NMDA application, administration of
glutamate (105103 M) failed to increase CoBF
significantly (maximal change was 992% at 103
M; P0.25) or to evoke a CSD (0/10 trials at each
concentration). The CoBF and the DC potential were
constant at the distant registration site following
glutamate application.
AMPA Does Not Elicit CSD but Increases CoBF
AMPA did not evoke CSD but increased CoBF by
6.891.7 and 1795%* (expressed as average CoBF
change of one minute at maximal rate of hyperemia;
*PB0.05) for 105 and 104 M on AMPA,
respectively (group 4). The CoBF increase was
gradual, reaching the maximum from the fourth to
fifth minutes of application. However, CoBF did not
change at the distant registration site and the DC
potential remained constant.
Glutamate and AMPA Reduce the Frequency of
NMDA-induced CSDs but Do Not Affect the CSD-
Independent Component of NMDA-induced CoBF
Increases
Glutamate was able to limit NMDA-induced CSD
development (group 3) when it was coapplied with
104 M (CSD failed to occur in 5 of 11 animals;
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Figure 3. NMDA evoked dose-dependent cortical blood ﬂow (CoBF) increases in rats. The higher dose of NMDA
(103 M) induced cortical spreading depressionrelated hyperemia with a signiﬁcantly shorter latency than the lower
(104 M) concentration (A). The magnitude of the total CoBF response (calculated as the average CoBF change of
eight minutes after the maximal or peak value) was also dependent on the dose of NMDA applied (B). A similar
difference was evident when analyzing its components; the peak (C), and the following, sustained CoBF increase or
wave (measured during a ﬁve-minute period starting one minute after the peak; D). The dashed lines on the schematic
icons show the beginning of NMDA application, whereas the arrows and ﬁlled areas determine the represented features
of the ﬂow response. Data are mean9standard error of the mean (n8; *PB0.05) via one-way repeated measures
analysis of variance and Tukey’s test.
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*PB0.05) but not with 103 M of NMDA (CSD
occurred in all 11 animals). Despite the suppression
of CSD expression with glutamate coapplication in
the five animals, NMDA at 104 M still increased
the CoBF significantly (Figure 4) to a level consis-
tent with the post-CSD wave when only NMDA was
applied (Figures 24).
Coapplication of AMPA also interfered with CSD
induction by NMDA (group 5). AMPA (104 M)
prevented the initiation of CSDs in all eight animals
when coapplied with 104 M (*PB0.05), and
prevented occurrence of CSD only in one of eight
animals when coapplied with 103 M of NMDA.
Despite the absence of CSD, coapplication of 104
M of NMDA still resulted in a significant increase in
CoBF, as compared with 104 M of AMPA alone
(Figure 4).
Kainate Does Not Elicit CSD but Increases CoBF
Kainate (group 6) increased CoBF by 3696* and
114916%* (105 and 104 M, respectively; *P
B0.05) but did not induce CSD in rats. However, in
contrast to AMPA and NMDA, CoBF did not return
to baseline, even after repeated aCSF flushing.
Consequently, due to the magnitude and the pro-
longed nature of the CoBF response, we did not
coapply kainate with NMDA.
NMDA Elicits Dose-Dependent CoBF Increase
without CSD in the Piglet
Topical application of NMDA (group 7A) produced
concentration-dependent increases in CoBF, as re-
corded under the cranial window (Figure 5). The
pattern of the CoBF responses was not consistent
with those seen in the rats during NMDA application
(Figure 5), and we did not detect significant CoBF
changes at the second, distant registration site
outside the window (392 and 290.5% to 104
and 103 M NMDA; P0.7 and 0.9, respectively).
The DC potential decreased gradually (by 510 mV)
and returned to the baseline level in approximately
two to three minutes after removal of the NMDA
with aCSF. Local activation of cortical neurons with
‘‘pinpricks,’’ using a sterile needle, although suffi-
cient to cause CSD in other models, also failed to
initiate CSD (0/5 animals) or significantly change
CoBF in piglets (3.291.2% in response to the first
pinprick; P0.5). In group 7B, we did not detect
the presence of CSDs during glutamate application,
and the increase in CoBF (8.391.4 and 9.591.1%
to 104 and 103 M of glutamate) was not
significant (P0.35 and 0.3).
DISCUSSION
The major findings of our experiments were: 1)
NMDA induced dose-dependent CoBF increases in
both species studied; 2) NMDA-evoked CSDs con-
tributed to the CoBF response in adult rats; 3)
stimulation of cortical AMPA- and kainate-receptors
also increased CoBF in rats without generating CSD;
4) glutamate failed to generate CSD-related CoBF
changes; 5) glutamate and AMPA reduced the
occurrence of NMDA-induced CSDs, thus unveiling
CSD-independent vasoactivity of NMDA; and fi-
nally, 6) NMDA-induced hyperemia was indepen-
dent of CSDs in piglets. After the elimination of the
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Figure 4. Cortical spreading depression (CSD)-inde-
pendent NMDA-evoked cortical blood ﬂow (CoBF)
increases in rats. Topical glutamate (103 M) and
AMPA (104 M) administration prevented the NMDA
(104 M)-induced CSD generation in 5 of 11 and 8 of 8
cases, respectively. Despite blocked CSD formation,
coapplication of 104 M NMDA still resulted in a
signiﬁcant increase in CoBF, as compared with AMPA
or glutamate application alone (expressed as average
CoBF change of one minute at maximal rate of
hyperemia). The CoBF increase was consistent with
the post-CSD wave when only NMDA was applied
(represented as the average increase of CoBF over a
one-minute interval, three minutes after the peak, time-
matched with CSD-independent CoBF increases). Data
are mean9standard error of the mean; (n58; *PB
0.05) via one-way repeated measures analysis of var-
iance and Tukey’s test.
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CSD-dependent component of the CoBF response to
NMDA in rats, the degree of cortical hyperemia to
NMDA was similar in rats and piglets.
NMDA evokes well-described dose-dependent pial
arteriolar dilation in vivo [10,12,32,16,17,19]; how-
ever, many studies failed to show NMDA-induced
vasodilation in isolated cerebral resistance vessels
[16,24,41]. NMDA-induced vasodilation is abol-
ished by NMDA-receptor antagonist MK-801 and
attenuated by inhibitors of neuronal nitric-oxide
synthase (nNOS) [4,16,18,32]. These findings sug-
gest that neuronal NMDA-receptor stimulation and
subsequent Ca influx/membrane depolarization
would activate nNOS, leading to vascular smooth
muscle relaxation by NO [8,14,21,35,44]. In addi-
tion to the unequivocal role of NO, the participation
of other species-specific factors, such as adenosine
[25], carbon monoxide (CO) [30], ATP-sensitive
potassium (KATP), and/or calcium-activated potas-
sium (KCa) channels [36] has been proposed.
Ayata and Moskowitz [2] suggested an alternative
mechanism of NMDA-induced pial arteriolar vaso-
dilation in mice. Using electrophysiological record-
ings and vessel-diameter measurements, they
demonstrated the involvement of CSD in the com-
plex vascular responses evoked by topical applica-
tion of as little as 50 mM of NMDA. However, there
are some limitations of that study. First, responses of
small arterioles (approximately 25 mm in diameter)
were tested that may not represent responses of
other resistance blood vessels during CSD. As
recently described, different vascular segments of
the cerebral circulation are exposed to varying
influences from dilator and constrictor stimuli dur-
ing CSD [7]. Second, pial arteriolar diameter may
not accurately reflect the overall response of the
cerebral vasculature to CSD [9,11,40]. And, third,
the CSD component of the overall responses to
NMDA was not removed, so that the direct effects
of NMDA could not be conclusively determined.
Our study provides novel evidence that NMDA-
evoked CSD is a major component of the overall
cerebral vascular response to higher (100 mM to 1
mM) doses of NMDA in the rat model; however,
detailed analysis of the response to NMDA revealed
nonCSD-dependent characteristics as well. CoBF
increases were dose dependent, which might be
explained by a faster, deeper penetration of the
drug at the higher dose and/or by a more extensive
receptor occupation. In the present study, we also
demonstrated the CSD-independent cerebrovascular
effect of AMPA and the inhibitory potential of
AMPA-receptor activation on NMDA-induced
CSDs. Importantly, even in the absence of CSDs,
the CSD-independent increase in CoBF upon NMDA
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Figure 5. A representative recording of cortical blood ﬂow (CoBF) and direct current (DC) potential and NMDA-
evoked dose-dependent cortical blood ﬂow (CoBF) increases in newborn pigs. Right panel: NMDA (103 M)
application onto the cortex elicited a transient CoBF increase (CoBF 1) and a prolonged DC potential deﬂection;
however, propagation of the CoBF response was not detected with the distant probe (CoBF 2). On the time axis, the 0
time point indicates the beginning of drug application onto the brain surface. The stimulus was removed 10 minutes
later, when the window was ﬂushed with artiﬁcial cerebrospinal ﬂuid. Left panel: Average CoBF change per minute was
calculated during a 10-minute period of drug application. Bars represent the maximal CoBF changes within the
examined time interval. Artiﬁcial cerebrospinal ﬂuid did not produce signiﬁcant CoBF changes, while topical NMDA
(104 and 103 M) increased CoBF in a concentration-dependent manner. Data are mean9standard error of the
mean (n5; *PB0.05) via one-way repeated measures analysis of variance and Tukey’s test.
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application remained intact. Similar to AMPA-
receptor activation, kainate application also in-
creased CoBF without producing CSDs. The dra-
matic, sustained CoBF effects of topical kainate
prevented the exploration of any potential modula-
tory influence of kainate on NMDA-induced CoBF
and CSD responses in the rat. We previously
described the pronounced, prolonged effects of
kainate on pial arterioles in piglets [5].
Unlike NMDA, AMPA, or kainate, the application of
the natural neurotransmitter, glutamate, failed to
significantly increase CoBF or to induce CSDs in the
rat. This apparent discrepancy is likely caused by
experimental conditions. The peak concentration of
glutamate in the synaptic cleft during neurotrans-
mission is unknown, but is estimated at about 1.1
mM in hippocampal glutamatergic synapses [13]. In
our study, glutamate and its analogs were applied
with a single application in a small volume (15
20 mL) under the cranial window to minimally
interfere with the laser-Doppler flowmetry signal
that is very sensitive to movement. The discrepancy
between the cerebrovascular effects of glutamate
and NMDA/AMPA/kainate may be due to the well-
known difference in the clearance of these drugs
from the extracellular space [34]. In our experi-
ments, glutamate concentration may not have stayed
high enough or reached the appropriate cell layers in
the stimulated cortex because of degradation and
neuronal/glial uptake to reproduce the cerebrovas-
cular effects of the selective analogues. Further, the
difference between glutamate and NMDA in facil-
itating CSDs has been described by other researchers
[29,33]. These results further indicate that the effect
of glutamate is complex, resulting not only from
NMDA receptor stimulation, but from the summa-
tion of different, and sometimes opposing, actions
via multiple receptors and vasoactive substances
[8,27]. The complex action of glutamate is further
suggested by its efficacy to reduce the incidence of
NMDA-induced CSDs. Glutamate has two more
ionotropic (AMPA and kainate) and numerous
metabotropic receptors. It is possible that the
activation of one or more of them acts antagonisti-
cally in terms of CSD initiation. The AMPA receptor
can be an important site of this effect, since AMPA
produced a similar inhibition in the present study.
AMPA is able to antagonize NMDA-induced changes
in rat cortical networks [1]. Conceivably, AMPA-
receptor activation may have antagonized CSD
initiation by NMDA, as well. Importantly, glutamate
or AMPA did not affect the CSD-independent
component of the CoBF response to NMDA, suggest-
ing that not the direct interaction with the NMDA
receptor, but the subsequent electrophysiological
sequence triggering a CSD, was impaired by gluta-
mate/AMPA.
Our findings in the piglet provide novel data on the
integrated CoBF responses to the activation of
cortical neuronal NMDA receptors in this important
experimental model and confirm our earlier results
concerning the dose-dependent nature of responses
to NMDA, based upon measurements of pial arter-
iolar diameters in this species [3,6,10,12,15,36].
The hemodynamic changes are not the consequence
of CSD-related events, but rather represent a direct,
specific effect on cortical neurons [8,14]. While CSD
has been shown to occur in the mature brains of all
mammalian species studied, the neonatal brain
appears to be relatively resistant to generation of
CSD [39]. For example, in the rat, it is difficult to
elicit CSD-like events before postnatal days 910
[38], and in the piglet, we have not been able to
induce CSD, even with mechanical means (i.e.,
pinpricks), during the first days of life. While the
inability of the neonatal brain to produce CSDs is
not completely understood, it seems likely that
factors such as lack of maturity of individual
neuronal and glial components and their incomplete
integration with each other, as well as different
expression of ion channels and neurotransmitter
receptors, are responsible for this phenomenon
[42]. In a recent study, Girouard et al. [23] found
that the cortical application of 40 mM of NMDA
increased CoBF in mice by 2025% without indu-
cing CSD. Additionally, they confirmed earlier
reports that cerebral vascular dilation to NMDA is
dependent on NO derived from neuronal NOS
[4,18]. The amount of the increase in CoBF
observed in mice, following NMDA application by
Girouard et al. [23], is similar to the non-CSD
component of the CoBF response that we observe in
rats and to the CoBF responses we see in piglets.
CONCLUSIONS
In summary, NMDA elicits dose-dependent CoBF
increases in rats and piglets. Although previous data
obtained by pial arteriolar diameter measurements
suggest many superficial similarities in the cerebro-
vascular responses to NMDA, our results show that
the underlying mechanisms are quite different
between these two models. In rats, NMDA-evoked
NMDA evokes CSDs and cortical hyperemia in rats
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CSD has a substantial, but not exclusive, contribu-
tion to the cerebrovascular response. In piglets,
however, the CoBF increase seems to be solely the
result of the local activation of neuronal NMDA
receptors without the confounding effect of CSDs.
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Cerebral ischemia/reperfusion (I/R) results in cellular energy failure and dysfunction of the neurovascular
unit that contribute to subsequent neuronal cell death in the neonate. PX-18 is a putative neuroprotective
inhibitor of secretory phospholipase A2 (sPLA2) but its in vivo testing has been limited by its poor solubility.
Our purpose was to assess whether PX-18 preserved neuronal–vascular reactivity to I/R-sensitive
endothelium-dependent (hypercapnia, bradykinin) and/or neuron-dependent (N-methyl-D-aspartate;
NMDA) stimuli. To make the drug available for in vivo studies, PX-18 was formulated as a 3% nanosuspension
applying high pressure homogenization. Newborn piglets (1-day old, n=40) were anesthetized and venti-
lated, and cerebrovascular reactivity to the above stimuli was determined by measuring changes in pial
arteriolar diameters using the closed cranial window/intravital videomicroscopy technique. Intravenous
infusion of PX-18 nanosuspension (6 mg/kg, 20 min) did not affect baseline arteriolar diameters, or
hypercapnia-, bradykinin-, or NMDA-induced pial arteriolar vasodilation under normoxic conditions. Global
cerebral ischemia (10 min) followed by 1 h of reperfusion signiﬁcantly attenuated hypercapnia-, bradykinin-,
and NMDA-induced vasodilation in untreated or vehicle-treated controls. However, PX-18 resulted in nearly
full preservation of cerebrovascular reactivity to all these stimuli. In conclusion, inhibition of sPLA2 by PX-18
improves neurovascular function both at the neuronal and the microvascular level following I/R. This effect of
PX-18 likely contributes to its neuroprotective effect.
© 2009 Elsevier Inc. All rights reserved.
Introduction
In the central nervous system, the metabolic homeostasis of
neurons critically depends on the continuous maintenance of ade-
quate blood supply and bidirectional transport of nutrients and meta-
bolites across the blood–brain barrier. This goal is achieved by the
functional and morphological interaction of parenchymal neurons,
astrocytes, cerebrovascular endothelial cells, pericytes, vascular
smooth muscle cells, and perivascular nerves. To identify this complex
system the term “neurovascular unit” has recently been coined (Lo
et al., 2003). Hypoxic/ischemic injury that occurs in the perinatal
period commonly results in a dysfunction of the neurovascular unit as
indicated by decreased responsiveness to important vasodilator sti-
muli. The newborn pig is a widely accepted model of the human term
neonate to study hypoxic/ischemic injury, based on the similarities in
brain structure, developmental stage, glucose metabolism and cardi-
ovascular regulation (Book and Bustad, 1974; Flecknell et al., 1980;
Gootman et al., 1972). Global cerebral ischemia/reperfusion (I/R) in
newborn pigs has been previously demonstrated to attenuate pial
arteriolar vasodilation to N-methyl-D-aspartate (NMDA) and hyper-
capnia, indicating injury to both neuronal and cerebrovascular mem-
bers of the neurovascular unit (Busija et al., 1996; Lefﬂer et al., 1989).
Cyclooxygenase (COX) activity plays a special Janus-faced role in the
cerebral circulation of the newborn. Both COX-1 and COX-2 expressed in
the piglet brain convert arachidonic acid to prostaglandin H2, the subs-
trate of further prostanoid biosynthesis (Peri et al., 1995). Prostanoids
are involved in the vasodilatory responses to hypercapnia, hypotension,
endogenous opiates, histamine, and the 38 amino acid form of pituitary
adenylyl cyclase activating polypeptide (PACAP) based on their
sensitivity to COX inhibition by indomethacin (Busija, 1994; Lenti et
al., 2007). However, after I/R, COX-2 derived reactive oxygen species
(ROS) and inﬂammatory prostanoids are believed to substantially con-
tribute to reperfusion injury (Armstead, 2003; Armstead et al., 1988;
Candelario-Jalil and Fiebich, 2008). Indomethacin and the COX-2 inhi-
bitor NS-398were shown to prevent the attenuation of the I/R-sensitive,
COX-independent vasodilatory response toNMDA(Domoki et al., 2001).
The use of COX inhibitors, however, necessarily impairs COX-dependent
cerebrovascular mechanisms and other physiological functions.
Arachidonic acid availability for COX is regulated by phospholipase
A2 (PLA2) activity, a diverse group of enzymes including a group of
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secretory (sPLA2) and Ca2+-dependent as well as independent groups
of cytoplasmic PLA2s. The physiological function of sPLA2s in the brain
appears to involve the ﬁssion and fusion of synaptic vesicles control-
ling neurotransmitter release, and also neurite outgrowth (Farooqui
and Horrocks, 2006). sPLA2s hydrolyze the acyl ester bond at the sn-2
position of glycerol in membrane phospholipids displaying no speciﬁ-
city for the fatty acid at this position. However, addition of ceramide, a
metabolite of sphingomyelin makes sPLA2 highly speciﬁc for arachi-
donic acid (Koumanov et al., 2002). During ischemia, uncontrolled acti-
vation of brain PLA2s results in a tremendous (N50-fold) increase in free
arachidonic acid concentrations in the cerebral cortex eliciting neuronal
injury (Bazan, 1970). The contribution of sPLA2s in the ampliﬁcation
phase of this “Bazan effect” is unknown. However, sPLA2s likely
participate in this process being released from the neurons undergoing
anoxic depolarization. Neuronal sPLA2 protein levels are increased 1–6h
after forebrain ischemia in rats suggesting a role for these enzymes in I/R
injury (Lauritzen et al., 1994). sPLA2 activity was shown previously to
induce or aggravate neuronal injury (Kolko et al., 2002) perhaps via
uncontrolled ROS production by COX. Selective inhibition of PLA2
isoenzymes may offer an appealing pharmacological target to reduce
the injurious effects of COX activation during I/R while preserving its
physiological function in the neurovascular unit.
PX-18 is a novel sPLA2 inhibitor (Rastogi et al., 2007), however, its
in vivo testing is hindered by poor solubility in aqueous media. For-
mulating poorly soluble drugs as nanocrystals is a promising approach
to overcome this problem. Drug nanocrystals are pure solid drug
particles with a mean particle size below 1 μm. Dispersions of drug
nanocrystals in liquid dispersion media stabilized with stabilizing
agents, typically surfactants or polymeric stabilizers, are called nano-
suspensions (Müller and Akkar, 2004). Due to the reduction of the
particle size into the nanometer range, nanosuspensions possess
several advantages, e.g. increased saturation solubility and conse-
quently an increased dissolution velocity, and an increased adhe-
sion to surfaces, which contribute to an enhanced oral bioavaila-
bility of active compounds (Müller et al., 2000; Rabinow, 2004; Van
Eerdenbrugh et al., 2008). The small size allows also injecting nano-
suspensions intravenously. After injection, the nanoparticles dissolve
relatively fast in the large blood volume.
Therefore, the speciﬁc aims of our present study were to test (1)
whether PX-18 can be successfully formulated and used as a nano-
suspension in anesthetized newborn pigs, (2) whether PX-18 nano-
suspension affects COX-dependent or -independent cerebrovascular
dilatory responses, and (3) whether PX-18 nanosuspension preserves
cerebrovascular reactivity to I/R-sensitive stimuli such as hypercapnia,
bradykinin, and NMDA.
Materials and methods
Materials
The drug and reagent sources were the following: Na-thiopental
(Biochemie, Vienna, Austria);α-chloralose, NMDA, bradykinin, Tween
80, and glycerol 85% (Sigma Aldrich, St. Louis, MO, USA). PX-18 and
PACAP-38 were gifts from Richard Berney Associates (LLC, Bethesda,
MD, USA), and from the Department of Medical Chemistry, University
of Szeged, Hungary, respectively.
Preparation of a 3% (w/w) PX-18 nanosuspension
A Micron LAB 40 (APV Deutschland GmbH, Unna, Germany)
equipped with awater jacket for temperature control was used for the
production of 3% (w/w) PX-18 nanosuspensions. The nanosuspension
was stabilized with 1% (w/w) Tween 80. Glycerol 85% was used for
isotonization of the nanosuspension. The PX-18 bulk material was
dispersed in the isotonic aqueous surfactant solution using a mortar
and pestle. The dispersion was pre-homogenized running 2 cycles at
150 bar followed by 2 cycles at 500 bar and 2 cycles at 1000 bar. The
obtained pre-dispersions were subjected to a high pressure homo-
genization applying 20 cycles at 1500 bar at5 °C. A 1% (w/w) Tween 80
solution isotonized with glycerol 85% served as vehicle control during
the experiments.
Photon correlation spectroscopy
The particle size of the nanosuspension was investigated by
photon correlation spectroscopy using a Zetasizer Nano ZS (Malvern
Instruments, Malvern, UK). Photon correlation spectroscopy yields the
mean particle size and the polydispersity index as a measure of the
width of the particle size distribution. The polydispersity index ranges
from 0 (=monodisperse) to 1 (=very broad size distribution).
Laser diffractometry (LD)
The particle size of the PX-18 bulk material and of the 3% (w/w)
PX-18 nanosuspension was determined by laser diffractometry (LD)
using a Coulter LS 230 (Beckman-Coulter, Krefeld, Germany). For data
evaluation water with a refractive index (RI) of 1.33 was used as a
measurement medium. The real RI of PX-18 is 1.496, the imaginary RI
of this compound is zero. The LD data were used to calculate the
diameters 50% (LD 50), 90% (LD 90) and 95% (LD 95), which means
that either 50%, 90% or 95% (volume distribution) of the measured
particles are below this size.
Stability study
To ensure the physical stability of the 3% (w/w) PX-18 nanosus-
pension over the period of the experiments, it was stored at 4 °C for
three months and the particle size was investigated on days 0, 1, 7, 14,
30, and 90 by photon correlation spectroscopy and LD measurements.
Intravital videomicroscopy of pial arterioles in piglets
All procedures were approved by the Animal Care and Use Com-
mittee of the University of Szeged. Newborn pigs (∼1-day old, 1.2–
2.5 kg, n=40) were initially anesthetized with Na-thiopental (40 mg/
kg ip) followed by α-chloralose (40 mg/kg, supplemented with 2–
5 mg kg1 h1 iv). Animals were intubated via tracheotomy and
artiﬁcially ventilated with a pressure-controlled ventilator using room
air. The ventilation rate (∼30 breaths/min) and tidal volume (∼20ml)
were adjusted to maintain arterial blood gas values and pH in the
physiological range. The right femoral artery and vein were catheter-
ized tomonitor arterial blood pressure and for administration of drugs
and ﬂuids, respectively. Body temperaturewasmaintained at 37–38 °C
with a water-circulating heating pad. The piglets were equipped with
a stainless steel closed cranial windowwith 3 injectible ports to follow
the diameter changes of a selected pial arteriole (baseline diameter
∼80–100 μm) using intravital videomicroscopy, as described pre-
viously (Domoki et al., 2005). The subarachnoidal space under the
cranial window (∼3 ml chamber volume) was ﬁlled with artiﬁcial
cerebrospinal ﬂuid (aCSF): KCl 220, MgCl2 132, CaCl2 221, NaCl 7710,
urea 402, dextrose 665, and NaHCO3 2066 in mg/l), warmed to 37 °C
and equilibrated with a gas mixture containing 6% O2, 6.5% CO2 and
87.5% N2. All drugs were diluted/dissolved in aCSF, and were applied
with a single injection through the ports of the cranial window (5 ml
of aCSF superfusion in 1 min) onto the parietal cortex.
Global cerebral ischemia
Cerebral ischemia was produced by infusion of aCSF to raise the
intracranial pressure (ICP) above the arterial pressure for 10 min.
Ischemia was veriﬁed by cessation of blood ﬂow in the vessels ob-
served through the cranial window. Venous blood was withdrawn as
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necessary to keep mean arterial blood pressure (MABP) near normal
values. At the end of the ischemic period, the infusion tube was
clamped and the ICP was allowed to return to the preischemic level.
The withdrawn and heparinized blood was reinfused.
Assessment of cerebrovascular reactivity (CR)
Pial arteriolar diameters were determined under baseline condi-
tions and then at each minute during application of vasodilatory
stimuli. Hypercapnia was elicited by ventilation with a gas mixture
(10% CO2, 21% O2, balance N2) for 7–10 min to allow maximal arte-
riolar dilation. PX-18 nanosuspension diluted in aCSF to a concen-
tration of 10−8 M–10−4 M, corresponding dilutions of its vehicle,
PACAP-38 (10−6 M), NMDA (10−4 M), or bradykinin (10−6 M) were
applied locally onto the parietal cortex under the cranial window for
5 min each. PX-18 nanosuspension (6 mg/kg) or its vehicle was also
given as a bolus intravenous injection or a continuous infusion for
20 min. Results are presented as the maximal vasodilationmaintained
for at least 2 min, and expressed as % changes from corresponding
baseline diameters. After completion of a stimulus, the cranial
windowwas ﬂushed repeatedly with aCSF and the arteriolar diameter
was allowed to return to baseline levels for 15 min before the appli-
cation of the next stimulus.
Experimental protocol
Instrumented pigletswere divided into seven experimental groups.
In Group 1 (n=5), CR was determined for local vehicle, local PX-18
nanosupension, systemic vehicle (iv bolus), and systemic PX-18
nanosuspension (iv bolus) administration, consecutively. In Group 2
(n=7), CR was determined to hypercapnia and PACAP38 before and
after local treatment with PX-18 nanosuspension (10−5 M, 20min). In
Group 3 (n=5), the protocol was the same as in Group 2, however, PX-
18 nanosuspension was given as an infusion (6 mg/kg, 20 min, iv). In
Group 4 (n=5), CR was determined to NMDA and bradykinin before
and after local PX-18 treatment, then after systemic PX-18 nanosus-
pension infusion. In Groups 5, 6 and 7 (n=8, 8, and 7, respectively), CR
was determined to hypercapnia, NMDA, and bradykinin before and 1 h
after 10 min of global cerebral ischemia. Prior to the induction of
ischemia, animals in Group 5, 6, or 7 received no treatment, vehicle
infusion, or PX-18 nanosuspension infusion, respectively.
Statistics
Data are expressed as mean±SEM. Data were analyzed with a
statistical software (SigmaStat, Systat Software Inc., San Jose, CA, USA)
using one-way or two-way repeated measures ANOVA, where appro-
priate. For post hoc analysis the Student–Newman–Keuls test was em-
ployed. p values of b0.05 were considered as statistically signiﬁcant.
Results
High pressure homogenization produced a PX-18 nanosuspension
reducing the mean particle size and simultaneously narrowing the
width of the size distribution (Figs. 1–2). 95% of the particles based on
Fig. 1.Mean particle size and polydispersity index (PI) measured by photon correlation
spectroscopy of a 3% (w/w) PX-18 nanosuspension after 2 homogenization cycles at
1000 bar, and 5, 10, 15 and 20 homogenization cycles at 1500 bar at 5 °C. A continuous
decrease in particles size with an increasing number of applied homogenization cycles
was observed, while PI did not change considerably. Themean particle size of the 3% (w/
w) PX-18 nanosuspenion was 183 nm after 20 homogenization cycles at 1500 bar that
was used for the in vivo experiments.
Fig. 2. Volume–size distribution curves measured by laser diffractometry (LD) of PX-18 bulk material and a 3% (w/w) PX-18 nanosuspension after 2 homogenization cycles at
1000 bar, as well as after 5, 10, 15 and 20 homogenization cycles at 1500 bar at 5 °C. The bulk material had a particle size in the micrometer range and an inhomogeneous particle size
distribution. After 5 homogenization cycles at 1500 bar no particles bigger than 5 μmwere detected in the formulation. Continuing the homogenization process the particle size could
be further decreased.
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a volume distribution measured by LD had a size smaller than 775 nm
in the ﬁnal nanosuspension used for the in vivo experiments (Fig. 2).
Table 1 provides an overview of the particle sizes measured over an
observation period of three months. The particle size of the 3% (w/w)
PX-18 nanosuspension stayed constant when stored at 4 °C. No par-
ticle growth was observed under the storage conditions over the
observation period.
PX-18 nanosuspension or its vehicle did not induce signiﬁ-
cant increase in pial arteriolar diameters when applied locally up to
10−5 M concentration. This dose was used for local PX-18 pretreat-
ments, where pial arteriolar diameters were essentially unchanged by
PX-18: the values were 92±4 versus 92±3 μm before versus during
10−5 M PX-18 application (data combined from Groups 1, 2, and 4,
n=14). In Group 1, rapid iv injection of PX-18 nanosuspension, but
not its vehicle, resulted in a transient drop in MABP with a simul-
taneous increase in pial arteriolar diameters, which both returned to
baseline levels in 4–6 min. However, heart rate was not signiﬁcantly
affected by PX-18 nanosuspension injection. The maximal changes in
MABP, pial arteriolar diameters, and heart rate before versus 2 min
after PX-18 nanosuspension injection were 62±7 versus 40±5⁎ mm
Hg, 92±6 versus 116±9⁎ μm, and 159±19 versus 155±17 1/min,
respectively (⁎pb0.05, n=5). These transient changes in cerebral
hemodynamics were prevented by administering PX-18 nanosuspen-
sion as an infusion (20 min) in Groups 3, 4, and 7 (data not shown).
Hypercapnia, PACAP38, bradykinin, and NMDA all elicited robust
pial arteriolar vasodilation (Groups 2–4, Fig. 3) that was unaffected by
both local and systemic administrations of PX-18; except vasodilation
to PACAP-38 which was signiﬁcantly reduced only by topical PX-18
(Fig. 3).
In piglets subjected to I/R, MABP and pial arteriolar diameters
returned to preischemic values by 1 h of reperfusion. MABP and base-
line arteriolar diameters, before versus 1 h after ischemia were: 60±3
versus 57±2 mm Hg and 106±7 versus 107±8 μm (Group 5), 70±4
versus 65±2 mm Hg and 95±6 versus 101±8 μm (Group 6), and
66±4 versus 64±4 mmHg, and 94±9 versus 92±9 μm (Group 7). I/
R signiﬁcantly attenuated the pial arteriolar dilation to hypercapnia,
NMDA, and bradykinin in the control (untreated) and the vehicle-
treated animals (Groups 5 and 6, respectively, Fig. 4). However, in
Group 7, hypercapnia-, NMDA-, and bradykinin-induced pial arteriolar
vasodilationwas similar before and after cerebral ischemia, thus PX-18
preserved cerebrovascular reactivity to these stimuli (Fig. 4).
Discussion
The major novel ﬁnding of our study is that the sPLA2 inhibitor
PX-18 preserves neurovascular reactivity after I/R in the newborn
Table 1
Particle size of a 3% (w/w) PX-18 nanosuspension stored at 4 °C over three months
determined by photon correlation spectroscopy and laser diffractometry (LD).
Parameter Day 0 Day 1 Day 7 Day 14 Day 30 Day 90
MPS [nm] 183 172 171 165 166 167
PI 0.450 0.469 0.491 0.514 0.477 0.513
LD 50 [nm] 566 587 571 586 573 577
LD 90 [nm] 725 765 742 782 751 757
LD 95 [nm] 775 812 786 815 795 805
MPS: mean particle size determined by PCS, PI: polydispersity index, LD 50–90–95: 50–
90–95% of the PX-18 volume distribution is below the indicated particle size
determined by LD, respectively.
Fig. 3. PX-18 minimally affects cerebrovascular reactivity. Hypercapnia induced by
ventilation with 10% CO2 (CO2), or topical application of the 38 amino acid isoform of
pituitary adenylyl cyclase activating peptide (10−6 M; PACAP), N-methyl-D-aspartate
(10−4 M, NMDA), and bradykinin (10−6 M, BK) all resulted in robust increases in pial
arteriolar diameters. Local pretreatmentwith PX-18 (10−5 M, upper panel) signiﬁcantly
reduced PACAP-induced vasodilation, but did not affect cerebrovascular reactivity to
hypercapnia, NMDA, or BK. Intravenous infusion of PX-18 (6 mg/kg, lower panel) did
not affect cerebrovascular reactivity to any stimuli; pb0.05, ⁎ versus corresponding
response before treatment, n=5–7 for each group.
Fig. 4. PX-18 preserves cerebrovascular reactivity after global ischemia/reperfusion
(I/R). Pial arteriolar dilations to hypercapnia induced by ventilationwith 10% CO2 (CO2),
topical application of N-methyl-D-aspartate (10−4 M, NMDA), and bradykinin (10−6 M,
BK)were all signiﬁcantly reduced after I/R injury in time control animals (control, upper
panel, n=8). Attenuation of cerebrovascular reactivity to all these stimuli was similar in
animals treated with the vehicle of PX-18 (vehicle, middle panel, n=8). In contrast, pial
arteriolar responses to CO2, NMDA, and BK remained intact after I/R in the PX-18-treated
group (PX-18, lower panel, n=7); pb0.05, ⁎ versus corresponding response before I/R, †
versus corresponding response after I/R in the control and vehicle-treated groups.
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piglet. Importantly, the protective dose of PX-18 does not interfere
with indomethacin-sensitive (i.e., COX-dependent) cerebrovascular
responses. Our data suggest that preservation of microvascular
function can contribute to the cardio- and neuroprotective effects of
PX-18 reported in a rabbit and gerbil I/Rmodel, respectively (Ockaili et
al., 2005; Wang et al., 2007).
The sPLA2 inhibitor PX-18 (Rastogi et al., 2007) was formulated as
drug nanosuspension suitable for iv injectionwith an active content of
3% (w/w) applying high pressure homogenization. Similar to o/w
emulsions for parenteral nutrition, the number of large particles
(above 1 μm) should be limited and no signiﬁcant number of particles
larger than 5 μm should be present in the formulation. The 3% (w/w)
PX-18 nanosuspension fulﬁlls these requirements; ≥99% of the
particles present in this formulation based on a volume distribution
have a size below 0.860 μm (Fig. 2). Therefore, formulating the poorly
soluble sPLA2 inhibitor PX-18 as nanosuspensionmakes it available for
pharmacological testing. Stability investigations of the PX-18 nano-
suspension with regard to the particle size showed, that under the
storage condition no changes in the particle size distribution occurred
(Table 1). Neither particle agglomeration or aggregation nor Ostwald
ripening (=crystal growth) took place in the formulation. The lack of
Ostwald ripening in the 3% (w/w) PX-18 nanosuspension produced by
high pressure homogenization is caused by the uniform particle size
and the absence of particles in the micrometer range (Moschwitzer et
al., 2004; Muller et al., 2001). This ensures a constant particle size
during the performance of the in vivo experiments.
In the newborn piglet, hypercapnia-induced vasodilation is an
endothelium-dependent and I/R-sensitive cerebrovascular response
since it is impaired by light/dye or I/R injury to the microvascular
endothelium (Lefﬂer et al., 1989; Lefﬂer et al., 1994). Hypercapnia-
induced vasodilation is also COX-dependent since inhibition of PLA2
activity with quinacrine or p-bromophenacyl bromide or inhibition of
COX with indomethacin abolishes pial arteriolar vasodilation to
hypercapnia (Wagerle and Mishra, 1988). Attenuation of hypercap-
nia-induced vasodilation after I/R is considered to be due to decreased
availability of arachidonic acid since exogenous supply of arachidonic
acid restores normal cerebrovascular reactivity to hypercapnia (Lefﬂer
et al., 1992). In the present study, PX-18 does not affect hypercapnia-
induced vasodilation, but prevents the postischemic attenuation of
this response suggesting that sPLA2s may not be involved in the PLA2
activity required for this response but may be involved in the critical
depletion of releasable arachidonic acid during I/R. In addition to
intact hypercapnia-induced vasodilation after PX-18, pial arteriolar
dilation to PACAP was also essentially unchanged. We have previously
demonstrated that pial arteriolar dilation to the 38 amino acid isoform
of PACAP is virtually abolished after indomethacin or the selective
COX-1 antagonist SC-560, but unaffected by the COX-2 inhibitor NS-
398 (Lenti et al., 2007). Although there was a signiﬁcant decrease in
PACAP-induced vasodilation when PX-18 was administered locally
(Fig. 3), the remaining response was still robust as compared to the
absent response after COX inhibitors in the previous study (Lenti et al.,
2007). Importantly, the systemic dose used to assess the protective
effect of PX-18 did not affect this COX-dependent response (Fig. 3).
Bradykinin dilates pial arterioles in the newborn piglet via an
endothelium-dependent but a COX-independentmechanism (Lacza et
al., 2002; Willis and Lefﬂer, 2001). A novel observation of the present
study is that pial arteriolar dilation to bradykinin is sensitive to I/R
(Fig. 4). Hypertension-induced dysfunction of cerebrovascular
endothelium had been known to reduce cerebrovascular reactivity
to bradykinin in rats (Yang et al., 1991a; Yang et al., 1991b), but our
present results demonstrate for the ﬁrst time that I/R-induced
endothelial injury is reﬂected in impaired cerebrovascular reactivity
to bradykinin in piglets. PX-18 preserved bradykinin-induced vasodi-
lation after I/R similar to hypercapnia-induced vasodilation, conﬁrm-
ing that preservation of endothelial function after I/R may be a
mechanism of the neuroprotection of this drug (Fig. 4).
NMDA-induced pial arteriolar vasodilation in the piglet is a very
well-characterized I/R-sensitive neuronal–vascular response that is
critically dependent on activation of neuronal NMDA receptors with
subsequent release of nitric oxide produced by neuronal nitric oxide
synthase (Busija et al., 2007). In addition to the indirect neuronal–
vascular mechanism of NMDA-induced vasodilation, direct cerebro-
vascular effects of glutamate and the NMDA-receptor agonist 1-
aminocyclopentane-cis-1,3-dicarboxylic acid (but not NMDA itself)
have been reported in the piglet (Fiumana et al., 2003; Parfenova et al.,
2003). However, we found that NMDA did not dilate pial arterioles ex
vivo and cerebral microvessels lacked functional NMDA receptors in
piglets (Domoki et al., 2008; Simandle et al., 2005). NMDA receptor
activation-induced increases in arteriolar diameters likely contribute
to the coupling of local cortical blood ﬂow to the metabolism of
neurons stimulated by the activation of NMDA receptors, and the
impairment of this response by I/R may be used as a sensitive bioassay
to assess the postischemic dysfunction of the neurovascular unit
(Busija et al., 2007). NMDA-induced vasodilation after I/R is impaired
by the postischemic generation of COX-derived ROS activity; ROS
scavengers, indomethacin, and the selective COX-2 inhibitor NS-398
were shown to preserve neurovascular reactivity to NMDA (Bari et al.,
1998; Busija et al., 2007; Domoki et al., 2001; Philip and Armstead,
2003). In the present study, PX-18 provided excellent, virtually total
preservation of NMDA-induced vasodilation (Fig. 4), in agreement
with the notion that inhibition of sPLA2 by PX-18 interferes with the
release of arachidonic acid during ischemia resulting in signiﬁcantly
less substrate for COX in the reperfusion.
In conclusion, the novel PLA2 inhibitor PX-18 could be successfully
formulated as nanosuspension suitable for iv injection. PX-18 pre-
serves the physiological neurovascular responsiveness to both
endothelium- and neuron-dependent dilator stimuli after I/R. The
protective effects of PX-18 are likely mediated by inhibition of arachi-
donic acid depletion and COX-dependent ROS production during I/R.
Thus, PX-18 improves the function of the neurovascular unit after I/R
contributing to its previously reported neuroprotective effect (Wang
et al., 2007). Selective modulation of brain PLA2 may identify new
pharmacological agents to reduce neuronal damage after hypoxic/
ischemic injury in the newborn.
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